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RESUMO 
 
 O vírus da imunodeficiência humana (VIH) é o agente causador do síndrome da 
imunodeficiência adquirida (SIDA) e o seu modo de actuação consiste, sobretudo, em 
infectar e destruir células T CD4+ do organismo hospedeiro. Existem dois tipos do 
vírus, VIH-1 e VIH-2, mas é o VIH-1 o mais virulento e o responsável pela maior parte 
dos casos de SIDA no mundo.  
 O envelope do vírus consiste numa bicamada lipídica, derivada da célula 
hospedeira, que possui um complexo glicoproteíco que confere ao vírus a capacidade 
para entrar nas células alvo. Este complexo é formado pelas subunidades gp120 
(subunidade superfície) e gp41 (subunidade transmembranar), que se mantêm 
associadas de modo não covalente e oligomerizam sob a forma de trímeros na superfície 
do vírus. A gp41 é uma proteína transmembranar constituída por um domínio 
extracelular (ectodomínio), um domínio transmembranar e um domínio intracelular 
(endodomínio). O ectodomínio da gp41 contém várias regiões funcionais importantes 
para o processo de fusão viral. O péptido de fusão, localizado no terminal N da proteína, 
é uma região hidrófoba e rica em resíduos de glicina. Este domínio é essencial para o 
processo de fusão, nomeadamente para a penetração inicial da membrana da célula alvo. 
No seguimento do péptido de fusão encontram-se duas regiões que têm tendência para 
formar superenrolamentos de hélice α. A região adjacente ao péptido de fusão é 
chamada NHR e a região CHR é a que precede o segmento transmembranar. Os 
péptidos derivados destas regiões são chamados péptidos N- e C-, respectivamente. No 
terminal C da proteína, entre a região CHR e o domínio transmembranar, situa-se a 
chamada região próxima da membrana (MPR – membrane proximal region). Esta 
região é rica em resíduos de triptofano e parece ter também um papel chave na fusão 
viral.  
 O primeiro passo no processo de infecção consiste na ligação da gp120 ao receptor 
(CD4) e co-receptores (CXCR4 ou CCR5) na superfície das células alvo. Esta 
interacção induz alterações conformacionais na gp120 e modula as interacções 
gp120/gp41. A gp41 sofre então uma alteração conformacional e a sua estrutura nativa 
transita para uma estrutura intermediária de pré-hairpin. Estas variações na gp41 
incluem a exposição do péptido de fusão e a sua inserção na membrana alvo. 
Posteriormente dá-se uma associação entre as regiões NHR e CHR levando à formação 
Resumo 
 viii 
 
da estrutura em hairpin (trímero em dímeros de hélices antiparalelas), activa para a 
fusão, o que leva à aproximação das membranas celular e viral. Na estrutura em hairpin 
a região NHR forma três hélices centrais arranjadas num superenrolamento trimérico, 
enquanto que a região CHR forma três hélices exteriores que encaixam de um modo 
antiparalelo em cavidades hidrófobas na superfície do superenrolamento. O que ocorre 
desde a aproximação das membranas até à fusão completa não está clarificado mas 
parece envolver a formação de agregados dos trímeros da proteína do envelope para 
formar poros de fusão.  
O tratamento mais comum para os doentes com SIDA baseia-se na aplicação de 
combinações de drogas anti-VIH, nomeadamente inibidores do transcriptase reversa e 
do protease, dois enzimas virais com importância ao nível da replicação do vírus. 
Apesar dos benefícios do uso destas drogas, a sua utilização é limitada devido os seus 
efeitos tóxicos e aparecimento de estirpes resistentes. Assim, tornou-se óbvia a 
necessidade de desenvolvimento de drogas mais eficientes, menos tóxicas e que 
permitam eliminar os efeitos adversos associados à acção das drogas no interior das 
células. 
Do trabalho científico desenvolvido nos últimos anos, resultaram fármacos que têm 
como objectivo actuar ao nível da entrada do vírus nas células, nomeadamente, na 
ligação da gp120 ao CD4, na ligação da gp120 aos co-receptores e na fusão do envelope 
do vírus com a membrana alvo. Apesar da enorme quantidade de compostos em 
desenvolvimento e até em fase de testes clínicos, o T20 (também chamado Enfuvirtide 
ou pelo nome comercial da marca Fuzeon), um inibidor de fusão, é o único já aprovado 
para aplicação clínica. No entanto, apesar da sua comprovada eficácia clínica, não há 
consenso sobre o seu modo de actuação ao nível molecular. O mecanismo de acção 
mais aceite envolve a interacção do T20 com a região NHR da gp41, na fase de pré-
hairpin, impedindo a formação da estrutura em hairpin e deste modo a fusão viral com 
a membrana celular.  
As membranas biológicas são entidades complexas, constituídas principalmente por 
lípidos e proteínas, que limitam as células, constituindo uma barreira entre o meio 
exterior e interior. A base estrutural das biomembranas é a bicamada lipídica. No 
entanto, a distribuição lipídica nas biomembranas pode ser assimétrica levando a que as 
duas camadas tenham uma composição lipídica diferente. Além disso, apesar de grande 
parte dos lipídos na bicamada formarem uma mistura uniforme e homogénea na 
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chamada fase fluida, podem ocorrer heterogeneidades laterais, ou domínios, com 
composições lipídicas distintas. Os rafts lipídicos, são domínios encontrados nas 
membranas plasmáticas que são enriquecidos em colesterol e esfingolípidos. Estes 
domínios existem numa fase de líquido ordenado que é mais ordenada e compacta que o 
resto da bicamada, em fase fluida. Tem sido proposto que os rafts podem funcionar 
como plataformas para a reunião de complexos macromoleculares associados a 
membranas com importância ao nível de vários processos celulares, entrada de vírus 
como o VIH-1 para as células (uma vez que receptores e co-receptores se encontram 
provavelmente associados a rafts) e a formação de vírus a partir da célula infectada. De 
resto, a membrana deste vírus é muito enriquecida em colesterol e esfingolípidos, 
relativamente aos níveis encontrados nas membranas das células alvo, sendo sugerido 
que isso se deve ao facto de a formação dos novos vírus se fazer através de rafts 
lipídicos. O colesterol possui um papel central uma vez que mantém os rafts num estado 
funcional.  
O estudo da interacção entre péptidos e/ou proteínas e biomembranas é muitas vezes 
necessário de modo a clarificar alguns processos em que ambos estejam envolvidos. No 
entanto, as membranas biológicas são sistemas demasiado complexos para serem usadas 
como tal neste tipo de estudo. Uma alternativa viável é o estudo destas interacções em 
sistemas modelo de membranas, nomeadamente vesículas lipídicas unilamelares. 
Podendo ser preparadas em diferentes tamanhos, foram no presente trabalho utilizados 
na sua maioria vesículas unilamelares grandes com diâmetro aproximado de 100 nm. 
Estes sistemas miméticos de membranas biológicas permitem uma base de estudo 
simplificada em simultâneo com a manutenção das principais propriedades das 
biomembranas.  
Os estudos realizados ao longo deste trabalho foram essencialmente biofísicos, 
baseados em técnicas de espectroscopia de fluorescência, dado o facto de os péptidos e 
proteínas estudados serem intrinsecamente fluorescentes sem necessidade de 
acoplamento de sondas.  
O T20, um péptido sintético que corresponde a uma sequência linear da gp41 do 
VIH-1 (entre o terminal C da região CHR e o terminal N da MPR), é um potente 
inibidor da fusão deste vírus. Apesar de estar aprovado para uso clínico, não existe 
ainda consenso acerca da sua acção ao nível molecular. Investigou-se a possível 
existência de um papel para as membranas lipídicas no modo de acção do T20, sendo 
que este envolvimento é sugerido tanto pela estrutura secundária do péptido, como por 
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estudos de hidrofobicidade teórica e por trabalhos já publicados. Os resultados obtidos 
permitem inferir um modelo para descrever a acção do T20. O T20 insere-se na 
membrana principalmente nas zonas mais fluidas, ao nível da camada externa da 
bicamada lipídica. Devido ao elevado conteúdo em colesterol do envelope do vírus, o 
T20 não tem tendência a ligar-se a este. Assim, o T20 concentra-se na membrana celular 
podendo esta funcionar como um reservatório. No entanto, a concentração do T20 no 
ambiente aquoso pode ficar suficientemente elevada de modo a permitir ligação à gp41, 
inibindo deste modo o processo de fusão pelo modelo de acção mais aceite. Por outro 
lado, a ligação do T20 à membrana pode possibilitar a sua ligação a outras regiões da 
gp41, diferentes da ligação que ocorre em solução aquosa, e que também permitem o 
bloqueio da fusão. 
O T-1249 é um péptido inibidor de fusão do VIH-1 de segunda geração, mais 
potente do que o T20 e activo em estirpes que apresentam resistência à inibição pelo 
T20. Este péptido foi obtido através de técnicas de design de drogas, sendo composto 
por sequências do VIH-1, VIH-2 e do vírus da imunodeficiência símio (VIS). Não 
havendo também consenso sobre o seu mecanismo de acção e tendo em conta os 
resultados obtidos com o T20, a interacção deste pétido com membranas lipídicas foi 
também investigada. Tal como o T20, o T-1249 insere-se na camada externa da 
bicamada lipídica, nas zonas fluídas da membrana. No entanto, ao contrário do T20, o 
T-1249 tem a capacidade de adsorver a domínios ricos em colesterol. Esta capacidade 
aumenta a concentração local de T-1249 quer nas zonas da célula onde ocorre a fusão, 
os rafts lipídicos, quer na membrana do vírus, também rica em colesterol. Assim, tanto 
a membrana da célula como a membrana do vírus podem funcionar como um 
reservatório de péptido. O aumento da eficácia clínica do T-1249 em relação ao T20 
pode estar relacionada com as diferenças da interacção de ambos com as membranas, 
descritas para os dois inibidores.  
O SARS-CoV é um novo coronavírus identificado como o agente causador do 
síndrome respiratório agudo. A glicoproteína S do envelope do vírus é responsável, à 
semelhança da gp120/gp41, pela entrada do vírus nas células alvo. Alguns estudos 
apontam para um mecanismo de entrada na célula semelhante ao usado pelo VIH-1. 
Sendo um novo vírus não estão ainda disponíveis medicamentos específicos para o 
inibir. Dadas as semelhanças entre os dois vírus e com base numa análise estrutural da 
gp41 e da proteína S2, foi proposto que o T20 poderia inibir a fusão do SARS-CoV, 
através de um mecanismo semelhante ao mais aceite, ou seja, a inibição da formação da 
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estrutura em hairpin. Num estudo efectuado no âmbito desta tese foi investigado o 
potencial do T20 e T-1249 para inibirem o SARS-CoV. Os resultados obtidos permitem 
concluir que apesar de ocorrer a interacção entre o T20 e o T-1249 e a região NHR do 
vírus, que pode levar à inibição do SARS-CoV, esta ligação pode não ser 
suficientemente forte para conseguir uma inibição efectiva.  
 A MPR no ectodomínio da gp41 do VIH-1 tem um papel chave no processo de 
fusão viral. Tem-se mostrado que esta região tem a capacidade de interactuar com 
membranas e provocar a sua destabilização, num processo semelhante à acção do 
péptido de fusão na membrana alvo. Dada a proximidade entre esta região e a 
membrana do vírus o efeito deve ser exercido sobre esta. Além disso, esta região 
contém uma pequena sequência normalmente definida como um domínio de ligação 
preferencial ao colesterol. Investigou-se a influência do colesterol na interacção com 
membranas de péptidos correspondentes à MPR como um todo e sem a sequência de 
ligação específica ao colesterol, e de um péptido correspondente apenas ao domínio de 
ligação ao colesterol. Propõe-se que a MPR pode ter uma função muito específica no 
processo de fusão viral de membranas, através da acção concertada de domínios de 
ligação ao colesterol e domínios que não ligam ao colesterol.  
 O 2F5 e o 4E10 são dois anticorpos com uma acção potente contra o VIH-1, cujos 
epitopos se encontram localizados na MPR no ectodomínio da gp41. Tem sido sugerido 
que as membranas lipídicas, mais concretamente a membrana do vírus, podem ter um 
papel no mecanismo de acção destes anticorpos, que ainda não é conhecido. Alguns 
estudos propuseram que estes anticorpos podem interactuar com a membrana viral 
através de uma superfíce hidrófoba presente numa das cadeias pesadas.  Estudou-se a 
interacção do 2F5 e do 4E10 com modelos de biomembranas, na presença e na ausência 
de um péptido que contempla o epitopo de ambos, de modo a investigar o possível 
papel das membranas no seu modo de acção. Tanto o 2F5 como o 4E10 têm a 
capacidade de interactuar com membranas, interacção mais fraca no caso do 2F5, e com 
o seu epitopo quando este está presente nas mesmas. Esta capacidade pode ser uma 
adaptação dos anticorpos para se ligarem a um epitopo que está tão próximo da 
membrana ou devido à existência de uma dependência da membrana na conformação do 
epitopo óptima para a ligação.  
 
 
 
Palavras Chave: HIV-1; gp41; membranas; T20; CHR; MPR 
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SUMMARY 
 
 The HIV-1 envelope glycoprotein complex plays an important role in viral entry. Its 
surface subunit gp120 is responsible for virus binding to cellular receptors, and the 
transmembrane subunit gp41 mediates fusion of the virus with the target cell. Different 
functional regions can be identified in gp41, each one with importance in the fusion 
process.  
 T20 and T-1249 are two HIV-1 fusion inhibitor peptides, being T20 already 
approved for clinical application in AIDS treatment. The work here presented describes 
research on the role of biomembranes on their mode of action. A model for the role of 
biomembranes was proposed. 
 Given the similarities between the HIV-1 and SARS-CoV, and the urgency to obtain 
licensed drugs to treat SARS, the possibility that T20 and T-1249 can work as SARS-
CoV inhibitors was investigated. The results obtained show that despite the hypothesis 
that T20 could inhibit SARS-CoV fusion is correct, the effect may not be strong enough 
for practical application. 
 A small sequence inside the HIV-1 gp41 ectodomain membrane proximal region 
(MPR) is commonly referred to as a cholesterol binding domain. As the MPR plays a 
key role in the HIV-1 fusion process and the viral envelope is rich in cholesterol, the 
influence of cholesterol on the interaction of the MPR derived peptides with membrane 
model systems was studied.  
 2F5 and 4E10 are two potent and broadly neutralizing antibodies against HIV-1, 
whose epitopes are localized in the gp41 MPR. It was proposed that these antibodies 
can interact with the viral membrane trough a hydrophobic surface present on their third 
complementarity-determining region of the heavy chain. The 2F5 and 4E10 interactions 
with biomembranes models, in the absence and presence of its epitopes, were 
investigated in order to reveal the membranes role in the antibodies mechanism of 
action. 
 
 
 
 
 
Key words: HIV-1; gp41; membranes; T20; CHR; MPR 
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Chapter I 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
1. HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
 
Human Immunodeficiency Virus (HIV) is the causative agent of the acquired 
immunodeficiency syndrome (AIDS). There are two types of HIV, HIV-1 and HIV-2, 
being the HIV-1 the most virulent (Weiss, 2000; Janeway et al., 2001). HIV can be 
transmitted by blood and blood products, vertically (from mother to child), or through 
sexual activity. By the end of 2006 the United Nations Programme on AIDS 
(UNAIDS)/World Health Organization (WHO) epidemic update estimated 39.5 million 
(34.1-47.1 million) of people worldwide living with HIV (UNAIDS/WHO AIDS 
epidemic update, http://www.unaids.org/en/HIV_data/epi2006/default.asp). Despite the 
efforts, no curative treatment or effective vaccine has yet been achieved. 
 
1.1 HIV replication cycle and antiviral strategies 
 
HIV-1 is an enveloped virus (member of the Lentivirus subfamily of the retrovirus 
family (Weiss et al., 2000)) that infects CD4 T cells, dendritic cells and macrophages 
(Janeway et al., 2001). The viral envelope, derived from the host cell membrane, is 
composed of a lipid bilayer and has at the surface a glycoprotein complex that allows 
the virus to enter in target cells. The envelope glycoprotein complex is initially 
synthesized as a single chain glycoprotein precursor (gp160) which is proteolytically 
cleaved by a cellular protease to generate the gp120 (surface glycoprotein) and the gp41 
(transmembrane glycoprotein) subunits. The virus contains also a viral capsid 
(constituted by the capsid protein), two copies of the viral genome and three essential 
enzymes: reverse transcriptase, integrase and protease (Figure I.1). Additionally the 
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virus has structural and accessory proteins important to the structural integrity and the 
virus replication process (reviewed in Vaishnav and Wong-Staal, 1991; Turner and 
Summers, 1999).  
 
 
 
Figure I.1 – Simplified representation of the HIV-1. The reverse transcriptase, integrase, and 
viral protease enzymes are packed in the viral capsid (in reality, many molecules of these 
enzymes are contained in each virion). The glycoprotein complex, at the surface of the viral 
envelope, is composed by the subunits gp120 and gp41. For simplicity, the other virus proteins 
were omitted (from Janeway et al., 2001). 
 
An outline of the HIV-1 replication cycle is shown in Figure I.2. The gp120 on the 
surface of the virus binds to the CD4 receptor on the surface of the target cells 
activating the process that leads to membrane fusion and subsequent viral entry. Once 
inside the cell the viral RNA genome is transcribed into viral DNA by the action of the 
viral reverse transcriptase. The later is inserted into the host cell genome by the viral 
integrase. The RNA transcripts produced from the integrated viral DNA serve both as 
mRNA to the synthesis of the viral proteins (in the form of polyprotein precursors) and 
as the RNA genome of new viral particles. New viral particles escape from the cell after 
budding at the plasma membrane. Then, the viral protease acts cleaving the polyproteins 
to produce independent and functional viral proteins. The final maturation process leads 
to the formation of infectious virions (reviewed in Vaishnav and Wong-Staal, 1991; 
Turner and Summers, 1999).  
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Figure I.2 – HIV replication cycle. The HIV life cycle presented shows the binding of the virus 
to CD4 and coreceptor on the surface of the target cell, followed by membranes fusion and viral 
entry; reverse transcription, integration and protein synthesis processes are also shown; 
processing, virus assembly, budding and maturation of nascent virions are the last steps 
(adapted from Reeves and Piefer, 2005). 
 
 Currently, there are three U.S. Food and Drug Administration (FDA)-approved 
classes of drugs to the treatment of HIV-1 infection: 1) reverse transcriptase inhibitors 
(RTIs), including nucleoside or nucleotide and non-nucleoside molecules; 2) protease 
inhibitors (PIs) and 3) entry inhibitors (only one drug was approved). Both RTIs and PIs 
act on post-entry steps of the virus on the cells. Combination therapy with RTIs and PIs 
(called highly active antiretroviral therapy, HAART), involving at least three drugs, is 
the most common current treatment of HIV-1 infection (reviewed in Gulick, 2003; Stolk 
and Lüers, 2004; Yeni, 2006). Despite the success of this therapy in reducing morbidity 
and mortality of HIV-1 infected patients (Palella et al., 1998; Mocroft et al., 2000; Li et 
al., 2000; Louie and Markowitz, 2002), the adverse effects and the emergence of drug 
resistant HIV-1 strains have limited its application (Brinkman et al., 1998; Carr et al., 
1999; Yerly et al., 1999; Hirsh et al., 1998; Carr, 2003). In an attempt to overcome these 
problems a third class of antiviral agents, the entry inhibitors, are receiving a lot of 
attention and large development. These inhibitors act extracellularly, targeting the first 
step in the HIV-1 replication cycle, i.e. preventing viral entry into target cells (reviewed 
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in Eckert and Kim, 2001a; LaBranche et al., 2001; O’Hara and Olson, 2002; Moore and 
Doms, 2003). 
 
1.2 HIV entry and its inhibition 
 
The HIV-1 envelope glycoprotein, expressed on the surface of the viral membrane 
as a trimer (Center et al., 2002), is composed of two subunits noncovalently associated 
(gp120 and gp41). The gp120 subunit interacts with cellular receptors and the gp41 
subunit is responsible for the fusion between the viral and cellular membranes 
(reviewed in Wyatt and Sodorski, 1998; Chan and Kim, 1998; Eckert and Kim, 2001a). 
The gp120/gp41 complex native conformation is not known in detail. Monomeric 
crystal structures of gp120 have been solved (Kwong et al., 1998; Wyatt et al., 1998) 
but no further information was achieved. Recent studies on the structure of the envelope 
glycoprotein complex showed contradictory results. For Zhu and colleagues a large 
globular domain comprises a gp120 trimer while the gp41 appears to form an open 
tripod (Zhu et al., 2006). The model derived by Zanetti et al. has the form of a 
mushroom with a more compact head domain and a gp41 stalk, rather than tripod legs 
(Zanetti et al., 2006). It was also proposed that the gp41 is folded in such way that 
brings the N- and C- terminal close to each other, stabilizing the native structure 
(Lorizate et al., 2006). 
 
gp41 is composed of an ectodomain (extracellular domain), a transmembrane 
domain (TM) and an endodomain (intracellular domain or cytoplasm tail (CT)) (Figure 
I.3). Several functional domains have been identified in the ectodomain. The fusion 
peptide (FP) is located at the ectodomain N-terminal. This region, hydrophobic and rich 
in glycine residues, interacts with the target cell membrane and plays an important role 
in membrane fusion (reviewed in Tamm and Han, 2000; Epand, 2003). Two heptad 
repeat regions (HR) are also included: the first (NHR or HR1) near the N-terminal is 
adjacent to the FP; the second (CHR or HR2) is located at the ectodomain C-terminal. 
As observed for other viral fusion proteins, the regions that follow the FP, NHR and 
CHR, have the tendency to form α-helical coiled-coils (Chambers et al., 1990), denoted 
respectively, N- and C-helices. Peptides derived from these regions are referred to as N- 
and C-peptides, respectively. The two HR are separated by a loop region (LR) that 
contains an intramolecular cysteine bridge. At the C-terminal between the CHR and the 
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TM is located a Trp-rich region, the membrane proximal region (MPR). Protein 
dissection combined with biophysical analysis demonstrated that the two HR regions 
within gp41 form a helical trimer of antiparallel dimers (Lu et al., 1995). The crystal 
structures of portions of the ectodomain (Chan et al., 1997; Tan et al., 1997; 
Weissenhorm et al., 1997) confirmed that the gp41 core tends to form a trimer of 
hairpins (or six-helix bundle (6HB)). Therefore, the N and C helices are arranged in a 
trimeric coiled coil. A central trimeric coiled coil formed by the N-peptide region is 
surrounded by three helical C-peptides that bind to conserved hydrophobic grooves on 
the coiled-coil surface in an antiparallel orientation. This structure represents the fusion-
active conformation of gp41.  
 
Figure I.3 – Schematic view of gp41 showing the location of the fusion peptide (FP), the N- 
and C-terminal heptad repeat regions (NHR and CHR), the loop region (LR), the membrane 
proximal region (MPR), the transmembrane domain (TM) and the cytoplasm tail (CT). 
 
HIV-1 entry into target cells (Figure I.4) is believed to be a multi-step and complex 
process (reviewed in Chan and Kim, 1998; Eckert and Kim, 2001a). The first step is the 
binding of gp120 to the target cell surface molecule CD4, which serves as the main 
receptor for HIV-1 (Maddon et al., 1986). However, CD4 alone is not sufficient for 
HIV-1 to fuse with the cells (Chesebro et al., 1990; Clapham et al., 1991). Two 
chemokine receptors, known as CCR5 and CXCR4, are the major HIV-1 coreceptors 
and all strains can use one (R5 and X4 viruses) or both (R5X4 viruses). CCR5 is 
particularly important as a coreceptor because R5 viruses are responsible for almost all 
cases of HIV-1 transmission and predominate during the early events of infection. X4 
and R5X4 viruses emerge in many but not all infected individuals in the late stages of 
the infection (reviewed in Moore et al., 1997; Berger et al., 1999; Clapham and 
 FP     NHR     CHR 
S S
 LR 
 TM 
MPR 
CT 
endodomain ectodomain 
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McKnight, 2002; Douek et al., 2003). The gp120-CD4 binding induces conformational 
changes in gp120 leading to the exposure or the formation of the coreceptor binding 
site. gp120 binding to the CD4 and coreceptor results in further conformational changes 
that lead to gp41 activation into its fusion-active state. The gp41 conformational 
changes leads to the insertion of its FP into the target cell membrane and the formation 
of a prehairpin intermediate that bridges the viral and cellular membranes. Subsequent 
changes within the gp41 ectodomain involve the interaction of CHR and NHR, and a 
6HB structure (also called hairpin structure) is formed. The hairpin formation brings the 
viral and cell membrane into closed proximity, allowing fusion of the membranes and 
then entry of the virus. It is likely that the free energy released with the 6HB formation 
must be sufficient to membranes fusion to occur. In fact it was demonstrated that fusion 
is caused by the movement of the protein into the 6HB rather than by the 6HB itself 
(Melikyan et al., 2000). Despite this widely accepted viral entry model, accumulation of 
new data indicates the model needs revision. Gallo et al. proposed that the gp120-CD4 
interaction triggers the prehairpin intermediate formation and that coreceptor binding 
leads to rapid 6HB formation (Gallo et al., 2001; Gallo et al., 2004). Also, the formation 
of the 6HB might not be complete until the fusion pore complex is formed. Some data 
suggest that the formation of some 6HB occur after a fusion pore has formed and in this 
way the essential role of this structure is to stabilize the fusion pore against collapse and 
ensure its growth (Markosyan et al., 2003).  
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Figure I.4 – HIV entry process. The fusion process for the trimeric envelope glycoprotein 
complex is depicted in schematic form. The sequential binding of the gp120 to CD4 and a 
coreceptor on the cell membrane drives conformational changes in gp41. These changes cause 
the insertion of the FP into the cell membrane and the formation of the prehairpin intermediate. 
Subsequent gp41 conformational changes create the 6HB, and the viral and cellular membranes 
are brought into close proximity for fusion to occur (adapted from Liu et al., 2007b). 
 
Each of the HIV-1 entry steps can be a target for entry inhibitors. The ones currently 
under development fall into three categories: gp120-CD4 binding inhibitors (or 
attachment inhibitors), gp120-coreceptors binding inhibitors (or chemokine coreceptors 
inhibitors) and fusion inhibitors (reviewed in De Clercq, 2004; Reeves and Piefer, 2005; 
Briz et al., 2006). Inhibitors that block the gp120-CD4 interaction include compounds 
that interact with the gp120 or CD4. PRO 542 (CD4-IgG2) is a recombinant tetrameric 
CD4-IgG2 fusion protein, which binds to gp120 (Allaway et al., 1995). BMS 806 (BMS 
378806) is a small molecule inhibitor with potent antiviral activity. Firstly reported to 
binds directly to gp120 (Guo et al., 2003) it was proposed later that it should interfere 
with gp41 CD4-induced conformational changes (Si et al., 2004). TNX 355 (Hu5A8) is 
a CD4 specific MAb that binds to domain 2 of the CD4 receptor (Burkly et al., 1992). 
The antiviral agent cyclotriazadisulfonamide (CADA) exerts its effect by down-
modulating the CD4 receptor (Vermeire et al., 2002). Several types of coreceptors 
inhibitors have been identified, namely low molecular weight CXCR4 and CCR5 
antagonists. These include AMD 070 (Schols et al., 2003) and KRH-1636 (Ichiyama et 
al., 2003) for CXCR4 and Schering D (Tagat et al., 2004), TAK 220 (De Clercq, 2004) 
and AK602 (Maeda et al., 2004) for CCR5. Fusion inhibitors such as T20 (also known 
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as DP-178, Enfuvirtide, or Fuzeon) and T-1249 (Tifuvirtide) are compounds whose 
mode of action involves binding to gp41 and interfere with the conformational changes 
that lead to the 6HB formation and membrane fusion. These kinds of inhibitors are the 
leading compounds, being T20 the most advanced and already approved by the FDA 
(Kilby and Eron, 2003; Robertson, 2003). 
 
1.3 HIV fusion inhibitors 
 
Some synthetic C-peptides, such as C34 and T20, are potent inhibitors of HIV-1 
infection (Wild et al., 1994a; Kilby et al., 1998). Despite being more potent, C34 is not 
a good candidate to a drug due to its low solubility (Otaka et al., 2002). C34 has been 
used in studies of HIV entry blocking by peptides, while T20 was developed as a novel 
anti-HIV drug. C34 sequence includes residues at the N-terminal that precede the T20 
sequence (Figure I.5). These residues include those that pack into the hydrophobic 
pocket on the surface of the N-peptide coiled coil in the 6HB conformation, and are 
critical for its antiviral activity (Chan et al., 1998). C34 lacks the T20 C-terminal 
residues that are crucial to T20 inhibitory activity. It has been proposed that these C-
peptides act by interfering with the formation of the 6HB in a dominant negative 
fashion, by binding to the NHR region exposed in the prehairpin intermediate (Lu et al., 
1995; Chen et al., 1995; Furuta et al., 1998; Chan and Kim, 1998; Kilgore et al., 2003). 
Despite synthetic N-peptides exhibit also inhibitory activity against HIV, they are less 
potent inhibitors than the C-peptides (Wild et al., 1992; Lu et al., 1995; Eckert and Kim, 
2001b). It was proposed that one of the main reasons for this behaviour is their tendency 
to aggregate in solution (Lu et al., 1995). N36 and DP107 are examples of N-peptide 
inhibitors (Figure I.5). In their mode of action, N-peptides may either target the CHR 
region (Lu et al., 1995) or intercalate with the NHR region (Wild et al., 1992; Wild et 
al., 1994b; Weng and Weiss, 1998). Based on the knowledge gathered on the structure, 
activity and function of these inhibitors, several modified peptides have been created, in 
an attempt to achieve better fusion inhibitors (reviewed in Liu et al., 2007a). One of 
these is the rationally designed, second generation fusion inhibitor T-1249, more potent 
than T20 and active against T20 resistant HIV-1 isolates (Greenberg et al., 2002). 
Another line of research is the design of recombinant proteins containing sequences of 
the gp41 NHR and/or CHR regions, which may act in a similar way as the N- and C-
peptides. 5-Helix inhibitor, for instance, consists of three N-peptides and two C-
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peptides connected by short linkers (Root et al., 2001). This inhibitor binds to the CHR 
region with high affinity and efficiently inhibits HIV-1 infection.  
 
 
Figure I.5 – Peptide inhibitors from the NHR and CHR regions of gp41. The sequences of N-
peptides N36 (residues 546-581) and DP107 (residues 553-590) are derived from the NHR 
region. The sequence of C-peptide C34 (residues 628-661) is derived from the CHR region, 
while that of T20 (residues 638-673) is derived from the CHR region and the MPR. 
 
The potency of the antiviral activity of these fusion inhibitors peptides targeting the 
gp41 stimulated the search for small molecules with the same function (reviewed in Liu 
et al., 2007a). Non-peptidic small molecules can be used as an alternative and have the 
advantage of being easier to mass-produce and purify, and may be orally bioavailable. 
Peptides lack oral bioavailability, and need to be injectable since they are degraded in 
the digestive track. Moreover, they can be subjected to metabolic degradation and have 
a high cost of production. 
 
1.4 Anti-HIV antibodies 
 
The antibody (Ab) response to HIV is directed to several viral proteins. In HIV-1 
infected individuals Abs against different proteins, including gp120 and gp41, are 
detectable (Pellegrin et al., 1996; Pilgrim et al., 1997; Richman et al., 2003; Aasa-
Chapman et al., 2004). However, only a fraction of the Abs are neutralizing (Wyatt and 
Sodroski, 1998), i.e. Abs that neutralize HIV-1 prior to its entry into target cells. On 
HIV-1 the envelope glycoprotein complex gp120/gp41 is the only viral target available 
for neutralizing Abs (Figure I.6). Neutralizing Abs target in the gp120, the CD4 binding 
 FP    NHR     CHR  TM MPR CT 
DP107                      NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ  
N36        SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 
C34          WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL 
T20                                       YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 
Introduction 
 10 
domain, carbohydrate structures, the CD4-induced coreceptor binding domains and in 
the gp41, structures that are exposed during membrane fusion (Wyatt and Sodroski, 
1998). Nevertheless, due to the envelope glycoprotein complex features, such as the 
extensive glycosilation, the occlusion of conserved domains within the oligomeric 
structure, and the transiently exposure during the viral entry process, potent neutralizing 
monoclonal Abs (MAbs) targeting these proteins are rare (reviewed in Wyatt and 
Sodroski, 1998; Ferrantelli and Ruprecht, 2002). Neutralizing MAbs against gp120 are 
directed predominantly to the CD4 binding domain and both the second and third 
hypervariable loops (V2 loop and V3 loop, respectively). Those that have been found to 
bind the gp41 ectodomain, target the MPR (reviewed in Zolla-Pazner, 2004). However, 
only few human MAbs with potent and broadly neutralizing activity have been isolated 
(Figure I.6). Of these, 2G12 and b12 bind to gp120 while 2F5, 4E10 and Z13 are 
directed to the MPR within gp41 (reviewed in Zolla-Pazner, 2004; Phogat et al., 2007). 
 
Figure I.6 – (A) The viral envelope glycoproteins gp120 and gp41 are targets for neutralizing 
Abs. Neutralizing Abs may also bind to cellular receptors sites implicated in HIV-1 entry as 
CD4 and CCR5. (B) The two broadly neutralizing MAbs to gp41, 2F5 and 4E10, bind to 
epitopes in the MPR; whereas 2G12 and b12 are the two broadly neutralizing gp120 Abs 
(adapted from Phogat et al., 2007). 
A B 
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2. BIOLOGICAL MEMBRANES 
 
Biological membranes, consisting primarily of proteins and lipids, are essential for 
the integrity and functionality of cells, providing a barrier between the inside and 
outside environments. In eukaryotic cells internal membranes also form the boundaries 
of organelles. Despite the biomembranes complexity, a lipid bilayer is its primary 
structural element. Due to the amphipatic nature of the component lipids, the bilayer 
presents a hydrocarbon environment in the interior core with the polar groups oriented 
toward the water phase (Figure I.7). Biomembranes are not only physical barriers. They 
are highly selective permeability barriers that control the transfer of information and the 
transport of ions and molecules between the inside and the outside of the cell. 
Biomembranes serve as the matrix and support for several proteins, which are involved 
in important functions of the cell as energy and signal transduction, solute transport, 
protein targeting and trafficking (Edidin, 2003a).  
 
Figure I.7 – Schematic depiction of a lipid bilayer. The lipid bilayer surrounds and protects the 
cell from its environment. In a bilayer, the lipids hydrophilic head group of is oriented toward 
the water phase, while the hydrocarbon tails form the inner hydrophobic part (adapted from 
Menger et al., 2005). 
 
2.1 Biological membranes lipid composition 
 
Cell membranes are extremely complex having many different lipids. However, four 
main types of lipids occur in biological membranes: glycerophospholipids, 
phosphosphingolipids, sterols and glycolipids (reviewed in Gennis, 1989; Zubay, 1998; 
Loura and de Almeida, 2004).  
 
Polar head groups 
Hydrophobic chains   
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Glycerophospholipids are the predominant class of lipids in biomembranes. Its 
hydrophobic section is composed of hydrocarbon chains esterified to sn-1 and sn-2 
positions of the glycerol backbone. These hydrocarbon chains are diverse in length and 
unsaturation. The sn-3 position is esterified to phosphoric acid. If no more groups are 
linked to the molecule, the resulting compound is phospatidic acid (PA). However, the 
phosphate group is generally linked to other group as choline (Figure I.8 A), 
ethanolamine, serine, glycerol, and inositol. The corresponding phospholipids are 
phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylcholine (PC), 
phosphatidylglycerol (PG), and phosphatidylinositol (PI). As the phosphate group is 
always negatively charged, the net charge of the molecule depends on the charge of the 
polar group moiety. In this way PG, PS, PI are negatively charged, while PC and PE 
have a net neutral charge. PC is the most abundant phospholipid of animal cell 
membranes, whereas PE is the major component in bacterial membranes (Gennis, 1989; 
Loura and de Almeida, 2004). 
 
 
Figure I.8 – Structure of a phosphatidylcholine, 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphocoline (POPC) (A) and sphingomyelin (Egg, chicken) (B) (from 
www.avantilipids.com). 
 
In phosphosphingolipids the hydrophobic group is a ceramide. Sphingolipids are rich in 
long and saturated hydrocarbon chains. Rarely found in plants and bacteria, 
sphingomyelin (SM) is the most abundant phosphosphingolipid in animal cell plasma 
membranes (Figure I.8 B). SM is structurally similar to PC. Both molecules have two 
long hydrocarbon side chains and a negatively charged phosphate group esterified to a 
choline.  
 
The basic structure of sterols is a four-ring hydrocarbon. In cholesterol (Chol), the most 
important sterol in animal membranes, the molecular structure includes a tetracyclic 
A 
B 
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fused ring skeleton, with a single hydroxyl group at carbon 3, a double bond between 
carbons 5 and 6, and a iso-octyl hydrocarbon side chain at carbon 17. The hydroxyl 
group gives Chol its slight amphipatic character and orients the molecule in membranes. 
Chol orients in a lipid bilayer with its polar hydroxyl group towards the aqueous phase 
and the hydrophobic ring system oriented parallel to, and buried in the hydrocarbon 
chains of the phospholipids. Other sterols are found in plant and yeast and other 
eukaryotic micro-organisms.  
 
In glycoglycerolipids the sn-3 position of glycerol forms a glycosidic link to a 
carbohydrate. This kind of lipids is abundant in chloroplast membranes, blue algae and 
bacteria, but rarely found in animals. Glycosphingolipids have a glycosidic linkage to 
the terminal hydroxyl of ceramide. The simplest form of glycosphingolipid is a 
cerebroside that contains a single glycosidic residue. Glycosphingolipids are located in 
the outer surface of the plasma membrane and are particularly abundant in the nervous 
system.  
 
2.2 Biological membranes asymmetry and heterogeneity 
 
Lipids in the plasma membrane are asymmetrically distributed, i.e., the two 
membrane leaflets have a different lipid composition. The outer leaflet of an animal cell 
plasma membrane is mainly composed by SM and PC, while the inner leaflet has a 
mixture of predominantly PE and PS (Zachowski, 1993). Several functional roles for 
this asymmetric distribution have been suggested. These include several proteins that 
appear to localize in the cytoplasmic face of the membrane trough their interaction with 
PS (Palfrey and Waseem, 1985; Meers and Mealy, 1993; MacDonald, 1993; O’Toole et 
al., 1999). Disruption of lipid asymmetry leads to exposure of PS on the outer surface of 
the plasma membrane that serves as a trigger for macrophage recognition of apoptotic 
cells (Fadok et al., 1992; Bratton et al., 1997; Shiratsuchi et al., 1997). 
 
In the Singer-Nicolson fluid mosaic model of biological membranes, bilayer lipids 
form a uniform and homogeneous fluid mixture, where lipid and proteins could move 
freely. Proteins are free to diffuse laterally or to rotate about an axis perpendicular to the 
plane of the membrane (Singer and Nicolson, 1972). However, the Singer-Nicolson 
model is now regarded as a simplistic description of the complex interactions and 
Introduction 
 14 
dynamics existent, namely by the presence of lateral heterogeneities like domains with 
distinct compositions. Examples of these are the apical and basolateral membranes of 
polarized epithelial cells that have distinct compositions, protein aggregation that result 
in domains that are enriched in a particular protein and lipid microdomains.  
 
2.3 Lipid rafts 
 
The fluidity of lipid bilayers is a function of temperature, pressure and lipid 
composition (length of the hydrocarbon chains and head group composition). The bulk 
of lipids in biomembranes are generally in the fluid liquid crystalline phase, and this 
state is essential for normal cell function (White et al., 2001). Pure phospholipid 
membranes show a temperature-dependent phase transition (Figure I.9). Phospholipid 
bilayers can exist in an ordered gel phase (So), where the lipid molecules are more 
condensed and the hydrocarbon chains highly ordered. Dependent on the head group 
composition the gel phase is Lβ (for PE) or Lβ’ (for PC). In the Lβ and Lβ’ phases, 
respectively, the chains are ordered parallel or show a tilt angle with the respect to the 
bilayer normal. Above a melting temperature (Tm), characteristic for each lipid, the 
bilayer is present in a phase termed liquid-crystalline or fluid phase (Lα, Ld), in which 
the phospholipid hydrocarbon chains are fluid and disordered (Gennis, 1989; 
Kranenburg and Smit, 2005). Chol has important effects on phase behaviour: decreases 
the order of the gel phase, increases the order of the fluid phase and stabilizes a new 
phase named liquid ordered (Lo). This Lo phase is characterized by high hydrocarbon 
chain order in combination with high lateral mobility in the bilayer, that is, has 
characteristics from both gel- and fluid-phase (Ipsen et al., 1990; Spink et al., 1996). In 
mixtures that comprise appropriate amounts of sphingomyelin, unsaturated 
phospholipids and cholesterol, Lo and Ld phases can co-exist (de Almeida et al., 2003; 
de Almeida et al., 2005).  
 
Figure I.9 – Lipid bilayer gel Lβ (A) and Lβ’ (B) phases and the fluid phase (C) (adapted from 
Kranenburg and Smit, 2005). 
A B C 
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Lipid rafts are described as microdomains enriched in sphingolipids and Chol, that 
are present in the biological membranes organized in a way similar to a liquid ordered 
phase, more ordered that the surrounding fluid membrane (Simons and Ikonen, 1997; 
Edidin, 2003b; Simons and Vaz, 2004). It is believed that lipid rafts can facilitate 
selective protein-protein interactions, by excluding or including proteins. Examples of 
proteins that preferentially partition into raft domains are glycosylphosphatidylinositol 
(GPI)-anchored proteins and cholesterol-binding proteins such as caveolins (Rajendran 
and Simons, 2005). Raft domains are postulated to function as platforms involved in the 
lateral sorting of certain proteins during their trafficking within the cells and signal 
transduction events (Simons and Ikonen, 1997; Edidin, 2003b; Simons and Vaz, 2004). 
However, recent evidence points to an additional role of protein-lipid and protein-
protein interactions in lipid rafts formation and stabilization. These evidence suggests 
that rafts are initially small and unstable but can be captured and stabilized by proteins 
(Jacobson et al., 2007; Hancock, 2007). Several methods have been used to study lipid 
rafts in model and cell membranes (Pike, 2004). Isolation of detergent-resistant 
membranes (DRMs) and disruption of the lipid rafts structure based on Chol-depletion 
are two of the most widely used. However, these methods have limitations and 
undesired effects (Lichtenberg et al., 2005), and despite growing evidence showing the 
rafts existence and importance for cell functions, the presence of these domains in 
biological membranes still controversial (Munro, 2003). In spite of the possibility to 
visualize ordered domains in model membranes (Feigenson and Buboltz, 2001; Silvius, 
2003; Veatch et al., 2004), visualize these domains in native cell membranes has 
revelled difficult. The small rafts size, its dynamic and unstable nature in cell 
membranes makes them difficult to be resolved by conventional microscopy techniques. 
Several techniques have been used to study the size of lipid rafts and their stability in 
vivo (Schütz et al., 2000; Pralle et al., 2000; Dietrich et al., 2002; Bacia et al., 2004) but 
no conclusive results were obtained so far. 
 
2.4 Cholesterol and rafts role on HIV infection 
 
Increasing amount of evidence now suggests that lipid rafts are involved in both 
early and late phases of the HIV-1 replication cycle (reviewed in Campbell et al., 2001),  
as well as in its infectivity. The HIV envelope is enriched in Chol and sphingolipids, 
which are characteristic of lipid rafts (Aloia et al., 1993; Brügger et al., 2006). It was 
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shown that removal of Chol from viral particles almost completely eliminates HIV-1 
infectivity (Campbell et al., 2002; Guyader et al., 2002; Graham et al., 2003; Campbell 
et al., 2004). The studies of the Chol and rafts role in viral entry have shown 
contradictory results. Some groups have shown that CD4 (Fragoso et al., 2003; Popik et 
al., 2002), CCR5 (Mañes et al., 1999; Popik et al., 2002) and, with reserve, CXCR4 
(Popik et al., 2002) localize on lipid rafts. It was proposed that lipid rafts can serve as 
platforms for HIV entry, where the gp120 docking to receptors occurs (Mañes et al., 
2000; Nguyen and Taub, 2002; Popik et al., 2002). However, coreceptors and CD4 may 
localize in different domains and it was suggested that initially HIV-1 binds to CD4 in 
rafts and subsequent interaction with CXCR4 requires the movement of the proteins 
complex out of the rafts (Kozak et al., 2002). A proposal based on Chol depletion of 
target cells indicates that although Chol is not required for viral entry, its depletion from 
cells with low coreceptor densities reduces the ability of gp120 to engage coreceptor 
clusters required to activate fusion (Viard et al., 2002). Additionally it was proposed 
that the presence of HIV-1 receptors in rafts is not required for viral infection and that 
Chol modulates the viral entry process independently of its ability to promote raft 
formation (Percherancier et al., 2003).  
It has been suggested that viral budding occurs in cell membrane lipid raft domains 
(Nguyen and Hildreth, 2000, Ono and Freed, 2001; Pickl et al., 2001), what may 
explain the high level of Chol and sphingolipids in the viral membrane. 
 
2.5 Membrane model systems 
 
Given biomembranes complexity, the study of the lipid bilayer structure and 
properties is very important. The use of membrane model systems enables a simplified 
basis for these studies, while maintaining the main properties of the biomembranes. 
Models systems can be prepared with pure lipids or a mixture of lipids. There are 
different types of membrane model systems such as: lipid monolayers at an air-water 
interface; planar bilayers (also called black lipid membranes or BLMs); and lipid 
vesicles (or liposomes), which are probably the most popular models. 
Liposomes preparation (Figure I.10) requires solubilization of lipids in organic 
solvents, followed by drying into a film and ressuspension in an aqueous environment. 
Suspensions of liposomes prepared in this manner form multilamellar vesicles (MLVs). 
MLVs are constituted by a heterogeneous mixture of vesicular structures which contain 
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multiple bilayers forming groups of concentric shells. Due to the size of the MLVs 
particles light scattering is very significant, which could difficult its application in 
photophysical studies. In this way, different strategies were created in order to obtain 
unilamellar liposomes (Menger et al., 2005). The so called small unilamellar vesicles 
(SUVs), unilamellar vesicles of small diameter (30-50nm), are mainly obtained by 
sonication of MLVs suspensions. Regarding their small diameter, their light scattering 
activity is minimal. However, the small radius of curvature of SUVs results in packing 
difficulties of lipids. This curvature is much higher than the curvature of cell 
membranes, resulting in poor mimics of the properties of biomembranes. Additionally, 
SUVs are not stable and fusion occurs easily. Larger unilamellar vesicles (LUVs) can be 
produced by extrusion of MLVs through polycarbonate filters (with a defined pore size) 
that allow to obtain vesicles with a diameter near the pore size of the filter used. These 
vesicles closely resemble the lipid packing density and curvature of biomembranes. 
Giant unilamellar vesicles or GUVs (5-200μm) can be prepared by gentle hydration and 
electroformation (Rodriguez et al., 2005). These vesicles are particularly suitable for 
microscopy applications as their size enables visualization. 
 
 
Figure I.10 – Schematic illustration of liposomes preparation that leads to MLVs, SUVs and 
LUVs (from www.avantilipids.com). 
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3. PEPTIDES 
 
3.1 Peptides as models 
 
Proteins complexity may difficult their functional and structural characterization as 
a whole. The study of protein-protein and protein-lipid interactions for instance is 
frequently important to understand the function of proteins and their role in supra-
molecular systems. The use of a peptide, whose sequence derives from a specific 
protein region can be a valuable strategy to study that specific protein sequence. 
Synthetic peptides are easier to manipulate, to obtain in large quantities, and can be 
mutated in relation to the primary sequence with extensive mutation possibilities. These 
peptides can be used to the study of a particular protein characteristic and understand 
the role of a particular amino acids sequence.  
In HIV-1 entry studies the envelope glycoprotein complex role is of crucial 
importance. Recently acquired knowledge of the gp41 and gp120 (Di Bello et al., 2004) 
function and behaviour was achieved by the study of the whole protein but also by the 
use of synthetic peptides derived from the proteins sequence. The study of gp41 
synthetic derived peptides allows to identify and to study different functional domains. 
Namely, taking into account the importance of the gp41 in the membranes fusion 
process, several studies use different peptides to unravel the membrane-active regions 
(Mobley et al., 2001; Moreno et al., 2004; Moreno et al., 2006). As the gp41 FP is 
responsible for the initial insertion of the gp41 on target cells membrane, the use of 
synthetic peptides to study the membrane binding properties of this region is very 
common (reviewed in Nieva and Agirre, 2003). The identification of key residues was 
possible due to the use of synthetic FP with different lengths and amino acids mutations 
(Pécheur et al., 1999). The use of peptides derived from the gp41 NHR and CHR 
regions is widely used to study the interactions of both regions involved in the 
formation of the 6HB structure (Chan et al., 1997; Tan et al., 1997; Lu et al., 1999). 
Additionally these peptides are also frequently studied to assess the involvement of the 
correspondent regions in membrane binding and destabilization, and consequently in the 
fusion process (Rabenstein and Shin, 1995; Peisajovich et al., 2000; Kliger et al., 2000; 
Sackett and Shai, 2002; Sackett and Shai, 2003; Shnaper et al., 2004; Pascual et al., 
2005a; Korazim et al., 2006). A direct role of the gp41 LR in the fusion process was 
also proposed based on studies with synthetic peptides (Santos et al., 1998; Contreras et 
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al., 2001; Pascual et al., 2005b). It has been proposed that the gp41 MPR is essential for 
the fusion process and the study with peptides has provided additional evidence for this 
function (Suárez et al., 2000a; Suárez et al., 2000b; Sáez-Cirion et al., 2002; Sáez-
Cirion et al., 2003). Even the gp41 CT was shown to interact with membranes by the 
use of peptides derived from this region (Kliger and Shai, 1997).   
 
3.2 Peptide-membrane interactions 
 
Understanding the interactions between peptides and membranes is important since 
such interactions play a key role in many biological processes. Antimicrobial peptides 
interact with microbial membranes as part of their mechanism of action and selectivity 
(Epand and Vogel, 1999; Hancock and Diamond, 2000; Zasloff, 2000), cell-penetrating 
peptides (CPPs) are able to translocate cell membranes non-endocytically (Derossi et 
al., 1998; Lindgren et al., 2000), and viral protein fragments are responsible for 
membranes fusion (Peisajovich and Shai, 2002; Tamm et al., 2002).  
Both entropic, so called “hydrophobic” (Wimley and White, 1993) and electrostatic 
effects play a central role in peptide partition from water into membranes. Hydrophobic 
interactions are related with the energetic requirements for insertion of nonpolar 
residues in the aqueous environment. Electrostatic interactions occur because basic 
amino acid residues will be attracted electrostatically to the membrane surface 
containing negatively charged lipids. This effect is of particular importance for 
positively charged amphipatic peptides, such as antibacterial peptides, which interact 
and disrupt the negatively charged bacterial membrane (Matsuzaki, 1999; Epand and 
Vogel, 1999). However, if the lipids are neutral the electrostatic influence is 
insignificant and if both lipids and peptides present negative charges, the electrostatic 
contribution becomes repulsive. The partition of peptides into membranes can promote 
changes on their conformation. It is frequent that peptides that in the aqueous 
environment have a random coil structure adopt an α-helical conformation when 
associated with the lipid bilayer (Ladokhin and White, 1999; Wieprecht et al., 1999). 
The change to an amphipatic structure at the membrane surface reduces the free energy 
and is in this way an important contribution for membrane binding. The aromatic amino 
acids Trp, Tyr and Phe are hydrophobic and important in defining the presence of the 
peptides in the bilayer. Trp amino acid residues have preference to being inserted into 
lipid bilayers at the membrane-water interface (Yau et al., 1998; Persson et al., 1998; 
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WWS,
LLS,
p /Vn
/Vn
K =
Killian and von Heijne, 2000; de Planque et al., 2003). Hydrophobicity scales (Wimley 
and White, 1996; White and Wimley, 1998) are composed of experimentally 
determined free energies of transfer between phases for each amino acid. These scales 
are a good tool in hydropathy analyses and in the prediction of peptide interactions with 
the bilayer. Two scales are used: one for partitioning from water to the bilayer interface 
and one for partitioning into n-octanol. The octanol scale appears to be a good measure 
of the partitioning to the bilayer interior (Wimley and White, 1996; White and Wimley, 
1998). The parameter that describes the partition of a peptide between the lipid and 
water phases is the partition coefficient (Kp): 
 
  
           
 
where nS,i are the moles of solute present in each phase (i = W, aqueous phase; i = L, 
lipid phase) and Vi is the phase volume (Santos et al., 2003). 
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Chapter II 
 
 
MEMBRANES ROLE 
ON THE MODE OF 
ACTION OF THE HIV-1 
FUSION INHIBITORS 
T20 and T-1249 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
HIV infection most common treatment comprises RTIs and PIs. However, 
limitations such as treatment failure, toxicity, intolerance and HIV drug resistance, 
demand for new classes of antiviral agents. Entry inhibitors are a new class of drugs; the 
first antiviral agents that act extracellularly. Fusion inhibitors are the leading 
compounds of this class and T20 is the only approved so far by the FDA for clinical use 
(Robertson, 2003). 
 
T20 is a synthetic 36 amino acids peptide derived from the C-terminal region of 
HIV-1 gp41 (Wild et al., 1994a; Wild et al., 1995). Its sequence contains residues from 
the CHR C-terminal and MPR N-terminal parts (Figure II.1). This fusion inhibitor is 
indicated for use as part of a combination therapy with other antiretroviral agents. 
Candidates for this therapy are treatment-experienced individuals with evidence of HIV-
1 replication despite ongoing antiretroviral therapy, and is not generally applied in 
treatment-naïve patients. The recommended dosage of T20 in adults is 90mg twice 
daily, administered by subcutaneous injection (Dando and Perry, 2003). The addition of 
T20 to an optimized antiretroviral background regimen improved the virological 
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suppression and immunological benefit in treatment-experienced HIV-infected patients 
(Lalezari et al., 2003; Lazzarin et al., 2003). The most common adverse effects 
associated with its use are local injection sites reactions, but this does not seem to be a 
limitation to the treatment (Dando and Perry, 2003). Potent synergy was observed for 
T20 in combination with other entry inhibitors in vitro (Nagashima et al., 2001; 
Tremblay et al., 2002). 
 
 
Figure II.1 – T20 sequence (residues 638-673) is derived from gp41 CHR and MPR. 
 
The mode of action by which T20 inhibits viral fusion is still unclear, but several 
proposals have been presented involving different target sites in gp41 and gp120. The 
most currently accepted mechanism (Figure II.2) is the one proposed for C-peptides in 
general, involving interaction with the gp41 NHR region in an early intermediate of 
fusion, thus preventing the conformational changes that lead to the fusion-active 
arrangement (Wild et al., 1994a; Wild et al., 1995; Chen et al., 1995; Lawless et al., 
1996; Rimsky et al., 1998; Kliger and Shai, 2000). In agreement, viral resistance to T20 
is associated with mutations in the GIV sequence of the NHR region (Rimsky et al., 
1998; Wei et al., 2002), and the LLSGIV sequence is important for the binding of T20 
to gp41 (Trivedi et al., 2003). Nevertheless, T20 lacks some N-terminal residues present 
in other gp41 inhibitory C-peptides (e.g. C34) postulated as essential for the binding to 
the NHR region and inhibiting HIV-1 entry (Wild et al., 1994a, Chan et al., 1998). 
Blumenthal and co-workers (Muñoz-Barroso et al., 1998) proposed the existence of a 
second binding site for T20 on gp41, involving the contact site of gp41 oligomers 
cluster to form a fusion pore, which is required for the occurrence of the complete 
fusion process (Blumenthal et al., 1996; Chan and Kim, 1998). In fact, it was suggested 
that T20 binding affinity to the NHR region cannot justify its strong inhibitory activity 
and should have at least two different interactions modes with gp41 (Ryu et al., 1999). 
In addition Shai and colleagues (Kliger et al., 2001) showed that T20 can bind to 
membranes and oligomerize on its surface, at variance with aqueous solution, it cannot 
 FP    NHR     CHR  TM MPR CT 
             YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 
T20 
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interact with the NHR region in the membrane environment. Therefore there are two 
possible T20 target sites proposed in gp41, both contributing to fusion inhibition: 
interaction with the NHR region in aqueous solution prevents the formation of the 6HB 
structure while interaction with the gp41 C-terminal region in the membrane 
environment inhibits fusion pore formation (Ryu et al., 1999; Muñoz-Barroso et al., 
1998; Kliger et al., 2001). When T20 is bound to membrane-anchored proteins 
expressed in genetically modified target cell of HIV-1 infection, replication of the virus 
was inhibited more than 100-fold (Hildinger et al., 2001). A less accepted, but also 
proposed T20 mode of action is its binding to the gp41 FP, preventing the insertion of 
the last into the target cell membrane and thus membrane fusion (Mobley et al., 2001; 
Jiang et al., 2002).  
 
Figure II.2 – Mode of action of T20 and T-1249. Schematic of the most accepted mechanism 
by which T20 and T-1249 inhibit viral entry into target cells. Both inhibitor peptides bind to the 
NHR region in a prehairpin intermediate, preventing the formation of a fusion active structure 
and thereby fusion and viral entry (adapted from Moore and Stevenson, 2000). 
 
CD4/coreceptor 
Native state Prehairpin intermediate    
 Cell membrane 
gp120 
gp41 
Viral membrane 
NHR 
CHR 
C-peptides 
Hairpin 
 Fusion 
No fusion 
T20 T-1249 
CD4/coreceptor 
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Coreceptor specificity, that is determined by the gp120 V3 loop region, appears to 
be a factor that can also modulate sensitivity to T20 since X4 viruses are much more 
sensitive to T20 than R5 viruses (Derdeyn et al., 2000). It was proposed that both 
gp120/coreceptor binding affinity and coreceptor expression levels are related with this 
sensitivity (Derdeyn et al., 2001; Reeves et al., 2002). Assuming that T20 binds to gp41 
after CD4 binding but prior to coreceptor binding (Furuta et al., 1998; Kliger and Shai, 
2000), increased gp120/coreceptor affinity and higher coreceptor expression levels 
result in faster membrane fusion, reducing the time during which gp41 is sensitive to 
T20. In a different way, some studies suggest that gp120 can be an additional target site 
that contributes to T20 inhibitory activity. T20 may act through binding to CXCR4 (Xu 
et al., 2000) and/or interaction with the gp120 coreceptor binding site, blocking gp120 
binding to the coreceptor (Yuan et al., 2004; Alam et al., 2004; Liu et al., 2005). This 
interaction with gp120 occurs in a CD4-induced manner (Yuan et al., 2004; Alam et al., 
2004) with the gp120 of X4 viruses, which could explain the increased T20 sensitivity 
of these viruses (Yuan et al., 2004). However, different studies have not identified 
significant differences in T20 susceptibility for patients harbouring CCR5, CXCR4 or 
dual tropic viruses, indicating that viral tropism has no clinically relevant effect on the 
T20 therapy efficiency (e.g., Greenberg and Cammack, 2004; Matthews et al., 2004). 
 
T-1249 is a second generation fusion inhibitor that follows T20. This 39 amino 
acids designed peptide is composed of sequences derived from HIV-1, HIV-2 and 
simian immunodeficiency virus (SIV) (Eron et al., 2004): 
 
WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF 
 
T-1249 is more potent than T20 and also retains activity against most T20-resistant 
HIV-1 strains (Gulick, 2003; Lalezari et al., 2005). Despite the need of clarification, it is 
believed that in its mechanism of action T-1249 (Figure II.2) acts like most C-peptides, 
interacting with NHR region preventing the 6HB formation (Kilby and Eron, 2003). 
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2. PUTATIVE ROLE OF MEMBRANES IN THE HIV FUSION 
INHIBITOR ENFUVIRTIDE MODE OF ACTION AT THE 
MOLECULAR LEVEL 
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Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode
of action at the molecular level
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Partition of the intrinsically fluorescent HIV fusion inhibitor
enfuvirtide into lipidic membranes is relatively high
(G=6.6 kcal · mol−1) and modulated by cholesterol. A shallow
position in the lipidic matrix makes it readily available for
interaction with gp41. No conformational energetic barrier
prevents enfuvirtide from being active in both aqueous solution
and lipidic membranes. Lipidic membranes may play a key role
in the enfuvirtide biochemical mode of action.
Key words: AIDS, enfuvirtide, fusion inhibitor, fuzeon, HIV, T20.
INTRODUCTION
Despite the promising clinical studies and trials, which led to a
fast and recent approval by the United States Food and Drug
Administration [1] for clinical use, action of the HIV fusion
inhibitor enfuvirtide (Fuzeon; Figure 1) at the molecular level is
largely unknown. Unlike other peptides based on the C-region
of gp41 (C-peptides), enfuvirtide lacks the eight-amino-acid se-
quence (628–635) thought to be essential for association with the
N-region [2].
The sequence of enfuvirtide and its eventual arrangement in an
α-helix (Figure 1), with amphipathic segments, clearly suggests
that it may interact with biological membranes. A theoretical
analysis (Membrane Protein Explorer, MPEx version 2.04; http://
blanco.biomol.uci.edu/mpex/) on the hydrophobicity and inter-
face affinity reinforces this idea (results not shown). Thus we were
prompted to study (i) the extent of the partition of enfuvirtide into
biological membrane models, (ii) its location in the lipidic matrix
and (iii) the interplay between partition and conformation. The
presence of tryptophan residues in enfuvirtide makes fluorescence
techniques suitable tools to probe this molecule with no need for
chemical derivatization.
EXPERIMENTAL
Materials
Enfuvirtide was a kind gift from Roche (Palo Alto, CA,
U.S.A.). POPC(1-palmitoyl-2-oleyl-sn-glycero-3-phosphocho-
line), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) and
POPG {1-palmitoyl-2-oleyl-sn-glycero-3-[phospho-rac-(1-glyce-
rol)]} were purchased from Avanti Polar-Lipids (Alabaster,
AL, U.S.A.), while cholesterol was from Sigma (St. Louis,
MO, U.S.A.). 5NS (5-doxyl-stearic acid) and 16NS (16-doxyl-
stearic acid) were from Aldrich Chem. Co. (Milwaukee, WI,
U.S.A.). L-Tryptophan, acrylamide, Hepes and NaCl were from
Merck (Darmstadt, Germany). The spectrofluorimeter used was
an SLM Aminco 8100 (double monochromators; 450 W Xe lamp)
and the CD spectrometer was a Jasco J720 (450 W lamp).
Abbreviations used: LUV, large unilamellar vesicles; POPC, 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine; DPPC, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine; POPG, 1-palmitoyl-2-oleyl-sn-glycero-3-[phospho-rac-(1-glycerol)]; 5NS, 5-doxyl-stearic acid; 16NS, 16-doxyl-stearic acid.
1 To whom correspondence should be addressed, at the Centro de Quı´mica e Bioquı´mica, Faculdade de Cieˆncias da Universidade de Lisboa (e-mail
castanho@fc.ul.pt).
Methods
We used 10 mM Hepes, pH 7.4/150 mM NaCl buffer, and pre-
pared lipidic LUVs (large unilamellar vesicles) by extrusion
techniques [3]. Quenching studies were carried out by solubili-
zation of the quenchers in ethanol followed by direct injection
in the lipidic vesicles suspension (ethanol in the final sample
was kept < 2%). Effective lipophilic quencher concentrations
inside the membrane were calculated for data-analysis purposes.
Excitation and emission wavelengths were 280 and 350 nm,
respectively, in all fluorescence measurements. For details of tran-
sient-state fluorescence experiments, see [4]. We prepared en-
fuvirtide stock solutions in buffer (2.2 × 10−4 M), diluted to a
final concentration of 7 × 10−6 M (fluorescence quenching), 1 ×
10−5 M (partition coefficient calculation) or 7 × 10−5 M (CD
experiments). Partition coefficient determination was carried out
by successive addition of small aliquots of LUV (15 mM), with
10 min incubations in between. The dilution effect on fluore-
scence intensity was corrected.
RESULTS AND DISCUSSION
UV-visible absorption and fluorescence spectra in buffer of en-
fuvirtide are identical to those of Trp in aqueous solution (results
not shown). No red-edge excitation effect (i.e. red shift of the
emission spectrum) was detected, which indicates that all Trp
residues sense similar local environments. Accordingly, the
fluorescence quenching of enfuvirtide by acrylamide (a hydro-
philic molecule) revealed that no hydrophobic pockets are present
(linear Stern–Volmer plots; results not shown). Although the
existence of hydrophobic pockets does not seem likely in a small
peptide, aggregation or clustering could eventually take place.
Aggregation is probably prevented by the intercalation of charged
residues among hydrophobic ones (Figure 1a).
In the presence of LUV of POPC, the fluorescence intensity
of enfuvirtide increases (Figure 2). Concomitantly, a fluorescence
emission blue shift occurs (11 nm when [POPC] = 5 mM), which
shows that the Trp residues in enfuvirtide are being incorpo-
rated progressively into the lipid and sensing a more hydrophobic
c© 2004 Biochemical Society
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Figure 1 Amino acid sequence of enfuvirtide (a) and its arrangement in an α-helix (b), as it appears in the crystallographic structure of gp41
Hydrophobic (blue), non-charged polar (green) and charged polar (red) residues form amphipathic segments in the helix. The top view in (b) shows that the hydrophobic side chains point towards
the same side of the chain. This is also apparent from the side view, when only the backbone is represented. Uncapped enfuvirtide at both ends is usually referred to as T20.
Figure 2 Partition coefficient determination
The fluorescence intensity of enfuvirtide increases upon addition of lipidic LUV as a result of
a higher quantum yield of the molecules inserted into the lipidic matrix. POPC without added
cholesterol () is the most efficient in the uptake of the peptides, followed by DPPC ().
The differences are probably due to fluidity: POPC forms fluid bilayers (similar to biological
membranes) while DPPC is in the gel state. POPC + cholesterol [33 % cholesterol (in molarity);
H17009] is the least efficient. The solid lines are fittings of eqn (1) to the experimental data [POPC,
K p = (1.6 +− 0.1) × 103;G = 6.6 kcal · mol−1]. The presence of the negatively charged lipid
POPG (20 %;) mimics the inner leaflet of mammals’ cell membranes and results in very weak
incorporation. Outer leaflets are electrically neutral and mimicked by POPC. [L] is the outer
leaflet lipidic (or lipid + cholesterol) concentration.
environment. The partition coefficient describing the distribution
of enfuvirtide between aqueous and lipidic media is Kp =
[enfuvirtide]L/[enfuvirtide]W, where [enfuvirtide]L and [enfuvir-
tide]W are the peptide concentrations in the lipidic and aqueous
Figure 3 Location of enfuvirtide Trp residues inside the membrane
(a) Stern–Volmer plot for the quenching of enfuvirtide fluorescence by 5NS () and 16NS
(H17009) in POPC (5 mM) vesicles. 5NS is a better quencher; therefore Trp residues are located in
a shallower position. (b) Quenching data (Table 1) were used to calculate the enfuvirtide Trp
residues in-depth frequency distribution along the lipidic bilayer using the SIMEXDA method
[9]. The shallow location is clear.
c© 2004 Biochemical Society
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Table 1 Average fluorescence lifetimes (〈τ〉) of enfuvirtide
The mean fluorescence lifetime (〈τ 〉) of enfuvirtide increases upon incorporation in lipidic mem-
branes. Differential diffusional fluorescence quenching by 5NS and 16NS inside the lipidic matrix
enables in-depth location of the Trp residues.
System 〈τ 〉 (ns)
Buffer 2.4
5 mM POPC 4.9
5 mM POPC/0.4 mM 5NS 3.0
5 mM POPC/0.4 mM 16NS 4.0
media, respectively. This can be calculated from the data (Fig-
ure 2) by fitting the following equation [5,6]:
I
IW
= 1 + KpγL[L]IL/IW
1 + KpγL[L] (1)
where I is the measured fluorescence intensity, IW and IL are
the fluorescence intensities when all the molecules are in the
aqueous or lipidic environment, respectively, γ L is the lipidic
molar volume [7] and [L] is the molar concentration of the acces-
sible lipid, i.e. that of the outer leaflet of the bilayer. For POPC,
a lipid with packing density and fluidity properties similar to bio-
logical membranes, a Kp value of (1.6 +− 0.1) × 103 (G =
Figure 4 Schematic representation of enfuvirtide action at the molecular level
Enfuvirtide attaches to membranes in an interfacial position reaching local high concentrations. Translocation is prevented due to charge effects (among others). When the virus approaches the cell
surface, its outer membrane will not compete for enfuvirtide uptake due to its high content of cholesterol. Therefore, enfuvirtide molecules remain as ‘guardians’ of the cell surface. The cell membrane
is a reservoir of enfuvirtide; the gp41 fusiogenic approach exposes the Leu-Ile zipper-like region to the peptides, which binds them (K b) [12]. However, local concentration of aqueous enfuvirtide is
kept high due to partition equilibrium (K p). Moreover, a high local concentration at the cell-membrane surface enables direct contact of the peptide with the gp41 C-region (K d) when the enfuvirtide
homologous sequence comes into contact with the lipidic matrix to form the fusion pore. Fusion peptide (FP) binding [2] also benefits from a high concentration of enfuvirtide at the cell surface.
6.6 kcal · mol−1) is obtained and this implies that, depending on
the lipid concentration, the local concentration in the membrane
can increase by several hundred- to thousand-fold relative to the
bulk (≈ 700-fold at [POPC] = 4 mM; ≈ 1600-fold at [POPC] <
0.1 mM). However, this is severely reversed by the presence
of cholesterol or physiological concentrations [8] of negatively
charged lipids (Figure 2). The cholesterol effect does not seem
totally caused by the condensation effect imposed by the sterol
on the lipid because peptide partition into gel-phase membranes
is more pronounced (Figure 2). The effect of negatively charged
lipids is probably due to simple electrostatic repulsion (enfuvirtide
has a overall negative net charge of − 5).
The in-depth location of fluorescent molecules in lipidic mem-
branes can be evaluated from quenching experiments with lipo-
philic molecules derivatized with quencher groups at selected
sites [9]. Stearic acid, for instance, can be derivatized at carbon-5
or -16 with doxyl groups (5NS and 16NS, respectively). When
placed in the membrane, the quencher group in 5NS locates at a
shallow position, near the interface, whereas in 16NS it locates
close to the hydrophobic core. 16NS is a better quencher for fluo-
rescent molecules buried deeply in the membrane while 5NS is a
better quencher for molecules near or at the interface. Enfuvirtide
is better quenched by 5NS (Figure 3a), meaning that the Trp
residues are located in a shallow position in the membrane. Fluo-
rescence-lifetime quenching data (Table 1) enabled the appli-
cation of the SIMEXDA method [9] to recover the Trp residues’
c© 2004 Biochemical Society
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in-depth distribution in the membrane (Figure 3B). A mean
shallow location and a fairly narrow distribution were observed.
Like other HIV gp41 C-peptides [10], enfuvirtide is not an α-
helix in solution (CD data not shown). It is known that several
peptides go through a random-coil-to-helix transition upon
binding to membranes [11]. However, this is not the case with
enfuvirtide, which remains in a random-coil conformation when
inserted in membranes (no alterations are detected in the CD
spectra; results not shown).
Based on the data described above, one can depict in general
terms what might be the action of enfuvirtide at the molecular
level. As shown in Figure 4, enfuvirtide inserts into the external
layer of the cell plasmalemma (non-charged lipids) and is pre-
vented from translocation due to the repulsion caused by the
negatively charged lipids of the inner layer, among other reasons.
When the HIV approaches the cell, the virus lipidic membrane
does not remove the enfuvirtide from the cell outer surface be-
cause of its high cholesterol content; i.e. enfuvirtide concentrates
at cell surfaces and tends to stay there. Therefore, cell membranes
are an enfuvirtide reservoir. The partition equilibrium tends to
stabilize the enfuvirtide concentration in the aqueous environment
when binding to gp41 occurs (i.e. improving fusion inhibition
efficiency). Moreover, the high levels of enfuvirtide accumulated
at the cell surface render the interaction with other segments
of gp41 possible if they reach the cell surface (i.e. if enfuvirtide
binding to the Leu-Ile-rich region fails and the fusion process pro-
ceeds). Binding of enfuvirtide and related molecules to the fusion
peptide and other gp41-derived peptides has been reported [2,12].
Enfuvirtide was a kind gift from Roche (Palo Alto, CA, U.S.A.). We acknowledge Dr Cla´udio
Soares (ITQB, Lisbon, Portugal) for helping with molecular modelling, and Professor M.
Prieto (Technical Univ. Lisbon) and Professor C. Saldanha (Univ. Lisbon) for valuable
discussions. FCT (Portugal) funded this work.
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3. HIV FUSION INHIBITOR PEPTIDE T-1249 IS ABLE TO 
INSERT OR ADSORB TO LIPIDIC BILAYERS. PUTATIVE 
CORRELATION WITH IMPROVED EFFICIENCY 
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HIV Fusion Inhibitor Peptide T-1249 Is Able To Insert or
Adsorb to Lipidic Bilayers. Putative Correlation with Improved
Efficiency
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Abstract: T-1249 is a HIV fusion inhibitor peptide under clinical trials. Its interaction with biological membrane
models (large unilamellar vesicles) was studied using fluorescence spectroscopy. A gp41 peptide that
includes one of the hydrophobic terminals of T-1249 was also studied. Both peptides partition extensively
to liquid-crystalline POPC (1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine) (¢G ) -7.0 kcal/mol and -8.7
kcal/mol, for T-1249 and terminal peptide, respectively) and are located at the interface of the membrane.
T-1249 is essentially in a random coil conformation in this lipidic medium, although a small R-helix contribution
is present. When other lipid compositions are used (DPPC, POPG + POPC, and POPC + cholesterol)
(DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) and POPG (1-palmitoyl-2-oleyl-sn-glycero-3-[phospho-
rac-(1-glycerol)), partition decreases, the most severe effect being the presence of cholesterol. Partition
experiments and fluorescence resonance energy transfer analysis show that T-1249 adsorbs to cholesterol-
rich membranes. The improved clinical efficiency of T-1249 relative to enfuvirtide (T20) may be related to
its bigger partition coefficient and ability to adsorb to rigid lipidic areas on the cell surface, where most
receptors are inserted. Moreover, adsorption to the sterol-rich viral membrane helps to increase the local
concentration of the inhibitor peptide at the fusion site.
Introduction
Human immunodeficiency virus type 1 (HIV-1) binding to
the target cell and fusion of the membranes of both depend on
the viral envelope glycoproteins complex formed by the
transmembrane protein gp41, and the surface protein gp120,
bounded to the external domain of gp41. The first step in the
process of HIV-1 infection of a cell is mediated by gp120
binding to the CD4 receptor, present in the surface of some
T-lymphocytes, macrophages, and other immune system cells.1
This contact induces a conformational change in gp120,
facilitating its connection to a second receptor, usually CCR52
or CXCR43. The binding of gp120 to CD4 and CCR5 (or
CXCR4) triggers a conformational change in gp41, exposing a
fusion peptide and allowing its insertion in the membrane of
the target cell, leading to the fusion of the two membranes and
mixing of the viral and cellular components.4
One feature of gp41 is the presence of two heptad repeat (HR1
and HR2) sequences.5 Enfuvirtide (T20: Fuzeon) is a synthetic
36-amino-acids peptide homologous to the C-terminal region
of HR2 of HIV-1 gp41.6,7 This compound is currently the most
advanced clinical drug for inhibiting HIV-1 entry6 and has
recently received approval from the Food and Drug Administra-
tion.8 Despite the therapeutic potency of enfuvirtide, it has met
with the emergence of resistant strains.6,8 T-1249 (a 39-amino-
acids peptide) is a second-generation fusion inhibitor, composed
of sequences derived from HIV-1, HIV-2, and simian immuno-† Faculdade de Cieˆncias da Universidade de Lisboa.‡ Faculdade de Medicina de Lisboa.
§ Instituto Superior Te´cnico.
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deficiency virus (SIV).9 Initial phase I/II clinical trials with
T-1249 have shown promising results; namely, it is a more
potent inhibitor than enfuvirtide (even with a single daily
administration instead of the two used for enfuvirtide) and
retains activity against most enfuvirtide-resistant strains.6,7,9,10
Similarly to enfuvirtide, the T-1249 sequence and presence
of amphipathic segments (Figure 1, A and B) suggest that the
peptide may interact with biological membranes. Theoretical
analysis on the hydrophobicity of the amino acid residues
sequence11,12 of the peptide further confirms this hypothesis.
We were prompted to study the interaction of T-1249 with
biological membrane models. A gp41 20-amino-acids peptide
that includes the hydrophobic C-terminal sequence of enfuvirtide
and T-1249 (hereafter named CTP-carboxyterminal peptide) was
also studied, to conclude on the mode of insertion of these
molecules in lipidic membranes.
Materials and Methods
Materials. Enfuvirtide and T-1249 were a kind gift from Roche (Palo
Alto, CA), and the CTP fragment of enfuvirtide was purchased from
AnaSpec, Inc. (San Jose, CA). 5NS (5-doxyl-stearic acid) and 16NS
(16-doxyl-stearic acid) were from Aldrich Chem. Co. (Milwaukee, WI).
L-Tryptophan, acrylamide, Hepes, and NaCl were from Merck (Darm-
stadt, Germany). POPC (1-palmitoyl-2-oleyl-sn-glycero-3-phospho-
choline), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), and
POPG (1-palmitoyl-2-oleyl-sn-glycero-3-[phospho-rac-(1-glycerol)])
were purchased from Avanti Polar-Lipids (Alabaster, AL), while
cholesterol and dehydroergosterol, DHE (ergosta-5,7,9(11),22-tetraen-
3â-ol), were from Sigma (St. Louis, MO). The spectrofluorimeter used
was an SLM Aminco 8100 (double monochromators; 450 W Xe lamp),
the UV-visible absorption spectrophotometer was a Jasco V-530, and
the CD spectropolarimeter was a Jasco J720 (450 W lamp). The time-
resolved instrumentation was previously described.13
Methods. All studied peptides contain tryptophan residues (Figure
1A), which make fluorescence techniques suitable tools to probe these
molecules. In all fluorescence measurements, the excitation wavelength
used was 280 nm (except time-resolved fluorescence experiments, 287
nm). 10mM Hepes, pH 7.4/150mM NaCl buffer was used throughout
the studies. Enfuvirtide, T-1249, and CTP stock solutions (2.2  10-4
M, 1.985  10-4 M, and 3.9  10-4 M, respectively) in buffer were
diluted to the final desired concentration. T-1249 and CTP solubilization
required mild sonication. Remaining macroscopic aggregates of CTP
were sometimes detected, although in very small quantities. In these
cases, a centrifugation step was added to separate the aggregates. Large
unilamellar vesicles (LUV) were prepared by extrusion techniques.14
Pure POPC and DPPC, POPC/POPG 80:20 (mol %), and POPC/
cholesterol 67:33, 75:25, and 82:18 (mol %) were used on the studies
of the interaction of the peptides with membrane models systems.
Average fluorescence lifetimes, 〈ô〉, were calculated from triexponential
intensity decays (error estimates of the lifetime components ranged from
0.2% to 3.2%).
Membrane partition studies were performed by successive additions
of small volumes of LUV (15mM) to the peptide samples (enfuvirtide
1  10-5 M, T-1249 6.7  10-6 M, or CTP 9.1  10-6 M) with a 10
(9) Eron, J. J.; Gulick, R. M.; Bartlett, J. A.; Merigan, T.; Arduino, R.; Kilby,
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Melby, T.; Raskino, C.; Rusnak, P.; Zhang, Y.; Spence, R.; Miralles, G.
D. J. Infect. Dis. 2004, 189, 1075-1083.
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Figure 1. (A) Amino acids sequence of T-1249 (top), enfuvirtide (middle), and CTP (bottom). The arrows indicate the sequence homology between the
CTP and the other peptides (black, T-1249; orange, enfuvirtide). (B) Top view of T-1249 (left) and CTP (right) arrangement in an R-helix. Hydrophobic
residues are blue, noncharged polar are green, and charged polar are red.
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min incubation in between. The emission wavelength used was 350
nm. Fluorescence intensity data were corrected for dilution effect.
Quenching studies were carried out by successive additions of small
amounts of 5NS or 16NS in ethanol to samples of the peptide incubated
with LUV (T-1249 4.5  10-6 M or CTP 6  10-6 M). Ethanol
concentration in the sample was kept below 2% (v/v). After each
addition of quencher, the sample was incubated for 10 min. The
effective quencher concentration in the membrane was calculated from
the partition coefficient of the quenchers to lipidic bilayers.15 The
emission wavelength used was 340 nm.
Fluorescence resonance energy transfer studies between the tryp-
tophan (donor) and fluorescently labeled vesicles with DHE (acceptor)
were used to study the binding of T1249 to POPC/sterol (67:33 mol
%) vesicles. The final concentration of T-1249 used was 2.2  10-6
M. The emission wavelength used to prevent interference of DHE
emission was 320 nm. The critical distance for energy transfer, R0,
was calculated according to Berberan-Santos and Prieto,16
where 2 is the orientation factor (the value 2 ) 2/3, relative to the
dynamic isotropic limit, was used in this study), …D is the donor
quantum yield in the absence of acceptor (…D ) 0.106, the value
measured in this study for high lipid concentration, was used), n is the
refractive index (n ) 1.4 was used in this study as the refractive index
within the vesicles17), I(ì) is the normalized donor emission spectrum,
and (ì) is the acceptor molar absorption spectrum (expressed as M-1
cm-1). If in eq 1 ì is in nm, the calculated R0 will be in Å. Energy
transfer efficiencies, E, were experimentally determined from
where IDA and ID are the fluorescence intensities of the donor in the
presence and absence of acceptor, respectively.
The final concentrations of T-1249 and enfuvirtide in the CD
experiments were 6.6  10-5 M and 7.3  10-5 M, respectively. CD
data are represented by the mean residue ellipticity, [ı], obtained from
the observed ellipticity (ı) according to the equation [ı] ) ı/(Nlc)
where l is the path length, c is the molar concentration, and N is the
number of amino acid residues in the peptide.5
Inner filter effects were corrected18 in the fluorescence emission
experiments.
Results and Discussion
Photophysical Characterization and Partition Coefficient
Determination. Red edge excitation shift effects were not
detected in the fluorescence emission of T-1249 and CTP
tryptophan residues. Linear Stern-Volmer plots were obtained
for peptides fluorescence quenching by acrylamide (not shown),
revealing that the Trp residues are not localized inside hydro-
phobic pockets.
Figure 2 shows the result of a theoretical analysis11,12 of the
hydrophobicity of T-1249. Enfuvirtide analysis is also shown
for the sake of comparison. ¢Goct < 0 reveals the tendency of
peptides to insert in the membrane.
As shown in Figure 3A and B, there is an increase in the
fluorescence intensity of T-1249 and CTP in the presence of
LUV of liquid-crystalline POPC. There is also a blue-shift of
the emission spectra (3 and 12 nm for T-1249 and CTP,
respectively, when [POPC] ) 5 mM). This spectral shift is
further evidence of the interaction of the peptides with the
membrane model system. The partition coefficient between the
lipid and aqueous phases, Kp ) [peptide]L/[peptide]W, was
determined in order to quantify the extent of interaction of the
peptides with the LUV. [peptide]L and [peptide]W are the peptide
concentrations in the lipidic and aqueous environment, respec-
tively. Since there is an increase in the fluorescence quantum
(15) Santos, N. C.; Prieto, M.; Castanho, M. A. R. B. Biochemistry 1998, 37,
8674-8682.
(16) Berberan-Santos, M. N.; Prieto, M. J. Chem. Soc., Faraday Trans. 1987,
83, 1391-1407.
(17) Davenport, L.; Dale, R. E.; Bisby, R. H.; Cundall, R. B. Biochemistry 1985,
24, 4097-4108.
(18) Coutinho, A.; Prieto, M. J. Chem. Educ. 1993, 70, 425-428.
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Figure 2. Theoretical analysis of partition into membranes of enfuvirtide
(A) and T-1249 (B). Values of ¢Goct < 0 indicate the residues of the
peptides with a higher tendency toward insertion in membranes. Figure 1
highlights the match of both peptides with CTP.
Figure 3. Partition coefficient determinations for T-1249 (A) and CTP
(B). For both peptides, the largest increase in fluorescence intensity is
detected in the presence of LUV of POPC(b). Although to a lesser extent,
there is also an increase in the fluorescence intensity in the presence of gel
state vesicles, DPPC ([), and negatively charged lipid POPG (20% POPG
in POPC; 9). The POPC/cholesterol mixture (33% mol cholesterol; 2) is
the least efficient; the increase of T-1249 fluorescence intensity is practically
null. The solid lines are fittings of eq 3 to the experimental data. [L] is the
concentration of the lipid available in the outer leaflet.
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yield upon membrane incorporation, Kp can be calculated from
the fluorescence intensity data, I, by fitting eq 319 to the data.
(IW and IL are the fluorescence intensities expected when all
the peptide is in water or in the lipidic phase, respectively; çL
is the lipidic molar volume;20 and [L] is the molar concentration
of the accessible lipid-outer leaflet of the bilayer.) Kp values
of (5.1 ( 0.7)  103 (¢G ) -7.0 kcal/mol) and (53 ( 8.5) 
103 (¢G ) -8.7 kcal/mol) were obtained for T-1249 and CTP,
respectively, in POPC. Thus the Kp obtained for CTP is
significantly larger than those obtained for T-1249 and enfu-
virtide.21 This indicates that the hydrophobic segment of
enfuvirtide and T-1249, which corresponds to CTP, is of major
importance for lipidic membrane partition, while the hydrophilic
segments tend to oppose them (theoretical expectations in Figure
2 are thus met). T-1249 has the hydrophobic amino acid moieties
more evenly distributed than enfuvirtide, which concentrates
the hydrophobic residues at both endings. This may explain the
differences found in Kp (1.6  103 vs 5.1  103 for enfuvirtide
and T-1249, respectively). When other lipid compositions are
used, the Kp values of CTP and T-1249 decrease (Figure 3A
and B). There is a decreased partition into gel phase membranes,
due to the higher rigidity of DPPC bilayers. The presence of
the 20% POPG-to-POPC ratio mimics the environment of the
inner leaflet of mammal biomembranes. T-1249 and CTP have
negative net formal charges of -4 and -2, respectively.
Decreased Kp in these systems can be related to electrostatic
repulsion. However the most severe effect is related to the
presence of sterol. For T-1249, the Kp is so small in cholesterol-
rich membranes that the partition cannot be quantified (Kp 
0). At variance with T-1249 and enfuvirtide, CTP partition in
these conditions occurs. Thus, the rigidity of the membrane is
not the only factor that conditions the partition of the peptides.
Interaction of Enfuvirtide and T-1249 with Cholesterol-
Containing Membranes. Lipidic rafts are plasma membrane
domains that are enriched in cholesterol and sphingolipid.22,23
They are organized in a tightly packed, liquid ordered manner,24
with cholesterol maintaining the rafts in a functional state.25 It
was proposed that rafts may function as platforms for the
assembly of membrane-associated macromolecular complexes
that are important in biological processes.26 This prompted us
to further investigate the interaction of HIV fusion inhibitor
peptides with cholesterol-containing membranes. Vesicles with
33% of cholesterol (i.e., 2 phospholipids:1 sterol) are
homogeneous27 (liquid ordered phase). Considering its rigidity,
this phase may be regarded as a crude mimic of lipid rafts.
Although Kp  0, adsorption of the peptides to the rigid bilayers
surface cannot be discarded because adsorption can leave Trp
residues exposed to the bulk aqueous environment, with
unchanged fluorescence quantum yield (i.e., not contributing
for Kp calculation). Vesicles with a lower content in cholesterol
are heterogeneous, having cholesterol-rich and cholesterol-poor
areas.27 Thus, the liquid disordered phase and raft-like ordered
phase coexist. If partition is only occurring to the disordered
phase (cholesterol-poor) areas and no adsorption to the ordered
phase (cholesterol-rich) is taking place, then one expects
partition curves (I/IW; eq 3) to be only dependent on the lipid
concentration which is involved in cholesterol-poor areas; i.e.,
partition plots against the concentration of POPC external to
ordered areas should all coincide, regardless of the cholesterol
content of the vesicles. “Free lipid” (i.e., in cholesterol-poor
areas) concentration can be calculated from lipid/cholesterol
phase diagrams27 (namely the lower and upper limits of two-
phase coexistence) using the lever rule (eq 4):
where x (5-33%) is the cholesterol mol % (18% and 25%, in
our study, Figure 4A and B).
Partition curves for enfuvirtide are almost mutually over-
lapped, regardless of the cholesterol content, showing that
enfuvirtide does not significantly adsorb to the cholesterol-rich
areas. When Kp is calculated for 18% and 25% cholesterol in
the [lipid]free domain, Kp is similar to those obtained with sterol-
free membranes. However, T-1249 (Figure 4B) shows a different
behavior: partition curves do not superimpose in the [lipid]free
domain, and I/IW decreases with cholesterol content. This may
be due to adsorption of the peptide to the cholesterol-rich areas,
without significant variation of the fluorescence quantum yield.
This additional equilibrium (adsorption) competes with partition,
decreasing the molar fraction of molecules embedded in the
lipidic bilayers. With the increase of the percentage of choles-
(19) Santos, N. C.; Prieto, M.; Castanho, M. A. R. B. Biochim. Biophys. Acta
2003, 1612, 123-135.
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(24) Alonso, M. A.; Milla´n, J. J. Cell Sci. 2001, 114, 3957-3965.
(25) Simons, K.; Ehehalt, R. J. Clin. InVest. 2002, 110, 597-603.
(26) Guyader, M.; Kiyokawa, E.; Abrami, L.; Turelli, P.; Trono, D. J. Virol.
2002, 76, 100356-10364.
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I
IW
)
1 + KPçL
IL
IW
[L]
1 + KPçL[L]
(3)
Figure 4. Partition plots of enfuvirtide (A) and T-1249 (B) to LUV of
POPC/cholesterol. Fluorescence intensities dependence on [lipid]free (eq 4)
for 0% (b), 18% ([), and 25% (9) cholesterol. Data sets overlap for
enfuvirtide (A) but not for T-1249 (B).
[lipid]free ) [lipid + sterol]total
33 - x
33 - 5 (4)
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terol, a larger area is occupied by the domains and more
adsorption of T-1249 occurs. Appendix 1 quantifies the
equilibria balance and rationalizes the altered partition plots.
This analysis takes into account partition of T-1249 to POPC
and adsorption to the POPC/Cholesterol domains. Data fitting
with eq A1.9 (appendix 1; Figure A1.2) leads to Ka ) 3.1 
103 and Ka ) 4.6  103 for 18% and 25% of cholesterol,
respectively (adsorption partition coefficient).
Interaction of T-1249 with Cholesterol-Rich Area Vesicles.
A FRET Study. To further confirm and quantify the adsorption
of T-1249 to the cholesterol-rich areas, we used a fluorescence
resonance energy transfer (FRET) methodology using DHE as
an acceptor for T-1249 tryptophan fluorescence. LUV of POPC/
cholesterol/DHE (33-9.9% cholesterol, 0-23.1% DHE) were
used. Figure 5 shows an increase in the energy transfer efficiency
with DHE content. Thus, the Trp moieties of T-1249 are in the
vicinity of the sterol; i.e., adsorption occurs. To quantify the
fraction of molecules adsorbed, we followed the methodology
described in appendix 2. The fraction of nonadsorbed molecules,
A1, is A1 ) 0.3 ( 0.1, corresponding to 70% of adsorbed
molecules when [POPC + cholesterol] ) 5 mM (33% molar
cholesterol). These values confirm that adsorption of T-1249
to sterol-rich membranes occurs. Equation A1.3 (appendix 1)
relates the adsorption partition constant, Ka, lipid and sterol
concentrations, and the molar fraction of the adsorbed peptide
(1 - A1). Therefore, 0.4  103 < Ka < 1.0  103, which broadly
concur to the values calculated in the previous section. Ka was
calculated from the volumic concentration of the peptide in the
membrane. The partition constant obtained from superficial
concentration, Ka,sup, can be obtained from Ka from Ka,sup )
Kah, where h is the half-bilayer thickness.
In-Depth Location of the Peptides in Membranes and
Secondary Structure Studies. Quenching methodologies were
used to evaluate the in-depth location of the Trp residues of
the peptides inserted in POPC vesicles. Stearic acid molecules
derivatized with doxyl (quencher) groups at carbon-5 (5NS) and
-16 (16NS) were used. 5NS is a better quencher for molecules
near or at the interface, while 16NS is better for molecules
buried deeply in the membrane.28 Figure 6A shows the Stern-
Volmer plots obtained for T-1249 (similar results were obtained
with CTP, not shown) using the effective concentration of 5NS
and 16NS in the bilayer matrix. The peptides are better quenched
by 5NS. So, the Trp residues of the peptides are located near
the interface of the membrane. Fluorescence lifetime quenching
data (Table 1) enable the application of the SIMEXDA method28
to obtain the in-depth distribution of the Trp residues of the
peptides (Figure 6B; CTP distribution is similar; result not
shown). This location distribution does not differ much from
the one obtained previously with enfuvirtide.21 The Trp moieties
are mainly located at the membrane interface.
CD experiments show that enfuvirtide and T-1249 are
essentially in a random coil conformation in both aqueous and
lipidic medium (POPC) (Figure 7). However, enfuvirtide has a
negligible R-helix content (8% and 10% in buffer and POPC,
respectively), while a helix component can be detected in
T-1249, albeit small (30% and 25% in buffer and POPC,
respectively). The obtained percentages of the R-helix content
of the peptides are independent of the method applied to
calculate them.29,30
(28) Fernandes, M. X.; de la Torre, J. G.; Castanho, M. A. R. B. Anal. Biochem.
2002, 307, 1-12.
(29) Kliger, Y.; Shai, Y. J. Mol. Biol. 2000, 295, 163-168.
(30) Mobley, P. W.; Pilpa, R.; Brown, C.; Waring, A. J.; Gordon, L. M. AIDS
Res. Hum. RetroViruses 2001, 17, 311-327.
Figure 5. Energy transfer efficiency from Trp residues of T-1249 (donors)
to DHE (acceptor) in POPC/cholesterol (33% mol cholesterol) vesicles (5
mM). Nonlinear regression (appendix 2) yields A1 ) 0.3 (molar fraction of
nonadsorbed peptides). The boundaries A1 ) 0.2 and A1 ) 0.4 are also
represented (dashed lines).
Figure 6. (A) Stern-Volmer plot for the quenching of T-1249 fluorescence
by the derivatized lipophilic molecules 5NS (b) and 16NS (2) in POPC
vesicles (5 mM). Effective quencher concentration in the membrane was
considered. (B) Using the SIMEXDA method28 and fluorescence lifetime
quenching data (Table 1), it was possible to determine the in-depth
distribution of T-1249 Trp residues in the lipidic bilayer. The location is
mainly interfacial.
Table 1. Average Fluorescence Lifetimes of T-1249 and CTPa
〈ô〉/ns
system T-1249 CTP
buffer 2.7 2.2
[POPC] ) 5 mM 4.4 4.4
[POPC] ) 5 mM, [5NS] ) 0.4 mM 2.9 3.2
[POPC] ) 5 mM, [16NS] ) 0.4 mM 3.6 3.6
a The average fluorescence life-time of peptides increases upon incor-
poration in lipidic membranes. Differential diffusional fluorescence quench-
ing by 5NS and 16NS inside the lipidic matrix enables in-depth location of
the Trp residues.
A R T I C L E S Veiga et al.
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Conclusions
T-1249 is a fusion inhibitor peptide under clinical trials but
its mode of action is not totally understood. The use of
fluorescence spectroscopy-based methodologies to study the
interaction of the peptide with model membranes shows that
(1) partition to LUV of POPC is very extensive and the peptide
is located near the lipids polar heads level, mainly in random
coil conformation; (2) in the presence of gel phase membranes
(rigid DPPC bilayers), POPG-containing bilayers that mimic
the environment of the inner leaflet of mammals biomembranes,
and cholesterol-rich membranes, insertion in the lipidic environ-
ment is severely decreased; (3) however, there is a very
significant adsorption of T-1249 to cholesterol-rich areas. Thus,
lipidic membranes may play an important role in the mode of
action of T-1249 (Figure 8). Namely, T-1249 can insert in the
external layer of cell while it is prevented from translocation
due to the repulsion caused by the negatively charged lipids of
the inner layer. This way, T-1249 concentrates at the cell
surfaces. Unlike enfuvirtide, T-1249 is able to adsorb to
cholesterol-rich membranes. This ability raises the concentration
of T-1249 in the surface of the cell directly at the fusion site
because HIV-1 receptor CD4 and co-receptors CXCR4/CCR5
are considered to be localized within lipid rafts.31 It is possible
that the coalescence of several small rafts, containing these
proteins, would be necessary to form an active larger raft
domain,25 enabling receptors oligomerization, viral binding, and
membrane fusion. Because the HIV membrane is very rich in
cholesterol,26,31 the local concentration of T-1249 is further
raised. Enfuvirtide inhibition occurs when target and viral
membranes are near each other (32 and references therein). The
increased extension of partition of T-1249 relative to enfu-
virtide,21 and the possibility to adsorb to cholesterol-rich
membranes might be the main cause of its improved efficiency
as HIV fusion inhibitor. Hydrophobic derivatives of enfuvirtide
proved to be 100 more efficient than enfuvirtide itself in HIV-1
replication inhibition.33 Gene therapeutic-based strategies are
currently being developed with membrane-anchored enfu-
virtide.34 T-1249’s longer half-life in circulation (enabling a
single daily administration, instead of the two daily administra-
tions of enfuvirtide), together with its promising results in
clinical trials, even with patients whose virus have reduced
susceptibility to enfuvirtide,9 can be (at least partially) justified
by T-1249 combination of hydrophobicity, membrane partition,
and “selective” adsorption, a capability not shared with enfu-
virtide.
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Figure 7. Far-UV CD spectra of enfuvirtide (dashed line) and T-1249 (solid
line) in the presence of POPC vesicles ([POPC] ) 2 mM; XL,Enfuvirtide )
0.54; XL,T-1249 ) 0.8). The increased helicity of T-1249 relative to
enfuvirtide is noticeable. Spectra in buffer are similar.
Figure 8. Schematic representation of the proposed involvement of lipidic
membranes in T-1249 mode of action. T-1249 attaches to cell membranes
in an interfacial position and adsorb to cholesterol-rich domains. Translo-
cation is prevented due to charge effects. The virus outer membrane has
loosely bound T-1249, contributing to the rise of the T-1249 local
concentration at the fusion site. Moreover, the ability to loosely bind to
lipid rafts in the direct vicinity of the receptors improves peptide action at
the fusion site. The cell membrane and the virus are a reservoir of the
peptide. gp41 fusogenic approach to the target membrane enables direct
contact of the peptide with the gp41 C-region, which leads to fusion
inhibition.
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APPENDIX 1 – Simultaneous partition and adsorption 
According to Figure A1.1, T-1249 is assumed to be distributed in 3 different locations: 
bulk aqueous media (W), ‘free’ POPC (L) and POPC/Cholesterol patches (LC). The total 
T-1249 fluorescence intensity is given by I = IW⋅XW + ILC⋅XLC + IL⋅XL, where Ii and Xi are 
the fluorescence intensities that would be obtained if all the peptides were located in the 
environment i and the molar fractions of the peptide in that environment, respectively. 
Considering that the quantum yield of the peptide in water is equal to the quantum yield of 
the peptide adsorbed in POPC/Cholesterol patches, then IW = ILC and: 
 
( ) LLLW XIX1II ⋅+−⋅=                                                                       (A1.1) 
 
Considering the equilibria in Figure A1.1 (insertion in sterol-poor domains and 
adsorption to sterol-rich domains): 
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where ni are the moles of the peptide in the environment i; Kp and Ka are the partition and 
adsorption coefficients, respectively, of the peptide, as defined in Eq. A1.4 and A1.5; [L], 
[LC] and [C] are the molar concentration of ‘free’ POPC, POPC in the cholesterol domains 
and cholesterol, respectively; γL and γLC, are, respectively, the average lipidic molar 
volumes of the POPC and the cholesterol-rich domains. Combining Eq. A1.2 and A1.3, it is 
possible to calculate both the molar fraction of peptides inserted in the sterol-poor domains 
(XL) and the molar fraction of peptides adsorbed to the sterol-rich domains (XLC): 
 
[ ]
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L
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1249-TK =                                                                                   (A1.4) 
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Therefore, 
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L UU1
UU1
X −
−=                                                                                   (A1.8) 
 
where Up and Ua are, respectively: 
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Eq. A1.1 can be rewritten as: 
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which describes the fluorescence intensity-dependence on lipid and sterol concentration. 
However, [C] and [LC] are not practical variables to work with. Therefore, they were 
related to a single independent variable. If fC is the cholesterol fraction and [L]T is the 
molar concentration of the total POPC, then: 
[ ] [ ]T
C
C L
f1
f
C −=                                                                                     (A1.12) 
The molar concentration of ‘free’ POPC, [L], is [L] = [L]T – 2[C] (sterol-rich domains in 
bilayer matrixes involves a ~2:1 lipid:sterol proportion, with minimal variations among the 
phosphatidylcholine lipids family). Thus, 
[ ] [ ] ⎟⎟⎠
⎞
⎜⎜⎝
⎛
−−= c
c
T f1
f
21LL                                                                                                            (A1.13) 
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C Lf1
f
3CL −=+                                                                                                            (A1.14) 
 
Combining Eq. A1.9, A1.10, A1.13 and A1.14, a practical function is obtained, which 
can be used for non-linear regression analysis of experimental data (Figure A1.2). Data 
fitting with Kp previously calculated from pure POPC vesicles (5.1 × 10-3) yielded Ka = 3.1 
× 103 and Ka = 4.6 × 103, for 18 and 25% of cholesterol, respectively. It was considered for 
the fitting that γLC ≈ γL. Although the strict statistical quality of the fit is not totally 
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satisfactory, probably due to the severe assumption of ILC = IW, the effect of adsorption on 
partition equilibrium in heterogeneous membranes is elucidative. 
 
 
Figure A1.1. Diagram representing T-1249 distribution in 3 different locations: bulk 
aqueous media (W), ‘free’ POPC (L) and POPC/Cholesterol patches (LC). 
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Figure A1.2. Partition plots of T-1249 to LUV of POPC/Cholesterol mixture. Fluorescence 
intensity dependence on the POPC concentration, [Lipid]Total, for 0% (•), 18% (♦) and 25% 
(?) cholesterol. Eq. A1.11 was fitted to the experimental data for 18 and 25 % cholesterol 
(solid lines) using the previously calculated Kp for pure POPC vesicles (•; Figure 3 A) and 
both Ka and IL as fitting parameters. 
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APPENDIX 2 – Fluorescence resonance energy transfer 
The decay of donor fluorescence intensity in the absence of acceptor is: 
 
( ) ( ) ( ) ( )tIA1tIAtI AD,1BD,1D −+=                                             (A2.1) 
 
where A1 (sole fitting parameter of the model) is the fraction of molecules in buffer.    
ID,B(t) and ID,A(t) are the fluorescence decays of the donor in buffer and adsorbed to 
POPC/cholesterol vesicles, respectively: 
( ) ⎟⎟⎠
⎞
⎜⎜⎝
⎛−= ∑
Bi,i
Bi,BD, τ
texpαtI                                                           (A2.2)   
 
( ) ⎟⎟⎠
⎞
⎜⎜⎝
⎛−= ∑
Ai,i
Ai,AD, τ
texpαtI                                                           (A2.3) 
 
In the presence of a sterol (membrane-bound) acceptor, the fluorescence decay of the 
buffer sub-population is not affected, but the adsorbed donors fluorescence is extinct by 
acceptors localized in two parallel planes (Figure A2.1). The values of W1 = 10 Å and     
W2 = 30 Å were obtained on the basis of bilayer widths reported by others authors1,2 and 
molecular models. The donor fluorescence decay, in the presence of the acceptor is: 
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( ) ( ) ( ) ( ) ( ) ( )tttIAtIAtI ADBDAD 21,1,1, 1 ρρ ⋅⋅⋅−+=                           (A2.4) 
 
The ρi (t) functions denote the RET rates to acceptors located on the planes W1 and W2 
away from the donor, respectively, and are given by 3: 
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where <τ> is the mean fluorescence lifetime of the donor, R0 is the Förster radius      (Eq. 
1) and n is the acceptor density (molecules/unit area), which was computed from: 
 
[ ]
[ ] ⎟⎠
⎞⎜⎝
⎛ −+⋅
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                                                    (A2.6) 
 
where [DHE] and [POPC] are the analytical concentrations of DHE and POPC, 
respectively; aPOPC and achol are the areas per POPC and cholesterol molecule, respectively, 
66.4 Å2,4 and 37.7 Å2,5 on the bilayer plane; and b is the condensation effect of cholesterol 
on the bilayer area, for this composition, 7 Å2/POPC molecule.5 
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 Finally, the FRET efficiency was calculated according to Eq. 2 where ID and IDA 
were obtained by numerical integration of the theoretical decay laws: 
 
( )dttiI DD ∫∞=
0
                                                                                   (A2.7)   
 
( )dttiI DADA ∫∞=
0
                                                                                 (A2.8) 
 
The sole fitting parameter, A1, was obtained from non-linear regression analysis of 
experimental data (Figure 5).  
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Figure A2.1. Diagram representing the donor-acceptor geometry in the lipidic bilayer: T-
1249 adsorbed at the surface and sterols (DHE) in both leaflets of the membrane. 
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Chapter III 
 
 
PUTATIVE INHIBITION OF 
SARS-CoV BY THE HIV-1 
FUSION INHIBITORS T20 
AND T-1249 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
Severe acute respiratory syndrome (SARS) is a new infectious disease that appeared 
in Guangdong Province (China) in November 2002 (WHO, 
http://www.who.int/csr/media/sars_wha.pdf). The disease had spread globally, about 
8000 people were infected, resulting in more than 800 deaths (WHO, 
http://www.who.int/csr/sars/country/2003_08_15/en/). The etiological agent was 
identified as a novel coronavirus (CoV), the SARS-associated CoV or SARS-CoV 
(Drosten et al., 2003; Ksiazek et al., 2003; Marra et al., 2003; Peiris et al., 2003; Rota et 
al., 2003). The SARS-CoV (Figure III.1) is neither a mutant nor a recombinant of any 
known CoVs. Its genome sequence reveals that this novel agent does not belong to any 
of the known groups of CoVs, constituting a new group within the CoV family (Rota et 
al., 2003; Marra et al., 2003), although extensive genome and proteome analysis 
suggested that it is distantly related to group 2 CoVs (Snijder, 2003). CoVs are a family 
of enveloped, single-stranded-RNA viruses causing disease in humans and animals, but 
the other known CoVs that affect humans cause only the common cold. SARS-CoV 
possibly infected the human population from an animal reservoir by way of the wet 
markets in Guangdong Province (Guan et al., 2003). How the precursor animal CoV 
adapted to humans to achieve efficient human-to-human transmission is not known. The 
Putative inhibition of SARS-CoV by the HIV-1 fusion inhibitors T20 and T-1249 
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virus was transmitted from person to person mainly via the respiratory route and close 
contact with patients (Stadler et al., 2003; Yu et al., 2004). SARS is an atypical 
pneumonia characterized by influenza-like symptoms including fever, cough and 
headache, non-treatable with conventional antibiotic therapy. Despite the lung is the 
most affected organ, the possibility of viral infection in multiple organs has been raised 
(Ding et al., 2004; Farcas et al., 2005). Although more than four years have passed since 
a large outbreak of SARS, SARS-CoV still represents a risk to humans. As SARS-CoV 
exists and can replicate in animal reservoirs, the possibility of its reintroduction in the 
human population and reemergence of its associate disease cannot be excluded 
(Webster, 2004; Lau et al., 2002; Li et al., 2005).  
 
 
Figure III.1 – Schematic structure of the SARS-CoV virion. A lipid bilayer composes the viral 
envelope that surrounds the helical nucleocapsid, which is formed by the viral RNA genome 
and the viral nucleocapsid (N) protein. A corona of large and distinctive spikes is present in the 
envelope, as well the membrane (M) glycoprotein and the envelope (E) protein. The spikes are 
oligomers of the spike (S) glycoprotein, responsible for binding to receptors on host cells and 
fuse the viral envelope with target cell membranes (from Stadler et al., 2003). 
 
The SARS-CoV genome encodes 28 proteins that include 16 non-structural proteins, 
4 structural proteins and 8 accessory proteins (Bartlam et al., 2007). The structural 
proteins are the spike (S), the envelope (E), the membrane (M) and the nucleocapsid (N) 
proteins (Figure III.1). The S protein consists of three domains, the external N-terminal 
domain with the S1 and S2 subunits, a TM, and a short cytoplasmic domain at the C-
terminal. This protein is a class I fusion protein that mediates the binding of the virus to 
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the host cell receptor and the subsequent fusion between the viral and host membranes 
(Gallagher and Buchmeier, 2001; Rota et al., 2003; Xiao and Dimitrov, 2004). 
However, unlike class I fusion proteins, cleavage between the S1 and S2 subunits of the 
S protein is not a requirement for fusion (Rota et al., 2003; Xiao et al., 2003; Xiao and 
Dimitrov, 2004). The S1 domain (N-terminal region) contains the sequence responsible 
for the binding to the SARS-CoV cell receptor, identified as the metallopeptidase 
angiotensin-converting enzyme 2 (ACE-2) (Li et al., 2003; Wong et al., 2004; 
Prabakaran et al., 2004). ACE-2 is present in lung alveolar epithelial cells, enterocytes 
of the small intestine, and the endothelial cells of arteries and veins and arterial smooth 
muscle in several organs (Hamming et al., 2004). ACE-2 localization may explain the 
tissue tropism of SARS-CoV for the lung and small intestine (Ding et al., 2004). 
Nevertheless, no virus infection is detected in endothelial cells, which express ACE-2 to 
a high level. The need of other cellular receptor(s) or coreceptor(s) may explain such 
behaviour (To and Lo, 2004). The S2 domain (membrane-anchored C-terminal region) 
that mediates membrane fusion, contains an internal FP and has two HR regions, NHR 
and CHR, forming coiled-coil structures (Bosch et al., 2004; Ingallinella et al., 2004; 
Liu et al., 2004; Tripet et al., 2004; Zhu et al., 2004). The putative FP has been 
identified upstream close to NHR (Sainz et al., 2005a). Similar to HIV-1, membrane-
active regions probably with a role in the membrane fusion process were identified in 
the S2 sequence (Guillén et al., 2005; Sainz et al., 2005b). In SARS-CoV (Bosch et al., 
2004; Ingallinella et al., 2004; Liu et al., 2004; Tripet et al., 2004; Zhu et al., 2004) as in 
several other viruses, HR regions have crucial importance for viral fusion. These 
regions form a 6HB structure, consisting of an inner trimeric coiled coil formed by 
NHR domains, with CHR domains surrounding the trimer, packed in antiparallel 
orientation (Supekar et al., 2004, Xu et al., 2004). This structure brings the viral and 
cellular membranes into close proximity, leading to membrane fusion. Synthetic 
peptides derived from the HR were shown to inhibit infection by either retroviruses 
(e.g., Lu et al., 1995; Kilby et al., 1998; Eckert and Kim, 2001a; Eckert and Kim, 
2001b), paramyxoviruses (e.g., Joshi et al., 1998) or coronavirus (e.g., Bosch et al., 
2003). Peptides derived from the CHR region can inhibit the viral infection by 
interfering with the 6HB formation. The possibility that CHR derived peptides act as 
SARS-CoV infection inhibitors was confirmed (Bosch et al., 2004; Liu et al., 2004; Zhu 
et al., 2004), albeit at much higher molar concentrations than similar inhibitors used to 
prevent HIV entry. Even though CHR peptides inhibitory properties may possibly be 
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affected by different factors, SARS-CoV 6HB lower stability, caused by a weaker 
interaction between the NHR and CHR regions, could be directly correlated with a 
lower potency of the CHR peptide in blocking the formation of this structure (Bosch et 
al., 2004; Liu et al., 2004; Supekar et al., 2004). 
Considering that there are no specific and efficacious treatments available to prevent 
or treat SARS, the development of anti-SARS drugs to be active in future SARS 
outbreaks is crucial. The development of entry inhibitors, including inhibitor peptides 
derived from the CHR region as referred above, are a valuable option (Cinatl et al., 
2005). However, the development and approval of novel antiviral drugs against SARS-
CoV may take years. Several drugs already approved and in clinical use to other viral 
diseases had been tested as anti-SARS-CoV (Chen and Cao, 2004; Yamamoto et al., 
2004; Chen et al., 2004; Zhang and Yap, 2004; Tan et al., 2004). Additionally and based 
on a structural analysis of HIV-1 gp41 and SARS-CoV S2 protein, Gallaher and Garry 
proposed that T20 could inhibit SARS-CoV infectivity, although with a limited activity 
(Gallaher and Garry, http://www.virology.net/Articles/sars/s2model.html). The study 
presented in this chapter helps to elucidate this theme. 
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2. WHY ARE HIV-1 FUSION INHIBITORS NOT EFFECTIVE 
AGAINST SARS-CoV? BIOPHYSICAL EVALUATION OF 
MOLECULAR INTERACTIONS 
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The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the
virus into target cells. Recent studies point out to a cell entry mechanism of this virus similar to other enveloped viruses, such as HIV-1. As it
happens with other viruses peptidic fusion inhibitors, SARS-CoV S protein HR2-derived peptides are potential therapeutic drugs against the virus.
It is believed that HR2 peptides block the six-helix bundle formation, a key structure in the viral fusion, by interacting with the HR1 region. It is a
matter of discussion if the HIV-1 gp41 HR2-derived peptide T20 (enfuvirtide) could be a possible SARS-CoV inhibitor given the similarities
between the two viruses. We tested the possibility of interaction between both T20 (HIV-1 gp41 HR2-derived peptide) and T-1249 with S protein
HR1- and HR2-derived peptides. Our biophysical data show a significant interaction between a SARS-CoV HR1-derived peptide and T20.
However, the interaction is only moderate (KB=(1.1T0.3)105 M1). This finding shows that the reasoning behind the hypothesis that T20,
already approved for clinical application in AIDS treatment, could inhibit the fusion of SARS-CoV with target cells is correct but the effect may
not be strong enough for application.
D 2005 Elsevier B.V. All rights reserved.Keywords: T20; Enfuvirtide; T-1249; Fusion inhibitor; HIV-1; SARS-CoV1. Introduction
The outbreak of severe acute respiratory syndrome (SARS)
was caused by a novel coronavirus, the SARS-associated
coronavirus (SARS-CoV) [1–5]. As SARS-CoV can replicate
in an animal reservoir, it might be reintroduced in the human
population (even as a more dangerous strain), originating a
seasonal disease [6]. Considering that there is no specific
treatment for this infection, it is necessary to develop antiviral
agents to prevent possible future epidemics. Coronavirus are
enveloped viruses and their entry into target cells is mediated
by the spike (S) envelope glycoprotein [5,7]. Although SARS-0304-4165/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbagen.2005.10.001
* Corresponding author. Fax: +351 21 7500088.
E-mail address: castanho@fc.ul.pt (M.A.R.B. Castanho).
1 These authors contributed equally to the work.CoV S protein can be classified as a class I viral fusion protein,
some features set it apart: for instance, cleavage between the S1
and S2 subunits of the S protein is not a requirement for fusion
[5,7]. The S1 domain (N-terminal region) contains the
sequence responsible for the binding to the SARS-CoV cell
receptor ACE2 (angiotensin-converting enzyme 2) [8,9]. The
S2 domain (membrane-anchored C-terminal region) mediates
membrane fusion, and contains two heptad repeat regions, HR1
and HR2, forming coiled-coil structures [10–14]. In a number
of viruses, including SARS-CoV [10–14], HR regions have
determining importance for viral fusion: these regions form a
six-helix bundle structure, consisting of an inner trimeric coiled
coil formed by HR1 domains, with HR2 domains surrounding
the trimer, packed in antiparallel orientation. This structure
brings the viral and cellular membranes into close proximity,
leading to membrane fusion. Synthetic peptides derived from
the HR were shown to inhibit infection by either retrovirusesta 1760 (2006) 55 – 61
http://www55
S. Veiga et al. / Biochimica et Biophysica Acta 1760 (2006) 55–6156(e.g., [15–18]), paramyxoviruses (e.g., [19]) or coronavirus
(e.g., [20]). The peptides derived from the HR2 region can
inhibit infection by interfering with the six-helix bundle
formation. Thus, based on the behavior of other enveloped
viruses like HIV-1, recent studies have suggested a cell entry
mechanism of SARS-CoV similar to viruses with class I viral
fusion proteins [10–13]. The potential of HR2-derived pep-
tides as inhibitors of SARS-CoV infection was demonstrated
[10,12,14]. In addition, based on a structural analysis of HIV-1
gp41 and SARS-CoV S protein, Gallaher and Garry proposed
that T20 (enfuvirtide) could inhibit SARS-CoV infectivity,
although with a limited activity [21]. T20 is a HIV-1 gp41
HR2-derived peptide that blocks entry of HIV-1 into the target
cells, which is already in clinical use [22]. T-1249 is a second-
generation HIV-1 fusion inhibitor with promising results [23].
In the present study, we have explored the potential of the HIV-
1 HR2-derived peptide T20 and the related peptide T-1249
against SARS-CoV, using S protein HR1- and HR2-derived
peptides (Table 1). The results obtained confirmed the
occurrence of an interaction between the HIV-1 peptides and
peptides derived from SARS-CoV HR1 as speculated [21].
However, the interaction does not seem to be strong enough to
grant therapeutic efficiency, which justifies the limited activity
foreseen by Gallaher and Garry [21] and recently confirmed in
infectivity assays [24].
2. Experimental
2.1. Materials
T20 and T-1249 were a kind gift from Roche (Palo Alto,
CA, USA). All the Na-l-Fmoc-protected amino acids,
coupling reagents (DIC) and HOBt were obtained from GL
Biochem (Shanghai, China). Fmoc rink MBHA resin (loading
0.44 mmol/g, 1% DVB, 100–200 mesh) was purchased from
Hecheng, Co. (Tianjin, China). Other reagents used in peptide
synthesis were obtained commercially and were of analytical
grade. Unless otherwise stated, all solvents for synthesis were
of analytical grade and used without further purification. DMF
was redistilled under reduced pressure after dried over 4 A˚
molecular sieves overnight. 1,8-ANS (8-phenylamino-1-
naphthalenesulfonic acid) and di-8-ANEPPS (4-[2-[6-(diocty-
lamino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridinium)
were purchased from Molecular Probes (Eugene, OR, USA).
POPC (1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine) wasTable 1
Sequences of HIV-1 fusion inhibitor peptides T20 and T-1249, and of the peptides de
1E and Pep 2B, Pep HR2, respectively)
Peptide Protein location
T20 –
T-1249 –
Pep 1D 900–921
Pep 1E 931–951
Pep 2B 1157–1178
Pep HR2 1150–1189
The corresponding amino acid residues in SARS-CoV S protein of the derived pep
56from Avanti Polar-Lipids (Alabaster, AL, USA). HEPES and
NaCl were from Merck (Darmstadt, Germany). 10 mM HEPES
buffer pH 7.4, 150 mM NaCl, was used throughout the studies.
T20 and T-1249 stock solutions in buffer were diluted to final
desired concentrations. Stock solutions of SARS-CoV S
protein-derived peptides were prepared in buffer with small
amounts of DMSO and diluted to final concentrations. Through
the experiments, DMSO concentration in the samples was at
most 1.4% (v/v). All peptides solubilization required mild
sonication, mainly HR1-derived peptides. The spectrofluorim-
eter used was a SLM Aminco 8100 with double monochro-
mators and 450 W Xe lamp.
2.2. Methods
2.2.1. Peptide synthesis
The peptides were synthesized by a standard Fmoc/t-Bu
protection strategy. After removal of Fmoc of Fmoc-rink
MBHA resin by 20% Piperidine/DMF (v:v) treatment for 10
min twice, the resin was thoroughly washed by DMF,
Methanol, DCM and DMF, three times each. Fmoc protective
amino acid was then coupled onto the resin for 45 min at room
temperature using 3-fold excess molar ratio of amino acid and
3-fold excess DIC and HOBt as coupling and additive reagents,
respectively. Until Kaiser’s test [25] showing to be negative,
the Fmoc-deprotection and washing steps were performed
again as described above. The next amino acid assembly was
repeated. In case of Kaiser’s test to be positive or weakly
positive, a double coupling step was carried out until Kaiser’s
test to be negative. Otherwise, the remaining amino group after
two-coupling steps was captured by 15% Ac2O/DCM (v:v) for
30 min at room temperature. After all amino acids were
successfully assembled onto resin, the last Fmoc group was
removed and the resin was rinsed thoroughly with DMF,
methanol and DCM. The resin must be completely dried under
airflow at room temperature before the peptide was cleaved off
resin.
Crude peptide attaching onto 100 mg resin was treated by
TFA (4.0 mL), thioanisole (0.2 mL), phenol (0.3 g), deionized
water (0.2 mL) and EDT (0.1 mL) for 2 h at room temperature.
The Fpeptide+resin_ mixture was filtered and the tube was
rinsed with 2–3 mL cleavage mixture. The combined solution
was dried under a slow flow of nitrogen gas and then treated
with ice-cooled methyl t-butyl ether-petroleum ether (3:1) to
precipitate the peptide. The crude peptide was washed twicerived from the HR1 and HR2 regions of SARS-CoV spike protein (Pep 1D, Pep
Sequence
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF
ENQKQIANQFNKAISQIQESLT
QDVVNQNAQALNTLVKQLSSN
SVVNIQKEIDRLNEVAKNLNES
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE
tides used is in the table.
Fig. 1. T20 (A) and T-1249 (B) fluorescence intensity variation in the presence
of Pep 1D (.) and Pep 2B (r). Small amounts of S peptides were added to a
sample of T20 (10 AM) or T-1249 (6.7 AM).
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air dried naturally. The crude peptide was dissolved in 30–60%
CH3CN–H2O (v:v) and purified by HPLC (Gilson 322 pump,
Gilson UV/vis-152 detector, and Gilson 215 liquid handler) on
a semi-preparative Vydac C18 column. The flow rate was 5
mL/min. The solvents were A: 5% CH3CN in H2O, B: 5% H2O
in CH3CN. The pH was adjusted with TFA 0.05% (v/v). The
detecting wavelength was 214 nm. Depending on the peptide
sequences, the gradient was adjusted until the expected HPLC
peak was separated very well. Collected fractions were
analyzed by our HPLC-MS system on a Vydac C18 analytic
column (4.6 Am25 cm). When both a purity of peptide over
95% and correct molecular weight were obtained, the peptide
was lyophilized and used as a powder for subsequent studies.
2.2.2. SARS-CoV S protein-derived peptides influence on
T20 and T-1249 fluorescence
S peptides are not intrinsically fluorescent, except for Pep
HR2, which is weakly fluorescent in the operation conditions
of our study, due to the Tyr residue. However, the presence of
tryptophan residues in T20 and T-1249 enable the use of
fluorescence techniques to study these molecules. To study the
influence of S peptides on T20 (10 AM) or T-1249 (6.7 AM)
fluorescence emission (kexc=280 nm; kem=350 nm) and
conclude on mutual association, these peptides were titrated
with successive additions of small amounts of S peptides (or
just the solvent for controls). After each addition of peptide the
sample was incubated for 10 min before measurement.
Fluorescence intensity data was corrected for the dilution
effect.
2.2.3. Hydrophobic interactions between T20 or T-1249 and S
protein SARS-CoV-derived peptides
The existence of hydrophobic interactions between T20 or
T-1249 and S peptides was studied by means of the ANS
probe fluorescence (kexc=372 nm; kem=480 nm). ANS was
added (final concentration 26 AM) to a sample of a selected
peptide (6.7 AM for T-1249 and 10 AM for all the other
peptides), and the other peptide was added in successive
aliquots. The inverse situation (i.e., exchange of titrated and
added peptide) was also carried out. To account for the
possible self-aggregation of the added peptides, the same
procedure was repeated in the absence of the titrated peptide,
i.e., titration of an aqueous ANS solution only. After each
peptide addition, the sample was incubated for 10 min before
measurement. DMSO additions, in the same amounts present
in peptide solutions, were used to control its effect on ANS
fluorescence. Fluorescence intensity data were corrected for
the dilution effect.
2.2.4. Membrane partition of SARS-CoV S protein-derived
peptides
POPC (in chloroform) and di-8-ANEPPS (from a stock
solution in ethanol) were mixed in a round bottom flask, and
the solution was dried under a stream of nitrogen. Solvent
removal was completed in vacuum, overnight. Large uni-
lamellar vesicles (LUV) were prepared by extrusion techniques[26]. Peptides were added afterwards. Di-8-ANEPPS excitation
spectra were obtained with emission at 603 nm [27,28]. The
final concentrations used were 200 AM for lipids, 10 AM for
di-8-ANEPPS and 15 AM for all peptides.
2.2.5. Membrane partition of T20 and T-1249 in the presence
of SARS-CoV S protein-derived peptides
POPC LUV were prepared by extrusion techniques [26] as
before, except that the di-8-ANEPPS probe was not used.
Membrane partition studies were performed by successive
additions of small volumes of LUV (15 mM) to the peptide
samples, with 10 min incubation in between. The peptide
samples were composed of T20 or T-1249 alone or in mixtures
with equimolar concentration of S peptides (T20 10 AM and
T-1249 6.7 AM). The excitation wavelength used was 280 nm
and the emission wavelength was 350 nm. Fluorescence
intensity data were corrected for the dilution effect.
3. Results
3.1. Pep 1D presence lead to fluorescence variations in T20
S peptides (Table 1) influence on T20 and T-1249
fluorescence emission was used for the evaluation of peptides
interactions. Titration of T20 with Pep 1D (Fig. 1A) or Pep 1E
(results not shown) leads to a fluorescence emission intensity
increase. A similar but not so pronounced result was obtained
with T-1249 (Fig. 1B). Fluorescence variation was not detected
for any of the others peptide pairs, e.g., T20 or T-1249 with Pep57
Fig. 2. ANS (26 AM) fluorescence intensity for the titration of (A) T20 with
Pep 1D (and vice-versa), (B) T20 with Pep 2B (and vice-versa), (C) T-1249
with Pep 1 D (and vice-versa) and (D) T-1249 with Pep 2B (and vice-versa)
Small amounts of Pep 1D or Pep 2B were added to a T20 or T-1249 sample
containing ANS, and vice-versa. T20 or T-1249 added to S peptide (0) and S
peptide added to T20 or T-1249 (.) lead to different results. Small amounts o
each peptide (r—T20 or T-1249; ˝—S peptide, Pep 1D in panels A and C
and Pep 2B in panels B and D) were added to a buffer/ANS sample to evaluate
self-aggregation.
S. Veiga et al. / Biochimica et Biophysica Acta 1760 (2006) 55–61582B (Fig. 1A and B, respectively). DMSO presence has no
effect on T20 and T-1249 fluorescence intensity.
3.2. Hydrophobic interactions occur between Pep 1D and T20
ANS (an environmentally sensitive probe) is essentially non
fluorescent in water, becoming fluorescent in a less polar
environment, e.g., when bound to hydrophobic sites in proteins
[29,30]. It was shown before that this probe can be used to
study peptide assemblies [30]. Therefore, we used the increase
in ANS fluorescence intensity (increased quantum yield) to
study the existence of hydrophobic binding between T20 or T-
1249 and S peptides because this binding may lead to the
formation of hydrophobic grooves where ANS can insert, with
a concomitant increase in fluorescence intensity. To evaluate
peptides interactions, pair-wise tests were carried out. Small
amounts of one peptide were added to the other peptide/ANS
sample. For each pair of studied peptides, reverse titration (i.e.,
titration of the first peptide with the second) was also carried
out. To take into account eventual self-aggregation of the
titrating peptide, all peptides were used to titrate ANS samples
in buffer. The results show that Pep 1D (Fig. 2A), T-1249 (Fig.
2C) and Pep 1E (data not shown) self-aggregate. However, the
ANS fluorescence increase observed with the addition of Pep
1D to T20 is larger than the observed with Pep 1D alone (self-
aggregation), which is indicative of mutual binding between
these peptides—Fig. 2A. The T20/Pep 1E mixture also
indicates interaction (data not shown). Although similar, T-
1249/Pep 1D results exhibit a larger variability (Fig. 2C). T-
1249 does not interact with Pep 1E. Both T20 and T-1249 show
no evidence of interaction when the other two S peptides are
used (results for the T20/Pep 2B and T-1249/Pep 2B systems
are shown in Fig. 2B and D, respectively, as an example). No
DMSO effect on ANS fluorescence was detected. Peptides Pep
1D and Pep HR2 interact with each other (data not shown), in
agreement with the results obtained by Liu et al. [12]. This
result serves as a positive control of the method.
3.3. S protein-derived peptides do not interact with membranes
Due to the lack of intrinsic fluorescence in S peptides, the
interaction studies with model membranes could not be done
by a direct method. Thus, di-8-ANEPPS was used as a probe
for peptide–membrane interaction. The magnitude of the
membrane dipole potential is affected by membrane binding
and by the insertion of molecules as such peptides. This change
on the potential magnitude may be monitored by means of
spectral shifts of the fluorescence indicator di-8-ANEPPS
[27,28]. Fig. 3 shows the fluorescence difference spectra for
all S peptides, as well as for T20 and T-1249. Fluorescence
difference spectra were obtained by subtracting the excitation
spectrum of di-8-ANEPPS-labeled POPC membranes in the
absence and presence of the peptides. Before subtraction, the
spectra were normalized to the integrated areas so that the
difference spectra reflect only spectral shifts. Fluorescence
intensity difference spectra for T20 and T-1249 (peptides
known to interact with membranes [31,32]) and S peptides58.
f
Fig. 4. Partition plots of T20 (10 AM) to LUVof POPC. The experiments were
done in the absence (.) and in the presence (r) of equimolar S peptides Pep
1D (A) and Pep 2B (B).
Fig. 3. Di-8-ANEPPS-labeled (10 AM) membranes (POPC 200 AM LUV)
fluorescence difference spectra (kem=603 nm). The spectra were obtained by
subtracting the excitation spectrum before the addition of peptides from the
excitation spectra after the peptides addition (15 AM). Before subtraction, the
spectra were normalized to the integrated areas so that the difference spectra
reflect only the spectral shifts. (A) T-1249, (B) T20 and (C) S peptides. The
latter spectra have no meaningful difference among each other.
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small DMSO amount present in the samples does not perturb
membrane structure [33].
3.4. Pep 1D interferes with the membrane partition of T20
T20 and T-1249 membrane partition experiments were done
in the presence and absence of S peptides as a tool to enable the
calculation of peptide binding constants. A decrease in the
partition occurs for T20 in the presence of Pep 1D (Fig. 4A). In
the presence of Pep 1E the result is not so striking, although
clear. T-1249 results were not conclusive. With Pep 2B and Pep
HR2 no difference occurs in T20 and T-1249 partition (Fig.
4B). The small DMSO amounts used do not perturb
membranes [33]. In agreement, DMSO had no significant
effect on T20 and T-1249 partition to membranes.
4. Discussion
SARS-CoV membrane fusion mechanism is similar to that
of class I viral fusion proteins, where HR regions have a very
important role. The HR1 regions form a trimer where the HR2
regions pack onto the grooves in an antiparallel manner to form
the six-helix bundle [12]. This structure leads to a close
apposition of viral and target cell membranes, favoring the
membrane fusion. The SARS-CoV S protein HR2-derived
peptides are able to inhibit viral entry. HR2 peptides compete
for binding to the HR1 region of the SARS-CoV S protein,
blocking the six-helix bundle structure formation, and thus
inhibiting fusion [10,12]. In our studies, we have explored the
interaction between T20 (HIV-1 gp41 HR2-derived peptide) or
T-1249 and SARS-CoV S protein HR1 (Pep 1D or Pep 1E)- or
HR2 (Pep 2B or Pep HR2)-derived peptides, in order to
explore a possible SARS-CoV fusion inhibition by the first
ones.
T20 fluorescence increases in the presence of Pep 1D or Pep
1E (although with a better signal/noise ratio in the first case),
but not in the presence of the other S peptides. The same occursfor T-1249, although the results are not so evident. This
increase in the fluorescence quantum yield probably indicates
tryptophan residues exposure to a less polar environment,
protected from the aqueous environment [34], revealing
peptides interaction. Alternative explanations, such as a
decrease in Trp fluorescence quenching by other peptide
residues, cannot be ruled out. Nevertheless, the increase of
ANS fluorescence intensity in the peptide/peptide titrations is
an evidence for the formation of hydrophobic pockets. To
assure that such increase is not due to the self-aggregation of
the titrating peptide, instead of inter-association of different
peptides, control experiments were performed in the absence of
the titrated peptides. Although self-aggregation occurs for T-
1249, Pep 1D and Pep 1E, a T20/Pep 1D inter-association of
hydrophobic nature is evident. However, the titration of T20
with Pep 1D does not lead to precisely the same result as the
opposite titration. The addition of Pep 1D to T20 lead to an
ANS fluorescence increase larger than the increase caused by
Pep 1D self-aggregation alone. The addition of T20 to Pep 1D
does not result in a similar fluorescence increase. This occurs
because T20 is not able to destroy Pep 1D aggregates, which
prevent peptides interaction in a larger extent. The T20/Pep 1E
and T-1249/Pep 1D systems lead to low signal/noise ratios,
preventing straightforward conclusions. Yet, T-1249 and Pep
1E show no evidence for interaction. Both T20 and T-1249
show no interaction with HR2-derived peptides detectable by
ANS fluorescence.59
S. Veiga et al. / Biochimica et Biophysica Acta 1760 (2006) 55–6160Di-8-ANEPPS was used to probe the peptides interaction
with membranes. It is known from other studies that both T20
and T-1249 interact with membranes to a reasonable extent
[31,32]. In agreement with the previous results, T-1249 is the
peptide that presents the most extensive interaction with
membranes. From the comparison between all the fluores-
cence difference spectra intensity obtained (Fig. 3), it can be
concluded that the S peptides have a very low or even null
partition to membranes.
T20 and T-1249 membrane partition experiments were done
in the absence and presence of S peptides (Fig. 4). T20
partition curves in the absence and in the presence of Pep 1D
do not overlap. One possible explanation is that peptides
interact in the aqueous medium and this additional equilibrium
(interaction) competes with partition, decreasing the molar
fraction of the molecules in the lipidic bilayers. The same
occurs for T-1249/Pep 1D and for both peptides in the presence
of Pep 1E. However, the statistical quality of the results
worsens in these cases. In the presence of Pep 2B or Pep HR2,
the partition of both T20 and T-1249 is not affected. It is
possible to quantify the equilibria balance and rationalize the
altered partition plots (Appendix A). This analysis takes into
account the partition of T20 and T-1249 to LUV of POPC and
the interaction in the aqueous medium with S peptides. Data
fitting with Eq. (A1.7) (Appendix A) for T20 in the presence of
Pep 1D (Appendix A; Fig. A1.2) leads to a binding coefficient
of KB=(1.1T0.3)105 M1 (meansT standard deviation of
four replicates). This value is in between the values obtained
for very strong and specific binding, such as the binding of the
S1 domain of SARS-CoV to ACE2 (¨108 M1; Ref. [35]) and
the values expected for moderately specific association pairs
(¨102 M1; Ref. [36]).
Taken together, the results obtained prove the occurrence
of an interaction between T20 and Pep 1D. Taking into
account that T20 is an HR2-derived peptide and Pep 1D is
an HR1 peptide, our results seem to confirm at a first
glance that SARS-CoV could be inhibited by T20, in
agreement with the speculative reasoning by others [21].
Nevertheless, the interaction is too moderate to be able to
provide therapeutic efficiency, even keeping in mind that
SARS-CoV HR2 peptides are less potent fusion inhibitors
than the corresponding HR2 peptides from other viruses
[10,12]. For SARS-CoV, the inhibitory peptides concentra-
tions were in the micromolar range, while T20, for instance,
has activity in the nanomolar range against HIV-1 entry.
Although the inhibitory properties of HR2 peptides could be
affected by many different factors, SARS-CoV six-helix
bundle lower stability, caused by a weaker interaction
between the HR1 and HR2 regions, could be directly
correlated with a lower potency of the HR2 peptide in
blocking the formation of this structure [10,12,37].
In conclusion, our studies indicate a significant interac-
tion between T20 and an S protein HR1-derived peptide
(Pep 1D). This interaction could in principle be responsible
for the inhibition of SARS-CoV membrane fusion by the
most accepted mechanism involving HR2-derived peptides.
However, the values found for KB justify the absence of60strong anti-SARS activity in the most recent activity studies
[24]. Lastly, it is worth mentioning that although a potential
use of Pep 1D to block HIV-1 fusion becomes apparent
from our work, it is known that HR1-derived peptides
usually are less potent fusion inhibitors than HR2-derived
peptides [16,38].
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APPENDIX 1 - Simultaneous partition and interaction  
Multiple equilibria are involved when T20 or T-1249 (generally referred to as TX 
hereafter) in solution are in the presence of S protein derived peptides (generally, PS) 
and membranes (Figure A1.1). TX may be free in the bulk aqueous media (FW), 
associated with PS in the bulk aqueous media (IW) or bound to POPC membranes (L). 
The total T20 or T-1249 fluorescence intensity is given by I = IFW⋅XFW + IIW⋅XIW + 
IL⋅XL, where Ii and Xi are the fluorescence intensities that would be obtained if all the 
peptides were located in the environment i (i = FW, IW or L) and the molar fractions of 
the peptide in that environment, respectively. In this simple model we assume both the 
interaction between TX and PS to be in a 1:1 proportion and no membrane partition of 
TX/PS. It is known from our experiments with the di-8-ANEPPS probe that PS partition 
into membranes does not occur at all. Considering that the quantum yield of the free TX 
peptide in bulk aqueous media does not differ much from the quantum yield of the 
associated peptide in water (see Figure 1 in the text – a moderate increase is expected), 
then IFW can be considered equal to IIW with reasonable approximation and: 
 
( ) LLLFW XIX1II +−=                                                                          (A1.1) 
 
Considering the equilibria in Figure A1.1 (interaction between TX and PS peptides in 
solution and insertion of TX in POPC membrane): 
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where ni are the moles of the peptide in the environment i; Kp and KB are the partition 
and binding coefficients, respectively, of the peptides, as defined in Eq. A1.4 and A1.5; 
[PS] and [L] are the S peptide and lipid molar concentrations, respectively; and, γL is the 
average lipid molar volume. Combining Eq. A1.2 and A1.3, it is possible to calculate 
the molar fraction of peptides inserted in the POPC membrane (XL; equation A1.6): 
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Thus, Eq. A1.1 can be rewritten as: 
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which describes the fluorescence intensity dependence on lipid concentration. 
Eq. A1.7 was fitted to the experimental data using the Kp and IL/IFW values calculated in 
the absence of S peptide (Figure A1.2). For the T20/Pep 1D pair KB = (1.1±0.3) × 105 
M-1 (means ± standard deviation of four replicates). 
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Figure A1.1. TX distribution: free in the bulk aqueous media (FW), interacting with PS 
in the bulk aqueous media (IW) and bound to POPC membranes (L). 
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Figure A1.2. Partition plots of T20 to LUV of POPC in the absence (•) and presence 
(?) of Pep 1D. Eq. A1.7 was fitted to the experimental data for T20 in the presence of 
Pep 1D (solid line) using the calculated Kp for T20 alone. KB is a fitting parameter. 
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Chapter IV 
 
 
THE gp41 MEMBRANE 
PROXIMAL REGION 
ROLE ON HIV-1 
FUSION PROCESS 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
HIV-1 entry into target cells occurs through a mechanism mediated by the 
gp120/gp41 envelope glycoprotein complex. gp120 binding to cellular receptors 
induces conformational changes in the gp120/gp41 complex that allows membrane 
fusion and viral entry to occur. Several gp41 regions have been involved in the 
membrane destabilization and fusion process: the FP is essential for the fusion process 
by inserting into the target cell membrane and causing membrane perturbations (e.g., 
Tamm and Han, 2000; Epand, 2003); the two HR sequences, NHR and CHR, tightly 
associate in order to form the 6HB structure that brings the viral and cell membrane into 
close proximity for fusion to occur (e.g., Chan and Kim, 1998; Wyatt and Sodroski, 
1998; Eckert and Kim, 2001a). It has been also proposed, based on the their behaviour 
in the presence of membranes, that these regions have a role in membrane fusion 
(Rabenstein and Shin, 1995; Peisajovich et al., 2000; Kliger et al., 2000; Sackett and 
Shai, 2002; Sackett and Shai, 2003; Shnaper et al., 2004; Pascual et al., 2005a; Korazim 
et al., 2006); due to its action on membranes an essential role for the LR in the fusion 
process was suggest (Santos et al., 1998; Contreras et al., 2001; Pascual et al., 2005b).  
The MPR, on the gp41 ectodomain C-terminal, is located between the CHR and the 
TM and is unusually rich in Trp residues (Figure IV.1). Mutational and functional 
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analyses on the gp41 ectodomain within the MPR showed a crucial role for this region 
in gp41-mediated membrane fusion (Salzwedel et al., 1999; Muñoz-Barroso et al., 
1999), being dispensable for the gp41/gp120 normal maturation, transport and CD4-
binding ability (Salzwedel, 1999). Studies with a synthetic peptide corresponding to the 
MPR sequence revealed its ability to interact with membranes, and induce membrane 
fusion and destabilization (Suárez et al., 2000a,b). Therefore this region could 
destabilize membranes, which is thought to be a crucial step in the membrane fusion 
process. This peptide adopts a α-helical conformation in membrane mimetic 
environment and inserts near the membrane interface, parallel to the membrane plane 
(Schibli et al., 2001). Some data also support a role for the MPR in gp41 aggregation at 
the fusion site (Sáez-Cirion et al., 2002; Sáez-Cirión et al., 2003), important to the 
fusion process since it seems that several trimers are needed to form a fusion pore.  
 
 
Figure IV.1 – gp41 membrane proximal region (MPR) location and sequence (residues 665-
683). 
 
The importance of the MPR for the membrane fusion process was confirmed in studies 
with the intact gp41, although it was suggested that the MPR is not required for 
membrane destabilization (Dimitrov et al., 2003). Given the proximity of the MPR to 
the viral membrane, it is conceivable that similarly to the FP effect on the target cell 
membrane, this gp41 region act primarily by perturbing the viral envelope. In fact, the 
presence of Chol and SM, major components of the viral membrane, have an important 
role on the membrane perturbing actions of a MPR derived peptide (Sáez-Cirion et al., 
2002; Shnaper et al., 2004). Leakage experiments revealed that SM presence activated 
the permeabilization induced by the peptide by increasing its surface aggregation in 
membranes. The presence of Chol stimulates the MPR membrane destabilization action 
(Sáez-Cirion et al., 2002). It was suggested that a C-terminal domain including both 
CHR and MPR is specific in its mode of action in perturbing Chol-rich membranes, 
 FP    NHR     CHR  TM MPR CT 
            KWASLWNWFNITNWLWYIK  
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while an N-terminal domain composed of both FP and NHR is potent toward 
membranes devoid of Chol (Shnaper et al., 2004). 
There is a growing interest in peptides and proteins that specifically bind to or are 
believed to be able to induce the formation of Chol-rich membrane domains. Peptides 
and proteins are supposed to promote the formation of Chol-rich domains by 
preferentially interacting with Chol, or alternatively as a result of being excluded from 
these domains while promoting their clustering (Epand, 2004; Epand, 2006). It was 
proposed that a small amino acid sequence within the MPR – LWYIK – is a Chol 
binding domain (Vincent et al., 2002), in agreement with a previously defined Chol 
recognition/interaction amino acid consensus pattern (-L/V-(X)1-5-Y-(X)1-5-R/K-), in 
which (X)1-5 represents between one and five residues of any amino acid (Li and 
Papadopoulos, 1998). The virus membrane is rich in Chol and SM (Aloia et al., 1993; 
Brügger et al., 2006), which is related to the preferential budding of the virions through 
lipid rafts domains (Nguyen and Hildreth, 2000; Ono and Freed, 2001; Pickl et al., 
2001). Studies with a small synthetic peptide corresponding to the putative gp41 MPR 
Chol binding sequence suggested that Chol can promote the insertion of the peptide into 
a membrane and the peptide will sequester Chol in order to produce Chol-enriched 
domains (Epand et al., 2003; Epand et al., 2005; Epand et al., 2006). This Chol binding 
activity was related to the ability of the gp41 to partition into Chol rich lipid raft 
domains. The following paper sheds light on this issue. 
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2. THE INFLUENCE OF CHOLESTEROL ON THE 
INTERACTION OF HIV GP41 MEMBRANE PROXIMAL 
REGION-DERIVED PEPTIDES WITH LIPID BILAYERS 
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The influence of cholesterol on the interaction of HIV gp41
membrane proximal region-derived peptides with lipid
bilayers
Ana S. Veiga and Miguel A. R. B. Castanho
Centro de Quı´mica e Bioquı´mica, Faculdade de Cieˆncias da Universidade de Lisboa, Portugal
HIV-1 entry into target cells occurs through a mecha-
nism mediated by the envelope glycoprotein. Expressed
on the surface of the viral membrane as an oligomeric
protein (trimer), this glycoprotein is composed of two
subunits that are noncovalently associated: gp120,
the surface glycoprotein, and gp41, the transmembrane
glycoprotein [e.g. 1–3]. gp120 binding to CD4 and
chemokine receptors in the surface of the target cells
induces a series of conformational changes in the
gp120 ⁄gp41 complex that allows membrane fusion and
viral entry to occur [e.g 1–4].
The virus membrane is rich in cholesterol and sphin-
gomyelin [5]; this composition is related to the prefer-
ential budding of the virions through lipid rafts
domains [6,7]. Enriched in cholesterol and sphingo-
lipid, lipid rafts are plasma membrane domains orga-
nized in a tightly packed, liquid-ordered manner and
are involved in several cellular processes besides viral
entry, such as membrane trafﬁcking or signal transduc-
tion [8,9].
The fusion peptide (on the amino-terminal region of
the gp41 ectodomain) serves an essential role for the
fusion process by inserting into the target cell mem-
brane and causing its destabilization [10,11]. The two
heptad repeat sequences (HR1, adjacent to the fusion
peptide and HR2, preceding the transmembrane
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A small amino acid sequence (LWYIK) inside the HIV-1 gp41 ectodomain
membrane proximal region (MPR) is commonly referred to as a choles-
terol-binding domain. To further study this unique and peculiar property
we have used ﬂuorescence spectroscopy techniques to unravel the mem-
brane interaction properties of three MPR-derived synthetic peptides: the
membrane proximal region peptide-complete (MPRP-C) which corresponds
to the complete MPR; the membrane proximal region peptide-short
(MPRP-S), which corresponds to the last ﬁve MPR amino acid residues
(the putative cholesterol-binding domain) and the membrane proximal
region peptide-intermediate (MPRP-I), which corresponds to the MPRP-C
peptide without the MPRP-S sequence. MPRP-C and MPRP-I membrane
interaction is largely independent of the membrane phase. Membrane inter-
action of MPRP-S occurs for ﬂuid phase membranes but not in gel phase
membranes or cholesterol-containing bilayers. The gp41 ectodomain MPR
may have a very speciﬁc function in viral fusion through the concerted
and combined action of cholesterol-binding and non-cholesterol-binding
domains (i.e. domains corresponding to MPRP-S and MPRP-I, respec-
tively).
Abbreviations
Ac, acetyl; FP, fusion peptide; HR1 and HR2, heptad repeat sequences; Kp, partition coefficient; LUV, large unilamellar vesicles; MPR,
membrane proximal region; MPRP-C, (membrane proximal region peptide-complete); MPRP-I, (membrane proximal region peptide-
intermediate); MPRP-S, (membrane proximal region peptide-short); POPC, 1-palmitoyl-2-oleyol-sn-glycero-3-phosphocholine; DPPC,
1,2-dipalmitoyl-sn-glycero-3-phosphocholine; POPG, 1-palmitoyl-2-oleyol-sn-glycero-3-[phospho-rac-(1-glycerol)]; di-8-ANEPPS, (4-[2-[6-(dioctyl-
amino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridinium); TM, transmembrane sequence; k, wavelength; kexc, excitation wavelength;
kem, emission wavelength.
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domain) tightly associate to form the six-helix bundle
structure that brings the viral and cell membrane into
close proximity for viral entry [1,3,4]. There is also a
membrane proximal region (MPR; unusually rich in
tryptophan residues) located between the HR2 and the
transmembrane domains (Fig. 1) that is essential in
gp41-mediated fusion [12–14]. The synthetic peptide
corresponding to this region has the capacity of parti-
tion into membranes, destabilizing them [15,16] and
the presence of cholesterol and sphingomyelin (major
components of the viral membrane) have an important
role for the membrane perturbing actions of the pep-
tide [17,18].
There is a growing interest in proteins and peptides
that speciﬁcally bind to or are able to induce the for-
mation of cholesterol-rich membrane domains. It was
proposed that a small amino acid sequence (LWYIK)
within the MPR is a cholesterol-binding domain [19],
in agreement with a previously deﬁned cholesterol
recognition ⁄ interaction amino acid consensus [20].
This small peptide was also suggested as a promoter
for cholesterol-rich domains [21–23].
In the present work we studied three synthetic pep-
tides, differing in length, derived from the gp41 ecto-
domain MPR (Table 1): membrane proximal region
peptide-complete (MPRP-C), which corresponds to the
complete region (19 amino acid residues); membrane
proximal region peptide-short (MPRP-S), which corre-
sponds to the last ﬁve amino acid residues (correspond-
ing to the domain considered to be cholesterol
binding); and membrane proximal region peptide-inter-
mediate (MPRP-I) which corresponds to the MPRP-C
peptide without the MPRP-S peptide sequence (14
amino acid residues). Our aim was to study the interac-
tion of the peptide MPRP-S [acetyl (Ac)-LWYIK-NH2]
with biological membrane models of different composi-
tion. A comparative study with the other two peptides
(MPRP-C and MPRP-I) was carried out to unravel the
role of the MPR domains in gp41–membrane interac-
tion, mainly with cholesterol-rich domains.
Results
Photophysical characterization
The maxima emission wavelengths (kem) measured (on
the corrected spectra) were 338, 346 and 339 nm for
MPRP-C, MPRP-S and MPRP-I, respectively (353,
360 and 356 nm, respectively, the noncorrected spec-
tra), as shown in Fig. 2A. There is a slightly nonlinear
dependence of the peptide ﬂuorescence intensity with
its concentration for MPRP-C and MPRP-I, whereas a
linear dependence is detected for MPRP-S (Fig. 2B).
Fluorescence quenching by acrylamide leads to nonlin-
ear Stern–Volmer plots for MPRP-C and MPRP-I and
a linear plot for MPRP-S (Fig. 2C).
Membrane partition studies
A theoretical hydrophobicity analysis of the MPR
sequence was performed to estimate the regions of the
sequence with a tendency to the membrane–water inter-
face (DGwif < 0) and with a higher tendency toward
insertion in membranes (DGoct < 0) [24]. The results
are shown in Fig. 3 and the tendency toward insertion
in membranes is evenly spread over the sequence. How-
ever, one cannot completely exclude the possibility that
some accumulation of negative-free energy for partition
into membranes is present in the short segment at the
end of the sequence, corresponding to the cholesterol-
binding domain (MPRP-S).
The peptides used in this work are intrinsically ﬂuo-
rescent and both ﬂuorescence intensity and anisotropy
data were collected to draw conclusions about the
interaction of peptides with large unilamellar vesicles
(LUV). The ﬂuorescence quantum yield is dependent on
the polarity of the microenvironment of the Trp resi-
dues, as well as on the peptide conformation. Both are
affected upon insertion of the peptides in membranes.
Additionally, the membranes are viscous media, which
dictate a potential increase in ﬂuorescence anisotropy
upon insertion of the peptides in membranes.
Fluorescence intensity measurements
In the presence of 1-palmitoyl-2-oleyol-sn-glycero-3-
phosphocholine (POPC) LUV, a liquid-crystalline lipid
with packing density and ﬂuidity properties similar to
Fig. 1. gp41 structure schematic representation. FP, fusion peptide;
HR1 and HR2, heptad repeat sequences; TM, transmembrane
sequence and MPR, membrane proximal region.
Table 1. Sequences of HIV-1 gp41 membrane proximal region
derived peptides MPRP-C, MPRP-S and MPRP-I used in the study.
The corresponding amino acid residues in gp41 protein of the
derived peptides used is in the table.
Peptide Protein location Sequence
MPRP-C 665–683 Ac-KWASLWNWFNITNWLWYIK-NH2
MPRP-S 679–683 Ac-LWYIK-NH2
MPRP-I 665–678 Ac-KWASLWNWFNITNW-NH2
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biological membranes, an increase in the peptides ﬂuo-
rescence intensity occurs, which is more pronounced
for MPRP-C and MPRP-I. Figure 4A–C shows the
results obtained for MPRP-C, MPRP-S and MPRP-I,
respectively. The ﬂuorescence intensity increase is coin-
cident with a ﬂuorescence emission spectra blue-shift
of 5, 3 and 11 nm for MPRP-C, MPRP-S and
MPRP-I, respectively, when [POPC] ¼ 3 mm. The
spectral shift is due to the incorporation of the
peptides in a more hydrophobic environment, the lipid.
The partition coefﬁcient between the aqueous and lipid
phases, Kp ¼ [peptide]L ⁄ [peptide]W, can be determined
to quantify the extent of the peptide incorporation
in LUV bilayers. [peptide]L and [peptide]W are the
peptide concentrations in the lipidic and aqueous
Fig. 2. (A) MPRP-C, MPRP-S and MPRP-I (10 lM for all peptides)
emission spectra (kexc ¼ 280 nm) in aqueous solution; (B) Peptide
fluorescence intensity dependence on concentration for MPRP-C
(d), MPRP-S (m) and MPRP-I (r). kexc ¼ 280 nm and kem ¼ 353,
360 and 356 nm for MPRP-C, MPRP-S and MPRP-I, respectively;
(C) Stern–Volmer plots for MPRP-C (d), MPRP-S (m) and MPRP-I
(r) fluorescence quenching by acrylamide. Small amounts of
quencher were added (in a range of 0–60 mM) to peptide sam-
ples (10 lM for all peptides) with 10 min incubation in between.
kexc ¼ 290 nm and kem ¼ 353, 360 and 356 nm for MPRP-C,
MPRP-S and MPRP-I, respectively. The data were corrected with
the correction factor C [34] accounting for both inner filter effect
and light absorption by the quencher.
Fig. 3. Theoretical analysis of partition into membranes of mem-
brane proximal region sequence. (A) Values of DGwif < 0 indicate
the sequence residues with tendency to the membrane–water
interface. (B) Values of DGoct < 0 indicate the residues with a
higher tendency towards insertion in membranes.
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environment, respectively. Kp is calculated from the
ﬂuorescence intensity data (I) using Eqn (1) [25]:
I
IW
¼
1þ KPcL ILIW ½L
1þ KPcL½L
ð1Þ
where IW and IL are the limit ﬂuorescence intensities
when all the peptide is in the water or lipidic phase,
respectively; cL is the lipidic molar volume [26] and
[L] is the concentration of the lipid accessible to
the peptide (the outer leaﬂet of the bilayer). In
the presence of POPC LUV, for MPRP-C,
MPRP-S and MPRP-I the obtained Kp values were
(2.5 ± 0.3) · 103, (1.2 ± 0.4) · 103 and (1.5 ±
0.3) · 103, respectively.
The results of ﬂuorescence intensity dependence on
other lipid compositions are also shown in Fig. 4A–C.
DPPC LUV allows the study of the partition of the
peptides into rigid membranes because 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC) bilayers are in gel
phase at 25 C. Kp values of (2.6 ± 0.3) · 103 and
(1.1 ± 0.3) · 103 were obtained for MPRP-C and
MPRP-I, respectively. MPRP-S partition is insigniﬁ-
cant and is not possible to calculate the exact Kp value
using Eqn (1).
Although POPC is a good model for the outer leaf-
let of mammal cell membranes, POPG 20 mol% in
POPC ⁄POPG LUV mimics the environment of the
inner leaﬂet of mammal biomembranes and it offers an
opportunity to study the inﬂuence of electrostatic
interaction in the partition of MPR peptides. MPRP-
C, MPRP-S and MPRP-I have positive net formal
charges of +2, +1 and +1, respectively. Kp values
of (9.5 ± 0.7) · 103 for MPRP-C, (0.9 ± 0.3) · 103
for MPRP-S and (2.3 ± 0.3) · 103 for MPRP-I were
obtained.
To study the effect of cholesterol on peptide–mem-
brane interactions, POPC ⁄ cholesterol LUV with an
increasing cholesterol content of 18, 25 and 33 mol%
were used. For MPRP-C the obtained Kp values are,
respectively, (2.0 ± 0.3) · 103, (2.2 ± 0.2) · 103 and
(2.5 ± 0.5) · 103 for 18, 25 and 33 mol% cholesterol.
With MPRP-I, Kp slightly decreases with increasing
cholesterol content: (1.9 ± 0.4) · 103, (1.4 ± 0.3) ·
103 and (1.0 ± 0.4) · 103, respectively. MPRP-S parti-
tion to POPC ⁄ cholesterol LUV is not detectable for
any of the different cholesterol contents and it is not
possible to calculate a Kp. Studies of MPRP-S with
POPC and POPC ⁄ cholesterol LUV have applied dif-
ferent peptide concentrations and incubation times,
and have found similar results (not shown). Table 2
Fig. 4. Partition plots (obtained with fluorescence intensity data) of
MPRP-C (A), MPRP-S (B) and MPRP-I (C) to LUV of POPC (d),
DPPC (r), negatively charged POPG (20% POPG in POPC; j), and
POPC ⁄ cholesterol mixtures [18% (m), 25% (*) and 33% mol cho-
lesterol (–)]. The solid lines are fittings of eqn (1) to the experimen-
tal data. [L] is the concentration of the lipid available in the outer
leaflet. kexc ¼ 280 nm and kem ¼ 353, 360 and 356 nm for
MPRP-C, MPRP-S and MPRP-I, respectively. All peptides were
used at a concentration of 10 lM. Table 2. Partition coefficients (Kp) for peptides MPRP-C, MPRP-S
and MPRP-I in the presence of different LUV compositions.
Kp ( · 103) MPRP-C MPRP-S MPRP-I
POPC 2.5 ± 0.3 1.2 ± 0.4 1.5 ± 0.3
DPPC 2.6 ± 0.3 – 1.1 ± 0.3
POPC ⁄ POPG
POPG 20 mol%
9.5 ± 0.7 0.9 ± 0.3 2.3 ± 0.3
POPC ⁄ cholesterol
cholesterol 18 mol%
2.0 ± 0.3 – 1.9 ± 0.4
POPC ⁄ cholesterol
cholesterol 25 mol%
2.2 ± 0.2 – 1.4 ± 0.3
POPC ⁄ cholesterol
cholesterol 33 mol%
2.5 ± 0.5 – 1.0 ± 0.4
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summarizes the partition coefﬁcients determined for
the peptides in the different lipid compositions studied.
Fluorescence anisotropy measurements
When only one Trp residue is present in a peptide
sequence, as is the case with MPRP-S, the application
of anisotropy-based methodologies is possible. At vari-
ance to this, when more than one Trp residue is pres-
ent (as in the case of MPRP-C and MPRP-I, where
ﬁve and four Trp residues are present, respectively)
anisotropy-based methodologies are not possible
because intramolecular energy migration (homo-trans-
fer) mechanisms are operative. Energy migration leads
to an anisotropy value close to zero regardless of the
rotational freedom of the ﬂuorophores or their excited
state life-time. In this way steady-state ﬂuorescence
anisotropy studies were carried out to obtain addi-
tional information about MPRP-S interaction with
POPC and POPC ⁄ cholesterol LUV. Equation (1) can
also be applied to calculate Kp values with ﬂuorescence
anisotropy data [25]. Results obtained with 30 lm
MPRP-S samples and 10 min incubation time, in the
presence of POPC and POPC ⁄ cholesterol (33 mol%
cholesterol) LUV are shown in Fig. 5. In agreement
with the results obtained with other peptide concentra-
tions and incubation time conditions (not shown),
there is evidence of peptide interaction with POPC
LUV, but not when cholesterol is present (for any of
the POPC ⁄ cholesterol LUV mixtures).
4-[2-[6-(Dioctylamino)-2-naphthalenyl]ethenyl]-
1-(3-sulfopropyl)-pyridinium (Di-8-ANEPPS)
fluorescence
Di-8-ANEPPS, a dye sensitive to changes in the mem-
brane dipole potential, was used as a probe for addi-
tional studies on peptide–membrane interaction. The
magnitude of the membrane dipole potential is affected
by membrane binding and by the insertion of molecules
(including peptides). The change of the potential mag-
nitude may be monitored through the spectral shifts of
the ﬂuorescence indicator di-8-ANEPPS [27,28]. Di-8-
ANEPPS excitation spectra were obtained setting kem
as the peak of the emission spectra, which depends on
the lipids used. Fluorescence difference spectra of di-
8-ANEPPS-labeled POPC or POPC ⁄ cholesterol mem-
branes were obtained by subtracting the excitation
spectrum before the addition of peptides from the exci-
tation spectrum in the presence of peptides. Before
subtraction, the spectra were normalized to the integ-
rated areas so that the difference spectra would
reﬂect only spectral shifts [27,28]. Figure 6A and B
shows the obtained ﬂuorescence difference spectra of
di-8-ANEPPS-labeled POPC and POPC ⁄ cholesterol
(33 mol% cholesterol), respectively, in the presence of
MPRP-C [30 lm (a)], MPRP-I [30 lm (b)] and MPRP-
S (50 lm (c)]. MPRP-C has the most signiﬁcant mem-
brane interaction, followed by MPRP-I and MPRP-S
Fig. 5. Partition plots (obtained with fluorescence anisotropy data)
of MPRP-S (30 lM) to LUV of POPC (d) and POPC ⁄ cholesterol
mixture, 33 mol% cholesterol (m). [L] is the total lipid concentra-
tion. kexc ¼ 290 nm and kem ¼ 360 nm.
Fig. 6. Di-8-ANEPPS-labeled POPC (A) and POPC ⁄ cholesterol,
33 mol% (B) LUV fluorescence difference spectra, in the presence
of (a) MPRP-C, (b) MPRP-I and (c) MPRP-S. The spectra were
obtained by subtracting the excitation spectrum before the addition
of peptides from the excitation spectra after addition of the pep-
tides (30 lM for MPRP-C and MPRP-I and 50 lM for MPRP-S), with
kem ¼ 578 nm and 568 nm for POPC and POPC ⁄ cholesterol LUV,
respectively. Before subtraction, the spectra were normalized to
the integrated areas to reflect only the spectral shifts. The dye and
lipid concentrations used were 10 lM and 200 lM, respectively.
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(for which the membrane interaction is undetectable)
for both LUV systems used. The results show that this
methodology is not sensitive enough to detect the bind-
ing of small peptides to lipid bilayers. The MPRP-S
partition cannot be detected with ANEPPS as it was
with partition studies. The results obtained in the pres-
ence of POPC ⁄ cholesterol LUV of 18 and 25 mol%
cholesterol (not shown) are in agreement with what is
shown in Fig. 6, as well as the results obtained with
other peptide concentrations (15 lm for MPRP-C and
MPRP-I and 30 lm for MPRP-S).
Discussion
The HIV-1 gp41 ectodomain comprises, in addition to
the fusion peptide and the two heptad repeat sequences
(HR1 and HR2), an MPR (rich in Trp residues) local-
ized between the HR2 and transmembrane domains
(Fig. 1). Several studies show the importance of
the MPR for membrane perturbing actions and the
fusion process mediated by gp41. The small sequence
LWYIK within the MPR is taken as a cholesterol-
binding domain. Peptides that speciﬁcally bind to or
are able to induce the formation of cholesterol-rich
domains are quite rare and peculiar, and therefore
attract a lot of attention. In our studies we have
explored the membrane interaction properties of three
gp41 MPR-derived synthetic peptides (Table 1), includ-
ing the cholesterol presence effect.
Because Trp residue emission is sensitive to the local
microenvironment of the residues [29], maxima kem
obtained for MPRP-C and MPRP-I in bulk-aqueous
phase are consistent with Trp residues in an apolar
environment, at variance with MPRP-S (350 nm is the
maximum kem of free Trp in bulk aqueous environ-
ment). Accordingly, nonlinear concentration effect and
solution ﬂuorescence quenching Stern–Volmer plots
revealed that hydrophobic pockets are present in
MPRP-C and MPRP-I, indicating that aggregation or
clustering may occur.
In the presence of POPC LUV, a lipid in ﬂuid
liquid–crystalline phase, MPRP-C has the more exten-
sive partition into the bilayer, followed by the other
two peptides with similar Kp values. For DPPC LUV
the MPRP-C partition constant is similar to the one
obtained with POPC. For MPRP-I the partition con-
stant slightly decreases, whereas for MPRP-S the parti-
tion constant becomes insigniﬁcant, probably due to
the rigidity of the bilayers, which are in gel phase. For
the POPC ⁄POPG mixture a remarkable increase in the
MPRP-C partition constant occurs, when compared
with the partition obtained with POPC. This result can
be related to electrostatic interactions between the
peptide, which has a +2 net formal charge, and the
negatively charged lipid. For MPRP-I, the partition
constant increase was not as high and in the case of
MPRP-S the partition constant remained unchanged
relative to POPC. The peptide charge has a more pro-
nounced effect in MPRP-C because it has +2 net
charge. The other peptides, MPRP-S and MPRP-I,
with a +1 net charge do not respond and respond
only weakly, respectively, to the electrostatic effect.
Depending on its molar fraction, the presence of
cholesterol on POPC LUV may lead to the formation
of a liquid-ordered phase. A moderate cholesterol con-
tent on the POPC ⁄ cholesterol LUV enables the coexis-
tence of cholesterol-rich (in a liquid-ordered phase)
and cholesterol-poor areas (in a liquid-disordered
phase). With an increase in cholesterol content, the
liquid-ordered membrane fraction increases and may
reach the point where all of the membrane is homoge-
neous. The MPRP-C is insensitive to the cholesterol
content in the membrane, which is in agreement with
the insensitivity of the peptide to the membrane phase
(Kp in DPPC and POPC remains constant). Therefore,
MPRP-C interacts with all membrane regions regardless
of its rigidity and no speciﬁc interaction with cholesterol
is detected. For MPRP-I the same trend applies,
although a slight decrease in Kp with cholesterol content
cannot be discarded. In the case of MPRP-S no mem-
brane interaction can be detected in the presence of cho-
lesterol, which is in agreement with Kp  0 in DPPC.
As for MPRP-C, it is the membrane phase that regu-
lates Kp, not speciﬁc interactions with cholesterol. The
partition curves obtained with anisotropy data further
conﬁrmed the partition data for MPRP-S. Membrane
interaction does not occur when cholesterol is present in
the LUV composition.
To investigate whether the interaction of peptides
with membranes could consist of superﬁcial adsorption
only, which could remain undetected in ﬂuorescence
intensity and anisotropy experiments due to the unre-
stricted exposition of the indole Trp moiety to bulk
aqueous phase, the di-8-ANEPPS dye was placed in the
lipid bilayers to detect any changes in the membrane
dipole potential due to peptide adsorption. In the pres-
ence of POPC and POPC ⁄ cholesterol (33 mol%) LUV
the ﬂuorescence difference spectra obtained conﬁrm the
trend previously discussed for Trp ﬂuorescence data:
a decrease on membrane interaction in the direction
MPRP-C > MPRP-I > MPRP-S (Fig. 6). The results
exclude extensive adsorption of MPRP-S to mem-
branes. Moreover, Fig. 6A shows that the MPRP-S
peptide does not perturb the membranes very much as
ANEPPS ﬂuorescence is not affected by the presence of
peptide in spite of Kp ¼ (1.2 ± 0.4) · 103.
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The membrane interaction behaviour of MPRP-C
and MPRP-I is independent of the membrane phase
but not of the presence of charged lipids. Cholesterol
does not reduce the extent of or potentiate membrane
interaction. The similarity of Kp values for MPRP-C
in the presence of membrane with or without choles-
terol is in agreement with other studies [17]. For
MPRP-S, peptide–membrane interaction occurs for
ﬂuid phase LUV (POPC and POPC ⁄POPG). However,
no interaction is detected in the presence of gel phase
membranes and cholesterol. The membrane phase gov-
erns the peptide–membrane interactions and no speciﬁc
interaction with cholesterol needs to be invoked.
MPRP-S interacts with: (a) exposed cholesteryl resi-
dues [19]; (b) cholesterol molecules cosolubilized with
lipid and peptide prior to preparation of the bilayers
[21]; and (c) cholesterol molecules in sonicated (unsta-
ble) vesicles challenged with high peptide ⁄ lipid molar
ratios (1:1 [22] and 1:10 [23]), where peptide-induced
perturbation of the bilayer may be extreme and bring
the peptide in contact with cholesterol. This interaction
is related to the presence of a cholesterol recognition
amino acid consensus pattern [20]. Although the Trp
residue may contribute to this recognition ⁄ interaction
[23], the main role belongs to Tyr [20,22,23], in agree-
ment with the ability of Tyr side chains to be modu-
lated by cholesterol in bilayers [30–33].
This study shows that in unperturbed bilayers the
consensus region (MPRP-S) of the ectodomain mem-
brane proximal region (MPRP-C) does not interact
with gel and liquid-ordered bilayers (i.e. cholesterol-
rich bilayers), where cholesterol is buried in the
membrane palisades. It is the MPRP-I sequence that
probably confers the main membrane interaction prop-
erties to the membrane proximal region. The most
peculiar property of MPRP-I (and MPRP-C) is the
insensitivity of Kp to lipid phase; this may be the key
to the pretransmembrane biological function because it
potentially interacts both with the HIV-1 envelope and
the host cell plasma membrane. However, one must
remember that membrane interactions of peptides
can be enhanced by a concerted action of several
membrane-binding motifs or by the particular dispo-
sition of key residues in the context of long peptides or
even in the context of the full protein. Bearing this in
mind, a MPRP-S role in the interaction of the MPR
with membranes cannot be excluded.
The gp41 ectodomain MPR may therefore have a
very speciﬁc function in viral fusion through the con-
certed and combined action of cholesterol-binding and
non-cholesterol-binding domains (i.e. domains corre-
sponding to MPRP-S and MPRP-I, respectively, in the
fusion process).
Experimental procedures
The peptides Ac-KWASLWNWFNITNWLWYIK-NH2
(MPRP-C), Ac-LWYIK-NH2 (MPRP-S) and Ac-KWA-
SLWNWFNITNW-NH2 (MPRP-I) were purchased >90%
pure from AnaSpec, Inc. (San Jose, CA). POPC, DPPC
and POPG were purchased from Avanti Polar-Lipids (Ala-
baster, AL), and cholesterol was purchased from Sigma (St.
Louis, MO). Di-8-ANEPPS was purchased from Molecular
Probes (Eugene, OR). Hepes and NaCl were from Merck
(Darmstadt, Germany). Hepes buffer 10 mm, pH 7.4,
150 mm NaCl, was used throughout the studies. MPRP-C,
MPRP-S and MPRP-I stock solutions in buffer were
diluted to ﬁnal desired concentrations. MPRP-I stock
solutions were prepared in buffer with small amounts of
dimethylsulfoxide. The ﬁnal concentration of dimethylsulf-
oxide in the samples through the experiments was at most
1.4% (v ⁄ v). The solubilization of all peptides was improved
with mild bath sonication. The spectroﬂuorimeter used was
a Jobin Ivon Fluorolog 3 (Edison, NJ, USA) (double
monochromators; 450 W Xe lamp).
Photophysical characterization of peptides
The studied peptides contain tryptophan residues
(Table 1), which makes ﬂuorescence techniques suitable
tools. To study the peptide concentration effect on the
ﬂuorescence emission of the peptide, ﬂuorescence emission
spectra (excitation wavelength, kexc ¼ 280 nm) were
determined for each peptide concentration (0.1–10 lm). In
quenching studies with acrylamide in solution, small
amounts of quencher were added (in a range of 0–60 mm)
to peptide samples (10 lm) with 10 min incubation
in between; kexc ¼ 290 nm and kem ¼ 353, 360 and
356 nm for MPRP-C, MPRP-S and MPRP-I, respectively.
The data were corrected with the correction factor C [34]
accounting for both inner ﬁlter effect and light absorption
by the quencher.
Membrane partition studies
MPRP-C, MPRP-S and MPRP-I membrane interaction
studies were carried out with large unilamellar vesicles as
membrane model systems. LUV of pure POPC and DPPC
and mixtures of POPC ⁄POPG 80 : 20 (mol%) and
POPC ⁄ cholesterol 67 : 33, 75 : 25 and 82 : 18 (mol%) were
used. DPPC or POPC and POPG or cholesterol (when
required), were mixed in chloroform, in a round-bottom
ﬂask and the solution was dried under a gentle stream of
nitrogen. Solvent removal was completed in vacuum for
8–10 h. LUV were prepared by extrusion techniques [35]
using 100 nm pore size ﬁlters.
Membrane partition studies were performed by adding
small volumes of concentrated LUV stock solutions to the
peptide samples (10 lm), followed by incubation for
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10 min before measurements. MPRP-S studies with POPC
and POPC ⁄ cholesterol mixtures were also carried out
using additional peptide samples of 5, 30 or 150 lm, fol-
lowed by immediate measurements or 10 min of incuba-
tion time.
Fluorescence intensity measurements
Fluorescence intensity data was measured at kexc ¼ 280 nm
and kem ¼ 353, 360 and 356 nm for MPRP-C, MPRP-S
and MPRP-I, respectively. All the data were corrected for
background intensities (by subtracting a blank vesicle sam-
ple), progressive peptide dilution and for light scattering
effects associated with LUV [36].
Fluorescence anisotropy measurements
Fluorescence anisotropies (r) were determined according to
Eqn (2):
r ¼ ðIVV  GIVHÞðIVV þ 2GIVHÞ ð2Þ
where IVV and IVH are the ﬂuorescence intensities from
polarized emission and G ¼ IHV ⁄ IHH is the instrumental
factor. The subscripts indicate the vertical (V) or horizontal
(H) orientations of the excitation and emission polarizers.
The ﬂuorescence intensities were measured at kexc ¼
290 nm and kem ¼ 360 nm and corrected for background
intensities (by subtracting a blank vesicle sample) and light
scattering effects associated with LUV.
di-8-ANEPPS fluorescence measurements
POPC and cholesterol (when required), in chloroform, and
di-8-ANEPPS (from a stock solution in ethanol) were
mixed in a round-bottom ﬂask. LUV were prepared as
described previously. Peptides MPRP-C, MPRP-I (at 15 lm
or 30 lm) and MPRP-S (at 30 lm or 50 lm) were added
afterwards. Di-8-ANEPPS excitation spectra were obtained
setting kem at 578 nm when in POPC membranes, and at
568 nm when in POPC ⁄ cholesterol membranes. The ﬁnal
concentrations used were 200 lm of lipid and 10 lm of di-
8-ANEPPS.
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Chapter V 
 
 
THE ROLE OF 
MEMBRANES IN THE 
HIV-1 ANTIBODIES 
2F5 AND 4E10 MODE 
OF ACTION 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
Only few human potent and broadly neutralizing MAbs against HIV-1 primary 
isolates, targeting different envelope glycoprotein complex epitopes, have been 
identified (Trkola et al., 1995; D’Souza et al., 1997; Zwick et al., 2001). 2F5 and 4E10 
are two of these (Conley et al., 1994; Trkola et al., 1995; Stiegler et al., 2001; Zwick et 
al., 2001) and recognize epitopes whose core sequences are ELDKWA and 
NWF(D/N)IT, respectively, both localized on the MPR gp41 ectodomain (Figure V.1). 
Nevertheless, the 2F5 epitope extends toward outside the MPR N-terminal (Muster et 
al., 1993; Parker et al., 2001; Stiegler et al., 2001; Zwick et al., 2001; Zwick et al., 
2005; Brunel et al., 2006). It is not well established the gp41 state at which 2F5 binds to 
its epitope since there were suggestions that 2F5 binds both to its epitope in the fusion 
intermediate prehairpin structure (Gorny and Zolla-Pazner, 2000; Follis et al., 2002; de 
Rosny et al., 2004) and in the native form of gp41 (Gorny and Zolla-Pazner, 2000; 
Barbato et al., 2003; de Rosny et al., 2004). For 4E10 it was also proposed that 
additionally to the MPR, it recognizes the N-terminal sequences of gp120 and gp41 on 
the native protein (Hager-Braun et al., 2006). 
 
The role of membranes in the HIV-1 antibodies 2F5 and 4E10 mode of action 
 82 
 
Figure V.1 – 2F5 and 4E10 binding sites on the gp41. 4E10 epitope is entirely within the MPR, 
while 2F5 epitope extends toward outside the MPR N-terminal end. Both MAbs epitopes are 
very close to the membrane (Adapted from Nabel, 2005). 
 
It was suggested based on the crystal structures of 2F5 (Ofek et al., 2004) and 4E10 
(Cardoso et al., 2005), that these MAbs can interact with the viral membrane (Figure 
V.2) through a hydrophobic surface present on the long third complementarity-
determining region of the heavy chain (CDR H3). Both 2F5 and 4E10 have an 
unusually long and hydrophobic CDR H3. This interaction possibly facilitates the 
binding to the MAbs epitopes, known to be localized very close to the viral membrane. 
For 2F5, the interactions between its CDR H3 and the epitope occur predominantly with 
residues at the CDR H3 base, the CDR H3 apex residues remaining unbound to gp41. 
Ofek and co-workers suggested the existence at the apex of a hydrophobic surface 
composed by the hydrophobic amino acids Leu, Phe, Val, and Ile, that may be 
responsible for 2F5 binding to the membrane, facilitating the epitope binding. The 4E10 
CDR H3 presents, similarly to 2F5, a large surface that is not implicated in the contact 
with the epitope, raising the possibility of further viral membrane contacts. The CDR 
H3 tip contains a hydrophobic surface, similar to the one described for the 2F5 CDR 
H3, in which two Trp residues could facilitate interactions with the viral membrane. 
Additionally, Gly residues present on the same surface may confer conformational 
flexibility that allows 4E10 to access the viral membrane when bound to the MPR gp41 
epitope (Cardoso et al., 2005).  
 
 FP    NHR     CHR TM MPR CT 
NEQELLELDKWASLWNWFNITNWLWYIK  
2F5 
epitope 
4E10 
epitope 
     CHR 
 MPR 
     NHR 
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Figure V.2 – Possible interaction of the MAbs 2F5 and 4E10 with the viral membrane through 
a hydrophobic patch present on the CDR H3 (Adapted from Nabel, 2005). 
 
 Actually, some studies indicate a correlation between these MAbs binding to the 
gp41 with the presence of membranes. Both MAbs recognize their epitopes when the 
gp41 is inserted in a membrane (Lenz et al., 2005). 2F5 and 4E10 binding affinity for 
the epitope is enhanced when gp41 is membrane-bound relative to gp41 in the absence 
of lipids. This result suggests a possible dependence of the epitope conformation on the 
presence or absence of lipid (Grundner et al., 2002; Ofek et al., 2004).  
 Further studies showed that a direct binding of both 2F5 and 4E10 to some 
membranes or membrane lipids can occur. Haynes et al. (Haynes et al., 2005) 
demonstrated that the MAbs 2F5 and 4E10 interact with cardiolipin (CL), a 
phospholipid to which Abs are formed in lupus, and others auto-antigens, in a similar 
way to those of Abs associated with autoimmune diseases (auto-antibodies). However, 
CL is usually present only on the inner membrane of mitochondria and has not been 
reported to be present on plasma membrane or HIV-1 envelope (Alving et al., 2006). 
Additionally these authors found that 4E10 react also with PS, PC, PE and SM (Haynes 
et al., 2005). Studies with membrane model systems reported 2F5 and 4E10 binding to 
PC, PG and CL liposomes (Sánchez-Martínez et al., 2006a; Sánchez-Martínez et al., 
2006b). Very recently, our study as well as other contemporary study showed that 2F5 
membrane interactions are weak when compared with those of 4E10, but binding of 2F5 
to CL seems to be specific (Sánchez-Martínez et al., 2006b). It was also shown that 
gp41-derived epitope sequences recognition by the MAbs can occurs in a membrane 
context (Sánchez-Martínez et al., 2006b; Alam et al., 2007). 4E10 can also bind to 
Viral membrane 
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phosphatidylinositol-4-phophate (PIP), specifically through a phosphate-binding subsite 
(Brown et al., 2007; Beck et al., 2007), resembling anti-PIP Abs (Brown et al., 2007). 
MAbs specific to PIP also resemble 4E10 in that they neutralize HIV-1 (Brown et al., 
2007). Since lipids like PS, PE or PIP might be exposed at the HIV surface (Alving et 
al., 2006), both 2F5 and 4E10 could in theory be used as Abs to lipids to neutralize 
HIV.  
The major challenge in the development of an AIDS vaccine that elicits broadly 
neutralizing Abs, is the design of immunogens that present the epitopes in a way that 
mimics their structure on the native HIV-1 envelope glycoprotein complex. Despite 2F5 
and 4E10 epitopes being particularly promising, eliciting these neutralizing MAbs has 
been revealed a not easy task (Coëffier et al., 2001; Joyce et al., 2002). The fusion 
inhibitor T20, whose sequence contains the 2F5 epitope, was proposed as a vaccine 
candidate. However, even with the use of T20 analogs with increased α-helix content 
that bind to 2F5 as well as or better than the native T20, conjugate vaccines prepared 
from the peptides fail to elicit neutralizing responses in vitro (Joyce et al., 2002). This 
general lack of success is probably a result of failure of the synthetic epitopes to adopt a 
conformation similar to the native epitope in the viral context, and in this way, Abs can 
be generated but cannot recognize the functional trimeric viral proteins. The studies 
presented in this chapter help to elucidate the membranes’ involvement on these MAbs 
action. 
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2. THE MEMBRANES’ ROLE IN THE HIV-1 NEUTRALIZING 
MONOCLONAL ANTIBODY 2F5 MODE OF ACTION NEEDS 
RE-EVALUATION 
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Abstract
2F5, a monoclonal antibody that neutralizes HIV-1 primary isolates, recognizes an epitope in the membrane proximal region of the glycoprotein
gp41 ectodomain. It is believed that binding to the viral membrane is a step in the antibody mode of action, as usual in ligand membrane receptor
interactions. We investigated the interaction of 2F5 with membrane model systems, namely large unilamellar vesicles, by means of fluorescence
techniques. There were no significant interactions of 2F5 with model viral membranes or with model target cell membranes. Thus, the usual
three-step ‘membrane catalysis’ method is not followed by 2F5 in its mode of action.
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Human immunodeficiency virus type 1 (HIV-1) entry into tar-
et cells occurs through a mechanism mediated by the envelope
lycoprotein. Expressed on the viral membrane surface as trimer,
his glycoprotein is composed of two noncovalently associated
ubunits, gp120 (surface glycoprotein) and gp41 (transmem-
rane glycoprotein) (Chan and Kim, 1998; Wyatt and Sodroski,
998; Eckert and Kim, 2001). The gp120 binding to CD4 and
hemokine receptors at the target cell surface induces conforma-
ional changes in the glycoprotein complex. Subsequent changes
ithin the gp41 ectodomain involve the formation of a six-helix
undle structure (hairpin structure) allowing membrane fusion
nd viral entry (Chan and Kim, 1998; Wyatt and Sodroski, 1998;
ckert and Kim, 2001; LaBranche et al., 2001; Cooley and
ewin, 2003).
A few human monoclonal antibodies (mAbs) that neutral-
ze a broad range of HIV-1 primary isolates, targeting different
nvelope glycoprotein epitopes, have been identified (Trkola
t al., 1995; D’Souza et al., 1997; Zwick et al., 2001). The
Ab 2F5 is one of these and recognizes an epitope, con-
aining the sequence ELDKWA, in the membrane proximal
egion of the gp41 ectodomain (Muster et al., 1993; Parker
tope in the prehairpin structure, a fusion intermediate (Gorny
and Zolla-Pazner, 2000; Follis et al., 2002; de Rosny et al.,
2004), although there are also indications that binding can
occur with the native form of gp41 (Gorny and Zolla-Pazner,
2000; Barbato et al., 2003; de Rosny et al., 2004). Addition-
ally, 2F5 binding affinity for the epitope is enhanced when gp41
is in a lipidic environment (Grundner et al., 2002; Ofek et al.,
2004). The interactions between the 2F5 third complementarity-
determining region of the heavy chain (CDR H3) and the epitope
in gp41 occur predominantly with residues at the CDR H3 base.
Thus, there are CDR H3 residues that remain unbound to gp41,
including at the apex (Ofek et al., 2004). Ofek et al. (2004)
suggested the existence at the apex of a hydrophobic surface
composed by the hydrophobic amino acids Leu, Phe, Val, and
Ile. Given the viral membrane proximity to the 2F5 epitope,
this hydrophobic surface may be responsible for 2F5 binding
to the membrane facilitating the epitope binding (Ofek et al.,
2004).
We investigated mAb 2F5 membrane interactions using
membrane model systems (large unilamellar vesicles, LUV) of
pure POPC (1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine;t al., 2001). It has been proposed that 2F5 can bind its epi-
∗ Corresponding author. Tel.: +351 21 7500931; fax: +351 21 7500088.
E-mail address: castanho@fc.ul.pt (M.A.R.B. Castanho).
Avanti Polar-Lipids, Alabaster, AL) and POPC/Cholesterol
67:33 (mol%). Cholesterol was purchased from Sigma (St.
Louis, MO). POPC is a lipid with packing density and fluid-
ity properties similar to biological membranes and the mixture
POPC/Cholesterol mimic the viral membrane, which is rich in166-3542/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
oi:10.1016/j.antiviral.2006.02.00287
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cholesterol (Aloia et al., 1993; Campbell et al., 2002; Raulin,
2002).
2F5 is intrinsically fluorescent due to the presence of aro-
matic amino acids (tryptophan, tyrosine and phenylalanine),
which enable the study of this molecule using fluorescence tech-
niques. A spectrofluorimeter SLM Aminco 8100 with double
monochromators and 450 W Xe lamp was used. Human HIV-
1 gp41 monoclonal antibody 2F5 (IgG1 isotype, kappa chain)
was provided by the EU Programme EVA Centralised Facility
for AIDS Reagents, National Institute for Biological Standards
and Control, UK, and from Dr. Hermann Katinger. 2F5 stock
solutions (100g of purified antibody in 2 mM acetic acid (pH
4.0) + 10% maltose) were diluted with buffer (10 mM Hepes
buffer pH 7.4, 150 mM NaCl) to the final desired concentrations.
Initially, an evaluation of the Fab 2F5 3D structure (PDB
entry 2F5B) revealed that some of the aromatic residues are
exposed at the mAb surface. As Trp and Tyr residues have
propensity to insert into membranes and a tendency to locate
at the membrane–water interface (White and Wimley, 1998;
Killian and von Heijne, 2000), they may potentially help the
interaction of the 2F5 with the viral membrane, in addition to
the hydrophobic surface proposed by others (Ofek et al., 2004).
As the Trp residues’ emission is sensitive to their local envi-
ronment (Lakowicz, 1999), the measured emission maximum
wavelength of∼330 nm (320 nm in the corrected spectrum com-
pared to 350nm of free Trp in aqueous environment) of 2F5
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Fig. 2. Partition plots of 2F5 (1.5M) to LUV of POPC () and POPC/Chol
(). For the sake of comparison, the partition plot of T-1249 (a molecule that
interacts moderately with membranes (Veiga et al., 2004)) to LUV of POPC is
presented (). [L] is the concentration of the lipid available to 2F5 or T-1249
(i.e., the outer hemilayer of the vesicles).
Large unilamellar vesicles (∼100 nm diameter) were used
to study the interaction of 2F5 with membranes. POPC alone
or mixed with cholesterol (in chloroform) were placed in a
round bottom flask, and the solution was dried under a stream of
nitrogen. Solvent removal was completed in vacuum, overnight.
Finally, the LUV were prepared by extrusion techniques (Mayer
et al., 1986). Membrane partition studies were achieved by
successive additions of small aliquots of LUV (15 mM) to
the mAb samples (1.5M) with 10 min incubation intervals.
The excitation and emission wavelengths used were 280 and
330 nm, respectively. Fluorescence intensity data was corrected
for the dilution effect. The results obtained show no occurrence
of shifts of the emission spectra upon addition of POPC or
POPC/Chol vesicles (the spectra are similar to those in aque-
ous solution—data not shown). No concomitant increase in 2F5
fluorescence intensity was observed (Fig. 2). These findings sug-
gest that 2F5 does not partition to the membranes through an
extensive anchoring of a significant number of Trp residues.
However, the hydrophobic surface proposed to interact with
membranes does not contain Trp residues and it could be argued
that a mild interaction with the membrane could take place
strictly involving this restricted surface. One Phe residue is
present but Phe fluorescence is less sensitive to environment
polarity than Trp fluorescence and the interaction with the
lipids could thus remain undetected. To test this hypothesis we
performed studies with di-8-ANEPPS (4-[2-[6-(dioctylamino)-
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b.5M (Fig. 1A) reveals that most Trp residues are buried
nside the protein in the absence of membranes. This result
as confirmed with a solution quenching study with acrylamide
Fig. 1B). The very small quenching efficiency shows that the
queous quencher does not contact the Trp residues.
ig. 1. (A) 2F5 (1.5M) emission spectra in aqueous solution. (B)
tern–Volmer plot for 2F5 () and free Trp in solution () fluorescence quench-
ng by acrylamide. Small amounts of quencher were added (in a range of
–60 mM) to a 2F5 sample (1.5M) with 10 min incubation interval. The exci-
ation and emission wavelengths used were 290 and 330 nm, respectively. The
ata were corrected with the correction factor C (Coutinho and Prieto, 1993)
ccounting for both inner filter effect and light absorption by the quencher. t
88-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridinium; Molec-
lar Probes, Eugene, OR), a dye sensitive to changes in the
embrane dipole potential, which has been shown to detect
rotein membrane interaction (O’Shea, 2003) and can thus be
sed to probe the 2F5 interaction with membranes. Changes on
he membrane dipole potential magnitude, incited by membrane
inding and insertion of molecules, may be monitored by means
f spectral shifts of the fluorescence indicator di-8-ANEPPS
Cladera and O’Shea, 1998; Cladera et al., 2001). POPC, and
holesterol when required, and di-8-ANEPPS (from a stock
olution in ethanol) were used to prepare LUV by extrusion tech-
iques as mentioned before. Di-8-ANEPPS excitation spectra
ere obtained with emissions set at 600 nm (for POPC mem-
ranes) or 578 nm (for POPC/Chol membranes). The concentra-
ions used were 200M for lipids, 10M for di-8-ANEPPS and
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Fig. 3. Fluorescence difference spectra of di-8-ANEPPS-labeled POPC and
POPC/Chol membranes in the presence of 2F5 (A). Both spectra overlap and
were obtained by subtracting the excitation spectrum before the addition of
2F5 from the excitation spectrum after 2F5 (2M) addition, with λem = 600 nm
and λem = 578 nm for POPC and POPC/Chol membranes, respectively. Before
subtraction, the spectra were normalized to the integrated areas to reflect
only the spectral shifts. Dye and lipid concentrations used were 10M and
200M, respectively. The difference spectrum obtained with di-8-ANEPPS-
labeled POPC membranes in the presence of T-1249 (a molecule that interacts
moderately with membranes (Veiga et al., 2004)) is depicted for comparison (B).
2M for 2F5. Fig. 3 shows the fluorescence difference spectra of
di-8-ANEPPS-labeled POPC or POPC/Chol membranes, which
were obtained by subtracting the excitation spectrum before the
addition of 2F5 from the excitation spectrum in the presence of
2F5. Before subtraction the spectra were normalized to the inte-
grated areas to reflect only spectral shifts (Cladera and O’Shea,
1998; Cladera et al., 2001). Difference spectra intensity obtained
for both studied cases indicates that there are no interactions
of 2F5 with the membranes, which is reinforced by comparing
with the fluorescence difference spectrum of T-1249 (Fig. 3), a
molecule known to interact moderately with membranes (Veiga
et al., 2004, 2006).
In conclusion, no interaction occurs between the mAb 2F5
and both the cell and viral model membranes. Thus 2F5 does
not use membrane interaction prior to gp41 docking, i.e., does
not follow the classical ‘membrane catalysis’ scheme (Sargent
and Schwyzer, 1986; Castanho and Fernandes, 2006). In the
classical ‘membrane catalysis’ scheme the local concentrating
effect of the membrane is expected to increase the occupied-to-
unoccupied binding sites in the membrane by a factor that equals
the molar ratio partition coefficient (Castanho and Fernandes,
2006). Probably, membranes play a role simply by inducing the
best epitope conformation for binding (Grundner et al., 2002;
Ofek et al., 2004), but not through a preparation of 2F5 for
better docking. Taking together the results in this study with the
others on the molecular level action of 2F5 (Ofek et al., 2004),
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3. REAL-TIME BIOSENSOR INTERACTIONS OF HIV-1 
ANTIBODIES 2F5 AND 4E10 WITH A GP41 EPITOPE 
PREBOUND TO HOST CELL AND VIRAL MEMBRANE 
MIMETICS 
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Abstract 
Two HIV-1 recognition domains to human monoclonal antibodies 2F5 (ELDKWA) 
and 4E10 (NWFNIT) serve as promising models for immunogens in vaccine 
development against HIV-1. However, the failure of these recognition domains to 
generate broadly reactive neutralizing antibodies, and known membrane-binding 
properties of the antibodies raised to these recognition domains suggests that additional 
features or recognition motifs are required to form an efficient immunogen, which could 
possibly include membrane components. In this study we use an extended peptide-
epitope sequence derived from the gp41 native sequence (H-
NEQELLELDKWASLWNWFNITNWLWYIK-NH) that contains the two recognition 
domains to 2F5 and 4E10, to examine the role of model cell (POPC) and viral 
(POPC/Cholesterol/sphingomyelin) membranes, to determine the role of membranes in 
the recognition of these two antibodies. Using a surface plasmon resonance biosensor, 
the binding of 2F5 and 4E10 is compared and contrasted to membranes in the presence 
and absence of prebound peptide-epitope showing the recognition of gp41-derived 
epitope sequences by 2F5 and 4E10 occurs in a membrane context. The recognition of 
the peptide-epitope is found to be distinctly different; in the case of 2F5 the membrane 
appears to directly participate in epitope recognition with greatly reduced binding of 
2F5 seen to membranes alone, but in contrast 4E10 can bind strongly to membranes in 
the presence or absence of the peptide-epitope with more favourable dissociation rates 
demonstrated in the presence of the peptide-epitope. 
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Introduction 
The viral envelope glycoprotein responsible for the human immunodeficiency virus 
type 1 (HIV-1) entry into target cells is composed of the surface glycoprotein gp120 and 
the transmembrane glycoprotein gp41 (10, 11, 31). The binding of gp120 to cellular 
receptors and subsequent changes within the gp41 ectodomain involve the formation of 
a six-helix bundle structure and leads to both membrane fusion and viral entry (e.g., 10, 
11, 17, 31).  
The human monoclonal antibodies (MAbs) 2F5 and 4E10 are two rare, broadly 
neutralizing antibodies against HIV-1 (27, 29, 34) that interact with epitopes in the 
membrane proximal region (MPR) of HIV-1 gp41. Specifically, these MAbs recognize 
epitopes in gp41 with core sequences ELDKWA, for 2F5 (extending a little over the 
MPR N-terminal limit), and NWF(D/N)IT, for 4E10 (8, 20, 22, 27, 34, 35). These 
peptidic epitopes have attracted increasing attention as promising models for 
immunogens in vaccine development (33).  
In designing a more efficient gp41-based immunogen, it is known that the binding 
affinity of 2F5 and 4E10 for the epitopes is enhanced when gp41 is in a lipidic or 
membrane environment (15, 18, 21). Indeed, based on the crystal structures of 2F5 and 
4E10, it has been proposed that these MAbs can interact with the viral membrane 
through a hydrophobic surface present on the third complementarity-determining region 
of the heavy chain (CDR H3), possibly facilitating binding to gp41 epitopes that lie 
close to the membrane (9, 21). Additional studies have shown diverse lipid species can 
be important to 2F5 and 4E10 recognition comprising both neutral and anionic 
phospholipids (23, 24), including specialised anionic lipids such phosphatidylinositol-4-
phophate (PIP) (5, 6) and cardiolipin (CL) (16) which has recently been studied using 
Surface Plasmon Resonance (SPR) (2). 
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An overall conclusion that has been drawn is the recognition of gp41-derived 
epitope sequences by 2F5 and 4E10 occurs in a membrane context (2, 24). However, the 
questions the field is still addressing is the relevance of a lipid environment; whether the 
membrane participates or is tolerated in binding to 2F5 and 4E10 as inferred by 
structural biologists, or whether a lipid environment allows small gp41 epitopes to adopt 
a more structured (immunogenic) conformation which is then recognised by the MAbs 
or whether it is a combination of membranes enhancing epitope structure as well as 
directly forming part of a combined lipid-peptide antigen? The implication of 
understanding how 2F5 and 4E10 MAbs recognise their gp41 epitopes could lead to the 
development of more successful immunogens which either utilise lipids to improve 
structure and foreignness or perhaps have designed gp41-like epitopes constrained in 
pre-ordered immunogenic conformations. 
In the present work we examine the role of both cell and viral membranes in the 
mechanism of action of these two MAbs. Specifically, the interactions of 2F5 and 4E10 
were investigated in the presence and absence of a gp41 peptide that encompasses both 
2F5 and 4E10 recognised epitopes, that were prebound to model cell and viral 
membranes. We employed an SPR optical biosensor, which are increasingly used to 
directly study membrane-mediated interactions, as opposed to the majority of 
membrane-binding studies that use liposome-based ELISA assays or fluorescent 
binding experiments that indirectly measure binding events. This study provides new 
insight into the molecular properties important to the recognition of gp41 epitopes by 
these two important MAbs. 
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Materials and Methods 
2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
(HATU), N-methyl pyrrolidone (NMP), dimethylformamide (DMF), 
diisoproylethylamine (DIPEA), piperidine, triisopropylsilane (TIPS) and trifluoroacetic 
acid (TFA) were of peptide synthesis grade and obtained from Auspep (Melbourne, 
Australia). POPC (1-palmitoyl-2-oleyol-sn-glycero-3-phosphocholine) was purchased 
from Avanti Polar-Lipids (Alabaster, AL, USA). Sphingomyelin (SM; chicken egg 
yolk), Cholesterol (Chol), (3-[3-Cholamidpropy)-dimethyl-ammonio]-1-
propanesulfonate (CHAPS) and Sodium Dodecyl Sulfate (SDS)) were obtained from 
Sigma (St. Louis, MO, USA). HEPES was obtained from Sigma (Castle Hill, NSW, 
Australia) and NaCl was from Amresco (Solon, OH, USA). 10mM HEPES buffer pH 
7.4, 150mM NaCl, was used throughout the studies by dilution from a 10x stock. The 
SPR system used was a BIACORE T100 analytical system (Biacore, Uppsala, Sweden) 
using L1 sensor chip (Series S; Biacore) for liposome attachment. The regeneration 
solutions were SDS 0.5% (w/v), 20mM CHAPS, 10mM NaOH (20% methanol) and 
10mM NaOH. All the solutions used in the T100 were freshly prepared and filtered 
through a 0.22μm filter. 
 
Antibodies 
Human HIV-1 gp41 monoclonal antibodies 2F5 and 4E10 from Dr. H. Katinger and 
Polymun Scientific were provided by the EU Programme EVA Centralised Facility for 
AIDS Reagents, National Institute for Biological Standards and Control, UK and were 
also purchased from Polymun Scientific (Vienna, Austria). In order to avoid signal 
response variations during the SPR experiments because of the differences between the 
MAb solutions and the running buffer, 2F5 and 4E10 (up to 100μL) were dialysed in 
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HEPES buffer (500mL) for >16h using a 10kDa SnakeSkinTM Pleated Dialysis Tubing 
(Pierce, Rockford, IL, USA). The MAbs were quantified with the modified Lowry, DC 
protein assay (Bio-Rad, Gladesville, NSW, Australia). The dialysis buffer was 
subsequently used as running buffer in SPR experiments, thereby removing refractive 
index changes between solutions. Refractive index differences between different MAb 
preparations was <2RU. 
 
Peptide synthesis 
Rink amide resin was obtained from Novabiochem (San Diego, CA, USA) and 
Fmoc-L-amino acids were obtained from GL Biochem (Shanghai, China). The peptide 
H-NEQELLELDKWASLWNWFNITNWLWYIK-NH (hereafter referred to as peptide-
epitope) was synthesised on a 0.1mmol scale on Rink amide resin using a LibertyTM 
microwave peptide synthesiser (CEMTM; NC, USA) employing Fmoc solid-phase 
techniques (for review see 12). The peptide-epitope was assembled by systemically 
repeated steps of “double” coupling and “double” deprotection.  “Double” coupling: 
Fmoc-amino acid (5 eq.), HATU (4.5 eq.), DIPEA (10 eq.), in NMP for 2 × 5min, with 
20W microwave irradiation at 75ºC. “Double” deprotection: 20% piperidine in NMP (1 
× 30s, with 40W irradiation at 38ºC; followed by 1 × 3min, with 40W irradiation at 
75ºC). Following linear assembly, the peptide was cleaved from the resin with 
simultaneous removal of side-chain protecting groups by treatment with a cleavage 
cocktail (2mL) consisting of TFA (95%), TIPS (2.5%) and H2O (2.5%) for 3h at room 
temperature. Suspended resin was removed by filtration and the peptide precipitated in 
ice-cold diethyl ether. Solid material was then collected in a sintered glass funnel (pore-
size 4), washed with diethyl ether, dissolved with 1:1 MeCN/H2O, and lyophilised. An 
initial analysis of the crude material by RP-HPLC and mass spectrometry suggested the 
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presence of multiple N-carboxy groups presumably resulting from the incomplete 
removal of t-butoxycarbonyl sidechain protection from the indol nitrogen of the five 
tryptophan residues present (13).  Decarboxylation of these carbamic acid intermediates 
was achieved by dissolving the crude material in 9:9:2 MeCN/H2O/CH3COOH and 
stirring at room temperature overnight. The peptide was then purified by preparative 
RP-HPLC using an Agilent HP1100 system fitted with a VydacTM C18 (250mm × 
22mm) reverse-phase column.  The eluents used were 0.1% TFA in H2O (A) and 0.1% 
TFA in MeCN (B); the peptide was eluted by applying a linear gradient (at 6mL/min) of 
0% to 60 % B over 60min. Fractions collected were examined by analytical RP-HPLC 
and those found to contain exclusively the desired product were pooled and lyophilised.  
Analysis of the purified final product by RP-HPLC indicated a purity of >90%. 
Successful synthesis was confirmed by electrospray-ionisation mass spectrometry 
(MWobserved: 3652.8; MWtheoretical: 3650.8). 
Peptide stock solutions were prepared in dimethyl sulfoxide (DMSO) and diluted to 
desired concentrations with HEPES buffer. The total DMSO concentration was 
maintained at 0.14% (v/v) in the peptide samples through the experiments to aid peptide 
solubility, as low DMSO concentrations are reported not to perturb particular liposomal 
compositions (1). This value is well below the chemical compatibility of the L1 chips 
(10%), and was confirmed not to cause observed baseline changes in this study using 
buffer-only injections over membrane surfaces. Peptide concentrations were quantified 
with the modified Lowry, DC protein assay (Bio-Rad, Gladesville, NSW, Australia). 
 
Liposome preparation and lipid bilayers formation 
Small unilamellar vesicles (SUV) of POPC and a mixture of POPC/Chol/SM (1:1:1) 
were used through the studies. POPC (dissolved in chloroform) alone or mixed with 
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Chol (in chloroform) and SM (in chloroform/methanol mixture 2:1 (v/v)) was dried 
under a gentle stream of nitrogen. Solvent removal was completed in vacuo, overnight. 
The lipid was suspended in HEPES buffer to a final concentration of 1mM, and sized by 
subjection to seven repeated freeze/thaw cycles and extrusion (19 times) through 
polycarbonate filters (50nm pore diameter). 
All biosensor experiments were conducted at 25°C, with sample injections using 
instrument high-performance parameters and collection rates at 10Hz. The L1 sensor 
chip surface was washed as part of a start-up cycle by the sequential injection of 20mM 
CHAPS (5μL/min flow rate, 60s contact time), 10mM NaOH in 20% methanol 
(50μL/min, 36s) and 10mM NaOH (50μL/min, 36s). SUVs were captured onto the L1 
surface at a flow rate of 2μL/min (2,400s). A 10mM NaOH pulse was used to remove 
loosely bound liposomes from the surface (50μL/min, 36s) resulting in a stable baseline. 
Typical capture levels were 10,000 – 12,000RU throughout the experiments. 
 
MAbs binding to the bilayer membranes 
Solutions of 2F5 (0.06μM-0.3μM) and 4E10 (0.06μM-0.5μM) in HEPES buffer 
were studied in the presence of peptide-epitope concentrations of 0.3, 0.5 and 1μM 
prebound to membrane surfaces. The MAb binding was also studied in the presence of a 
blank control of DMSO 0.14% (v/v) in buffer. Pre-binding of the peptide-epitope (or 
blank control treatment) was achieved by injection of solutions over the membrane 
surfaces (5μL/min, 180s). Upon completion of the injection, the flow was continued at 
5μL/min for a dissociation time of 60s before the MAb solutions were injected over the 
lipid surface containing the peptide (or blank). The MAb solutions were injected using 
different contact times at a constant flow of 5μL/min (2F5 contact time 90s, 4E10 
contact time 60s), followed by a uniform dissociation time of 600s. After each MAb 
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binding assay, the sensor surface was regenerated with 0.5% (w/v) SDS (5μL/min, 60s), 
followed by the sequential injection of 20mM CHAPS (5μL/min, 60s), 10mM NaOH in 
20% methanol (50μL/min, 36s) and 10mM NaOH (50μL/min, 36s). 
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Results  
We investigated the interaction of the HIV-1 MAbs 2F5 and 4E10 with model 
membranes using an SPR biosensor, which detects changes in the refractive index at the 
sensor surface caused by mass changes. Throughout the studies we used model 
membrane systems that mimic the conditions present on both the target cell and viral 
membranes. Liposomes of POPC were used to mimic the target cell membrane as 
POPC is a neutral lipid (at the pH conditions used) with fluidity properties similar to 
biological membranes (14). Liposomes composed of POPC/Chol/SM (1:1:1) were used 
to mimic the viral membrane, which is rich in Chol and SM (3, 7). Liposomes were 
reproducibly immobilized on the surface of the sensor chip to ~10,000RU for POPC and 
~12,000RU for POPC/Chol/SM vesicles. The interaction of the MAbs with each 
membrane was investigated in the presence and absence of the peptide-epitope. The 
peptide-epitope was prebound at either 0.3, 0.5 or 1μM to concentration-dependent 
levels ranging from 350 – 500 RU for POPC and for POPC/Chol/SM. Immediately 
following pre-binding (60s), injections of the MAbs were subsequently made to 
determine the binding of the MAbs to the different peptide-epitope membranes. When 
the MAbs were injected across the immobilized liposomes over a range of 
concentrations (0.06-0.3μM for 2F5 and 0.06-0.5μM for 4E10), the surface response, 
reporting protein bounded to the membrane, was found to increase with higher protein 
concentrations. A fresh liposome surface was generated for each MAb binding test to 
prevent carry-over of bound material influencing subsequent measurements. It was 
found a more rigorous regeneration protocol was necessary to completely restore 
baseline conditions; requiring two detergent washes, a Methanol:sodium hydroxide 
pulse and sodium hydroxide pulse to ensure the regeneration detergents did not carry-
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over to impede subsequent liposomal capture or form mixed micelles with captured 
liposomes. 
 
2F5 membrane interactions 
Figures 1A and B show the sensorgrams obtained for the binding of 2F5 to POPC 
and POPC/Chol/SM liposomes in the absence of the peptide-epitope. The results 
obtained were very similar for both membranes, with a general increase in binding 
concomitant to increasing concentrations of 2F5.  
In general the shapes of the sensorgrams for 2F5 interactions in the absence of the 
peptide-epitope with both POPC and POPC/Chol/SM are non-ideal, showing a 
dispersion-like effect at the end of the association phase, which is more pronounced in 
Figure 1B (POPC/Chol/SM). Such dispersion effects are typically caused by collapsing 
of the separating “bubbles” that partition the sample plug from running buffer as part of 
high-performance injections, causing the injected sample to be diluted by running buffer 
during the course of injections. In this manner, dispersion only influences the final parts 
of the association phase during the course of the injection which can be seen on the 
POPC surfaces (Figure 1A). We do not conclude DMSO carryover between injections 
has caused the effect as it is not seen in analogous 4E10 experiments with the blank 
control or subsequent 2F5 experiments in the presence of the peptide-epitope, 
furthermore the effect of DMSO is to cause a significant increase in the response due to 
the higher refractive index of DMSO than the buffer solution, as opposed to reduced 
responses observed here. Similarly we do not conclude the dialysis was incomplete as 
dialysis conditions were exhaustive (16h) and do not show the same effects in other 2F5 
experiments using the same batch of buffer-exchanged MAb. The POPC/Chol/SM 
surfaces (Figure 1B) suggests an explanation as there are more pronounced effects 
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which continue after the association phase, before rising after 200s on the sensorgrams, 
resulting in a net higher response than baseline or expected from the initial dissociation 
levels prior to 200s. Because the dispersion-like effect continues beyond the association 
phase it suggests remodelling of the surface may occur in the presence of the 2F5 MAb 
– possibly enhanced by the DMSO on the surface prior to 2F5 being injected. Despite 
the dispersion-like effect, it is notable the binding of 2F5 to both of the membranes 
appears to be reversible; in general there is significant dissociation of 2F5, though the 
signal often did not return to baseline, reflecting the presence of a small proportion of 
strongly bound 2F5 to the membranes in the absence of the peptide-epitope. 
To study the 2F5 membrane interactions in the presence of the membrane bound 
peptide-epitope, the binding of 2F5 at each concentration was measured with a range of 
peptide-epitope concentrations pre-bound to the membrane. Figure 2 shows the 
sensorgrams for 0.1 and 0.2μM 2F5 using a range of peptide-epitope concentrations 
(0.3-1μM) and it is evident that; binding is so tight that very little 2F5 comes off the 
surface during the dissociation phase, indicating an almost irreversible association of 
2F5 in the presence of the peptide-epitope over the course of the assay for both 
membranes studied and for all 2F5 concentrations (Figures 2 and 3) as opposed to 
membranes alone (Figure 1). Thus, the binding of the MAb in the presence of the 
peptide-epitope is much stronger than the binding to the membrane alone. However, for 
the 2F5 0.06-0.1μM concentration range in the presence of POPC and 0.06-0.08μM in 
the presence of POPC/Chol/SM, there was no simple correlation between the 2F5 
binding and the concentration of peptide-epitope present. Figures 2A and C show that 
for 2F5 0.1μM in POPC and for 2F5 0.08μM in POPC/Chol/SM, for instance, the 
presence of a lower peptide-epitope concentration leads to higher 2F5 response 
increases. Analysis of the other 2F5 concentrations (0.2-0.3μM in POPC and 0.1-0.3μM 
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in POPC/Chol/SM) revealed the opposite trend, an increase in MAb binding with 
epitope concentration bound. As shown in Figures 2B and D for 2F5 0.2μM in POPC 
and POPC/Chol/SM, respectively, the higher MAb response increase occurs in the 
presence of higher peptide-epitope concentrations.  
Additionally, the variation of the 2F5 concentrations with a fixed peptide-epitope 
concentration leads to a binding increase proportional to the MAb concentration, as is 
shown in Figures 3A and B for peptide-epitope 1μM (as an example) in POPC and 
POPC/Chol/SM, respectively.  
 
4E10 membrane interactions 
The sensorgrams associated with the membrane binding properties of 4E10 in the 
presence of POPC and POPC/Chol/SM liposomes, respectively, are shown in Figures 
4A and B. In both cases the response observed at the end of the association phase 
increased with increases in 4E10 concentration, with two exceptions: 0.5μM on POPC 
liposomes (not shown) and 0.2 and 0.3μM 4E10 on POPC/Chol/SM liposomes. 
Nevertheless, globally the 4E10 membrane binding is reversible displaying a distinct 
dissociation phase following the clear and regularly shaped association phase. 
The interaction of 4E10 with each membrane in the presence of the membrane 
bound peptide-epitope was performed at 4E10 concentrations of 0.06-0.5μM with a 
range of peptide-epitope concentrations of 0.3-1μM. For POPC liposomes at the lower 
4E10 concentrations (0.06-0.3μM), there is a general decrease in the MAb response 
with increasing peptide-epitope concentration, as shown in Figure 5A. At higher 4E10 
concentrations (0.5μM) (Figure 5B) there was an increase in the MAb response in the 
presence of two different peptide-epitope concentrations. However, for all peptide-
epitope concentrations the dissociation phase shows less 4E10 dissociation when 
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compared with the blank indicating that the presence of the peptide epitope increases 
the affinity of the 4E10 for the membrane. 
In POPC/Chol/SM liposomes, the sensorgrams obtained for lower 4E10 
concentrations show less relative MAb response increase when the peptide-epitope is 
present. For higher 4E10 concentrations the response is similar, regardless of the 
presence of peptide-epitope. Nevertheless the observed 4E10 dissociation rate is less, 
with less 4E10 leaving the surface when the peptide-epitope is present (Figure 5C and 
D, for 4E10 0.3 and 0.5μM, respectively), as observed before for POPC liposomes.  
Overall it can be concluded from the sensorgrams in Figures 6A and B obtained for 
a range of 4E10 concentrations, that at a particular peptide-epitope concentration the 
MAb response increase is proportional to the MAb concentration, with 1μM peptide-
epitope in POPC and POPC/Chol/SM, respectively.  
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Discussion 
2F5 and 4E10 are two MAbs against HIV-1 whose epitopes are closely localized in 
the gp41 MPR (2F5 epitope extends slightly outside the MPR N-terminus), in the 
vicinity of the viral membrane. In the native state the MPR is believed to lie parallel to 
the surface of the viral membrane external layer (32). However, previous experimental 
studies show that the MPR has tendency to partition into membranes (26, 28) and it is 
possible that this region is membrane-associated during the virus-cell fusion event. In a 
membrane mimetic environment an MPR synthetic peptide has been shown to adopt a 
helical conformation parallel to the membrane, near the lipid interfacial region (25). The 
x-ray crystal structure of 2F5 and 4E10 complexed to its synthetic epitopes revealed that 
the epitopes adopt a β-turn and α-helical conformation, respectively (9, 21). However 
the crystallographic evidence lacks a membrane context there is no general consensus 
about the MPR structure in the context of the native gp120-gp41 or during the fusion 
process. It has been proposed that the 2F5 and 4E10 MAbs interact with the viral 
membrane through a CDR H3 hydrophobic surface (9, 21) and other studies with 
liposomes have shown that the binding of 2F5 and 4E10 to the epitopes increases when 
gp41 is presented in a lipid environment (15, 21). The goal of this present study was to 
examine the membrane interactions of 2F5 and 4E10 using POPC and POPC/Chol/SM 
liposomes as membrane models to mimic the host cell and viral membranes, 
respectively. The study was performed in the presence and absence of a peptide-epitope 
(H-NEQELLELDKWASLWNWFNITNWLWYIK-NH), which has membrane binding 
properties and contains both 2F5 (ELDKWA) and 4E10 (NWFNIT) epitopes flanked by 
native gp41 sequences. The use of this peptide-epitope, rather than each MAb core 
epitope sequence separately, allows the binding properties of each MAb to be studied 
with the inclusion of the flanking residues, which are naturally included in the whole 
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gp41 envelope, can facilitating secondary structure and providing a more substantive 
context to the epitopes and thereby stabilize a better mimetic of the natural epitope 
conformation.  
The results obtained allow a number of conclusions to be made about the membrane 
binding characteristics of the MAbs. In addition, it was not possible to calculate the 
detailed kinetics and affinity parameters associated with the binding because most of the 
experimental sensorgrams are more complex than can be analysed by the currently 
available kinetic models preventing any curve fitting to be performed. 
The analysis of the sensorgrams obtained for 2F5 demonstrate that the membrane 
binding behaviour of the MAb is similar in both POPC and POPC/Chol/SM model 
membranes. Specifically, 2F5 binds reversibly to the membrane in the absence of the 
peptide-epitope. Although weak compared to binding with membrane peptide-epitopes, 
2F5 membrane binding was detectable, at variance with fluorescence techniques (30). 
This can be related to the difference in the methods and experimental conditions used. 
Namely, the detection of membrane binding by Trp fluorescence is only detectable if 
there is a significant change in Trp fluorescence upon membrane binding. In contrast, 
the sensitive SPR technique allows the membrane binding to be followed in real-time 
during the entire binding process.  
The binding of 2F5 was increased significantly in the presence of the membrane-
bound peptide-epitope complex and exhibited irreversible binding over the course of the 
assay, i.e. there was no desorption during the dissociation phase. At low 2F5 
concentrations there was no correlation between the level of bound MAb and the 
concentration of peptide-epitope bound to the membrane. However, at high 2F5 
concentrations increases in the peptide-epitope concentration enhanced the MAb 
binding.  
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In contrast, 4E10 bound strongly to both POPC and POPC/Chol/SM membranes 
even when the peptide-epitope was absent, and clearly bound more strongly to each 
membrane studied than 2F5, which is in agreement with other studies (24). When the 
membrane bound peptide-epitope is present the results obtained are also different from 
those observed with 2F5. Interestingly, in the presence of the peptide-epitope, a 
decrease in the response is obtained for low 4E10 concentrations. For high MAb 
concentrations similar responses to the blank (membrane only) were obtained. However, 
in all situations the 4E10 dissociation is decreased in the presence of the peptide-epitope 
when compared with the membrane alone. Thus, 4E10 binds to the membrane equally 
well in the presence or absence of peptide-epitope but the presence of the peptide 
significantly stabilizes the binding resulting in very little dissociation in both POPC and 
POPC/Chol/SM membranes.  
Given the proximity of 2F5 and 4E10 epitopes to the viral membrane, it may be 
anticipated that the MAbs may bind more strongly to the model viral membrane 
(POPC/Chol/SM) than to the model mammalian membrane (POPC). However, the 
binding of each MAbs was similar with both lipid mixtures, both in the presence and 
absence of the peptide epitope. 
These results agree in part with other studies that show that 2F5 and 4E10 bind non-
specifically to neutral and anionic phospholipids (Phosphatidylcholine and 
Phosphatidylglycerol for 2F5 and Phosphatidylcholine, Sphingomyelin, 
Phosphatidylethanolamine, Phosphatidylglycerol and Phosphatidylserine for 4E10), and 
bind more strongly to CL (16, 23, 24). Nevertheless, Chol seems to be important to the 
4E10 epitope recognition (19). 
The results obtained also show that 2F5 binding to the membrane increases 
significantly in the presence of the peptide-epitope while 4E10 binding to either 
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membrane is not solely dependent on the presence of the epitope. These results are not 
in agreement with previous studies (24), where the binding to membrane alone of both 
MAbs was decreased when compared to the membrane loaded with the epitope. The 
differences obtained could be related to the different techniques used in both studies, 
liposome-based ELISA vs. SPR. Additionally, both 2F5 and 4E10 could probably be 
used as MAbs to lipids to neutralize HIV but 4E10 is a better candidate given its 
stronger membrane binding properties. It has been reported that 4E10 may bind 
specifically to a PIP through a phosphate-binding subsite (5, 6). Lipids like PS or PIP 
might be exposed at the HIV surface (4). 
In conclusion the results suggest that both 2F5 and 4E10 have the capacity to bind to 
membranes (although weakly for 2F5) and membrane-bound epitopes. This shows that 
4E10 has a greater capacity to access the epitope located close to the membrane surface. 
This association is quite extensive by itself and not enhanced by the presence of the 
epitope, though the dissociation from the complex is notably reduced in the presence of 
the peptide-epitope. Although this membrane binding property of 4E10 can reduce the 
global concentration of free MAbs, it is at the same time a unique property that allows 
recognition of an epitope which is so close to the membrane. 2F5 has lower affinity for 
the membranes but binds strongly to its epitope in a membrane context. Our results 
confirm that this high affinity for the epitope in the presence of a membrane is a result 
of the induction of a membrane-dependent epitope conformation optimal for the binding 
(15, 21). However, a small contribution of the lipids to stabilize epitope binding, given 
the membrane proximity, cannot be discarded. This contribution probably involves the 
hydrophobic surface of the 2F5 CDR H3 region. For the MAb 4E10 the binding to the 
membrane is strong and does not depend of the peptide-epitope presence. However the 
binding seems to be stabilized in the presence of the epitope. Probably the 4E10 innate 
 The role of membranes in the HIV-1 antibodies 2F5 and 4E10 mode of action 
 111
capacity to binds membranes allows a stable binding with the epitope in a membrane 
context. These differences in the MAbs behaviour could be related to different epitope 
gp41 positions or the way they recognize and/or bind to the epitope.  
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Figure Legends 
 
Figure 1 – Sensorgrams obtained for 2F5 binding to immobilized POPC (A) and 
POPC/Chol/SM (1:1:1) (B) lipid membrane surface (L1 chip). 2F5 was injected over a 
freshly prepared lipid surface, and the subsequent association and dissociation were 
monitored. 2F5 0.06μM, 0.08μM and 0.1μM (a), 0.2μM (b) and 0.3μM (c) in (A); 2F5 
0.06μM (a), 0.08μM (b), 0.1μM (c), 0.2μM (d) and 0.3μM (e) in (B). 
 
Figure 2 – Sensorgrams obtained for 2F5 binding to immobilized POPC (A and B) and 
POPC/Chol/SM (1:1:1) (C and D) lipid membrane surface (L1 chip) in the presence of 
peptide-epitope range of concentrations (0μM (a), 0.3μM (d), 0.5μM (c) and 1μM (b) in 
(A); 0μM (a), 0.3μM (b), 0.5μM (c) and 1μM (d) in (B); 0μM (a), 0.3μM (d), 0.5μM 
(b) and 1μM (c) in (C); 0μM (a), 0.3μM (b), 0.5μM (c) and 1μM (d) in (D)). 2F5 
concentrations of 0.1μM (A), 0.2μM (B), 0.08μM (C) and 0.2μM (D) were injected 
over a freshly prepared lipid surface, and the subsequent association and dissociation 
were monitored. 
 
Figure 3 – Sensorgrams obtained for 2F5 binding to immobilized POPC (A) and 
POPC/Chol/SM (1:1:1) (B) lipid membrane surface (L1 chip) in the presence of 1μM of 
peptide-epitope. 2F5 of varying concentrations (0.06μM (a), 0.08μM (b), 0.1μM (c), 
0.2μM (d), and 0.3μM (e) in (A); 0.06μM (a), 0.08μM and 0.1μM (b), 0.2μM (c), and 
0.3μM (d) in (B)) was injected over a freshly prepared lipid surface, and the subsequent 
association and dissociation were monitored.  
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Figure 4 – Sensorgrams obtained for 4E10 binding to immobilized POPC (A) and 
POPC/Chol/SM (1:1:1) (B) lipid membrane surface (L1 chip). 4E10 of varying 
concentrations was injected over a freshly prepared lipid surface, and the subsequent 
association and dissociation were monitored. 4E10 0.06μM (a), 0.08μM (b), 0.1μM (c), 
0.2μM (d), and 0.3μM (e) in (A); 4E10 0.06μM (a), 0.08μM (b), 0.1μM (c), 0.2μM (e), 
0.3μM (d), and 0.5μM (f) in (B). 
 
Figure 5 – Sensorgrams obtained for 4E10 binding to immobilized POPC (A and B) 
and POPC/Chol/SM (1:1:1) (C and D) lipid membrane surface (L1 chip) in the presence 
of peptide-epitope range of concentrations (0μM (b), 0.3μM (c), 0.5μM (a) and 1μM (d) 
in (A); 0μM (a), 0.3μM (c), 0.5μM (b) and 1μM (d) in (B); 0μM (a), 0.3μM (d), 0.5μM 
(c) and 1μM (b) in (C); 0μM (a), 0.3μM (c), 0.5μM (b) and 1μM (d) in (D)). 4E10 
concentrations of 0.3μM (A), 0.5μM (B), 0.2μM (C) and 0.5μM (D) were injected over 
a freshly prepared lipid surface, and the subsequent association and dissociation were 
monitored. 
 
Figure 6 – Sensorgrams obtained for 4E10 binding to immobilized POPC (A) and 
POPC/Chol/SM (1:1:1) (B) lipid membrane surface (L1 chip) in the presence of 1μM of 
peptide-epitope. 4E10 of varying concentrations (0.06μM (a), 0.08μM (b), 0.1μM (c), 
0.2μM (d), 0.3μM (f), and 0.5μM (e) in (A); 0.06μM (a), 0.08μM (b), 0.1μM (c), 
0.2μM (d), 0.3μM (e), and 0.5μM (f) in (B)) was injected over a freshly prepared lipid 
surface, and the subsequent association and dissociation were monitored.  
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Chapter VI 
 
 
FINAL CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 With an estimated 39.5 (34.1-47.1) million individuals infected HIV-1 worldwide, 
there is an urgent need to identify new anti-viral approaches and develop neutralizing 
vaccines to combat this virus. The HIV-1 envelope glycoprotein complex is an 
attractive therapeutic target because it mediates the viral entry. Inhibitors that target 
these proteins act at the viral entry level, thus preventing infection. Despite the 
substantial scientific effort on the HIV-1 entry mechanism investigation and the huge 
progress that has been made in the last years, several aspects of the molecular 
mechanism remain unclear. Additionally, structural and functional studies of the 
envelope proteins have led to the development of viral entry inhibitors, but no complete 
clarification of the structure adopted by the proteins during the entry process exist. All 
these uncertainties limit the improvement of existent antivirals and also the 
development of new and more efficient ones, and ultimately the development of a 
vaccine. 
The studies presented in this work were essentially biophysical, particularly 
fluorescence spectroscopy studies, in the characterization of the biomembranes role on a 
number of HIV-1 gp41 related processes. These studies are also a demonstration of the 
potential of biophysical applications to this kind of studies. Membrane model systems 
were used in this work to obtain a quantitative basis for the studies, controlling the 
variables in the experiments, essential in the studies performed, while maintaining the 
main properties of the biomembranes. The questions studied here are still object of an 
open debate, namely, the biomembranes role on the mode of action of the HIV-1 fusion 
inhibitors T20 and T-1249, the importance of biomembranes for the MAbs 2F5 and 
4E10 neutralizing action, and the role of the gp41 MPR on the membranes fusion 
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process in the viral entry. To understand the interactions between viral peptides in the 
entry process, as the precise mechanism of viral inhibitors action, is essential to the 
improvement of the existing antiviral strategies and to the development of new ones 
with a more effective action. 
 T20, a HIV-1 fusion inhibitor, was the first of a new class, the entry inhibitors, to be 
approved for clinical use. Despite its proven clinical efficacy and being already in 
clinical use, its mode of inhibition is not yet clearly understood. The most accepted 
mechanism of action is the one proposed to C-peptides in general, which involve the 
binding to the NHR region blocking the 6HB structure formation. In this study, a 
theoretical analysis of the hydrophobicity and interface affinity of T20 amino acids 
sequence clearly suggests that it may interact with biological membranes, which was 
confirmed experimentally. The results obtained allow to propose an alternative or 
additional model for the T20 action at the molecular level. T20 attaches to membranes 
in an interfacial position reaching local high concentrations. When the virus approaches 
the cell surface, its outer membrane will not compete for T20 uptake due to its high 
content in Chol. Therefore, the cell membrane can function as a reservoir of T20, 
increasing local concentration at the fusion site. However, local concentration of 
aqueous T20 is kept high to allow interaction with the NHR region in the aqueous 
solution. Moreover, high local concentration at the cell membrane surface enable direct 
contact of the peptide with gp41 C-terminal region, when T20 homologous sequence 
comes in contact with the lipidic matrix to form the fusion pore. The possible binding of 
T20 to its gp41 homologous sequence in a membrane context, inhibiting pore 
formation, has been reported by other authors (Muñoz-Barroso et al., 1998; Kliger et al., 
2001). T20 interactions with lipid bilayers was also reported in recent studies as having 
importance on its membrane fusion inhibitory activity (Liu et al., 2007b). 
 In fact the binding of T20 to the NHR region to create a stable 6HB structure has 
never been demonstrated, and some recent studies re-open this question (Liu et al., 
2005; Liu et al., 2007b). They showed that, unlike C34, T20 cannot interact with NHR 
region derived peptides to form a stable 6HB. Thus, although T20 can bind to the gp41 
NHR, this binding may not be strong enough to justify its strong inhibitory activity. It 
was suggested that T20 can have multiple sites of action in gp41 and gp120, and its 
inhibitory activity may be a combinatory effect of different action mechanisms (Liu et 
al., 2005). T20 can exert its effect by interacting with gp41 NHR region, inhibiting the 
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6HB formation. Additionally, T20 can inhibit viral fusion by interfering with the FP 
(Mobley et al., 2001). T20 can interact with the gp41 C-terminal region, acting at a later 
step of membrane fusion to prevent fusion pore formation, as also proposed by other 
authors (Muñoz-Barroso et al., 1998; Kliger et al., 2001). The coreceptor binding site on 
gp120 may be another target site for T20, blocking the interaction with coreceptors. 
These findings are in agreement with other studies that showed that T20 can bind to 
CXCR4 (Xu et al., 2000) and/or can interact with the gp120 coreceptor binding site 
(Yuan et al., 2004; Alam et al., 2004). All of these interactions can cause inhibition of 
viral fusion by T20.  
 Gene therapy based approaches are being developed to achieve an alternative 
administration of these inhibitory peptides. It was shown that membrane-anchored T20, 
expressed on target cells surface, inhibit viral replication at the level of HIV-1 entry 
(Hildinger et al., 2001). This expression at the target cells surface leads to high local 
concentration of the peptide at the action site. Other study has shown that liposome-
reconstituted trimeric gp41 fragments, containing C-terminal gp41 regions that include 
T20 sequence, also have HIV-1 inhibitory activity (Lenz et al., 2005). Melikyan et al. 
compared the mechanism of action of membrane-anchored peptides expressed by target 
cells with the ones coexpressed with the envelope glycoprotein on effector cells. While 
peptides at the target cell surface block inhibition by the binding to the NHR and 
prevent 6HB formation, peptides expressed by effector cells bind to an new found 
intermediate, between the prehairpin and the 6HB, preventing pore formation (Melikyan 
et al., 2006). 
 Based on the knowledge on T20 properties, other C-peptides have been designed in 
order to obtain inhibitors with improved efficiency, including against the viruses that 
are resistant to T20 (Dwyer et al., 2007; Deng et al., 2007).  
 T-1249, a second generation fusion inhibitor, is more potent than T20 and also 
retains activity against most T20-resistant HIV-1 strains. Although its mechanism of 
action is not well known, it is believed that T-1249 acts like most C-peptides. Its 
propensity to interact with biomembranes was studied. At variance with T20, T-1249 
adsorbs to raft like platforms in lipid membranes. It was suggested that T-1249 ability to 
bind both to the target cell and virus membranes may play an important role in T-1249 
mode of action and provide a peptide reservoir at the site of action. The differences 
relative to T20 in membrane interaction properties, help to explain its improved activity. 
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In spite of the promising results, T-1249 clinical development was put on indefinite 
hold. The decision was made not because safety, efficacy and tolerability reasons, but 
because the current formulation of T-1249 would not be suitable for use in large-scale 
clinical trials (Martín-Carbonero, 2004).  
 SARS-CoV is the viral agent responsible for SARS. Identified as a novel CoV, there 
is no specific treatment for this disease. Due to the need to identify antiviral agents with 
efficacy against this virus, several drugs already approved and in clinical use were 
tested. A structural analysis of the SARS-CoV glycoprotein S2 showed a number of 
similarities with the HIV-1 gp41, like the presence of a NHR, a CHR and a MPR rich in 
aromatic amino acid residues (Gallaher and Garry, 
http://www.virology.net/Articles/sars/s2model.html). At the CHR there is a sequence, 
ELDKY, very similar to the HIV-1 gp41 sequence ELDKW. In HIV-1 the peptide 
ELDKWA is a neutralization epitope recognized by the MAb 2F5. Based on a possible 
cross-reactivity with the ELDKY region, this MAb can have some neutralizing activity 
against SARS-CoV (Gallaher and Garry, 
http://www.virology.net/Articles/sars/s2model.html). However, to the best of my 
knowledge, this possibility was never tested. The HIV-1 gp41 ELDKWA motif is also 
present on T20. It was proposed that T20 may have some activity against SARS-CoV 
(Gallaher and Garry, http://www.virology.net/Articles/sars/s2model.html). As in HIV-1, 
SARS-CoV HR regions form a 6HB structure that brings the viral and cellular 
membranes into close proximity, leading to membrane fusion. Synthetic peptides 
derived from the CHR were able to inhibit viral infection by interfering with the 6HB 
formation (Bosch et al., 2004; Liu et al., 2004; Zhu et al., 2004). Based on the most 
commonly accepted mechanism of action, T20 can bind to the NHR region blocking 
6HB formation. The study presented here focus on the interaction of T20 and T-1249 
with SARS-CoV S2 protein NHR and CHR derived peptides. It was shown that there is 
interaction between T20 and a SARS-CoV S2 protein NHR derived peptide, but this 
interaction could be too weak to inhibit infection. On the other hand and based on the 
recent proposals for T20 action, it could be speculated that it can inhibit SARS-CoV 
targeting different regions, as it targets gp41 and gp120 on HIV-1. However, Yamamoto 
et al. that performed a study to identify anti-SARS drugs available for clinical use, 
including T20 and found no viral inhibition with this peptide (Yamamoto et al., 2004). 
Nevertheless, this result is questionable since the results obtained for other drugs tested 
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are contradictory with the results obtained by other similar studies. While Yamamoto et 
al. reported the inhibition of SARS-CoV replication by nelfinavir, a widely used HIV-1 
protease inhibitor, other study by Tan et al. showed that this inhibition does not occur 
(Tan et al., 2004). In the same way, Zhang and Yap (Zhang and Yap, 2004) proposed 
that two others HIV-1 PIs, lopinavir and ritonavir, could inhibit SARS-CoV, at variance 
with the results reported by reported by Yamamoto et al.. 
The results showed in chapter IV confirm that the HIV-1 gp41 MPR has a key role 
in the viral fusion process. It has been shown that this region has the capacity to interact 
with and destabilize membranes, in a similar way to the FP action in the target cell 
membrane. Due to the Chol-rich viral membrane proximity, the MPR effect could be 
exerted at this level. Besides, this region contains at its C-terminal a small sequence 
defined as a Chol binding domain. The influence of Chol in the membrane interactions 
of MPR-derived peptides was investigated. In this study the peptides used correspond to 
the whole MPR, to the Chol binding sequence and to the peptide corresponding to the 
MPR without the Chol binding sequence. The results obtained are not in agreement with 
a direct interaction of the small sequence with Chol. However, one needs to stress that 
in the studies where the specific interaction was proposed, the small Chol binding 
sequence interactions with Chol were tested in extreme conditions (Vincent et al., 2002; 
Epand et al., 2003; Epand et al., 2005; Epand et al., 2006). The results presented in this 
study show that the Chol binding sequence does not interact with gel and liquid-ordered 
membranes (i.e. Chol-rich membranes). It is the remaining part of the complete MPR 
sequence that confers the main membrane-interaction properties. Both this sequence and 
the complete MPR are insensitive to the lipid phase, which may be the key for the MPR 
biological function. By interacting equally well with the HIV-1 envelope and target cell 
membrane, the MPR promotes their contact, viral fusion evolving from the physical 
contact of these bilayers. MPR ability to bind to viral and host cell membranes 
simultaneously leads to the merging of the two membranes (fusion). This is in 
agreement with findings that show that the MPR is essential for fusion. Upon virus-cell 
membrane contact, the two bilayers will perturb each other and the lamellar phases will 
be locally disrupted. In this step, the Chol binding domain may come in contact with 
Chol released by the perturbed viral membrane and sequester it. A Chol-depleted 
membrane is easier to merge with the more fluid cell membrane, thus facilitating the 
fusion process. Therefore, the gp41 ectodomain MPR may have a very specific function 
in viral fusion through the concerted and combined action of Chol-binding and non-
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Chol binding domains (i.e. domains corresponding to the Chol binding sequence and the 
peptide corresponding to the MPR without the Chol binding sequence, respectively, in 
the fusion process). However, one needs to recall that membrane interactions of 
peptides can be enhanced by a concerted action of several membrane-binding motifs or 
by the particular disposition of key residues in the context of long peptides or even in 
the context of the whole protein. In this way, one cannot exclude a role for the small 
Chol binding sequence in the interaction of the MPR with membranes.  
 2F5 and 4E10 are two potent and broadly neutralizing MAbs against HIV-1, whose 
epitopes are localized in the gp41 MPR. It was proposed separately, based on 
crystallography studies, its interaction with membranes through a hydrophobic surface 
present on the CDR H3 (Ofek et al., 2004; Cardoso et al., 2005). In this study both 
MAbs membrane interactions were studied by the use of target cell and viral 
membranes models. In the initial study here presented, no relevant membrane 
interactions were detected for 2F5. However, studies by other authors suggest that 2F5 
binds to membranes of selected compositions, but the simultaneous study of 4E10 
showed that, in comparative terms, 2F5 binding is weak (Haynes et al., 2005; Sánchez-
Martínez et al., 2006 a,b; Brown et al., 2007). In the second study presented here, 2F5 
and 4E10 membrane interactions were studied in the presence and absence of a peptide 
that contains both MAbs epitope. Both 2F5 and 4E10 have the capacity to bind to both 
target cell and viral model membranes, being 2F5 interactions very weak, especially 
when compared to 4E10. Both MAbs bind irreversibly to membranes when its epitope 
is present, showing a high degree of recognition of the epitope presented in membranes. 
This capacity of interactions with biomembranes can be a MAbs adaptation to bind to 
an epitope that is so close to the membrane and/or, there exist an epitope optimal 
conformation that is membrane-dependent. 
 As a whole this thesis contributed to the state-of-the-art in the understanding of lipid 
membranes role in viral inhibition during pre-infective stages by showing that: 
1) Fusion inhibitor peptides T20 and T-1249 have the ability to interact with 
membranes and this might have a role on their action mechanism 
2) Membrane lipid phase modulate the fusion inhibitors membrane interactions and 
this might be related with their differential efficiency 
3) Both MAbs 2F5 and 4E10 have the capacity to interact with membranes in the 
absence and presence of their epitopes and membrane might be implicated on 
these MAbs mode of action 
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4) The membrane catalyst principle (Castanho and Fernandes, 2006) can be applied 
to the mechanism of action of fusion inhibitor peptides and MAbs, although 
peptides don’t have a specific membrane receptor 
5) Protein-lipid interaction in HIV fusion is not limited to the action of the FP 
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Abstract: The main strategies nowadays to fight AIDS rely on chemical therapy to inhibit the reverse transcriptase or
protease of HIV. However, a synthetic 36 amino-acids peptide that blocks the entry of the virus in the target cells
(enfuvirtide) has recently reached approval for clinical application. This molecule may probably be just the leader of a
new generation of drugs that is about to emerge to interrupt the first step in the HIV life cycle, i.e. preventing the virus
from actually entering cells. This paper reviews the enfuvirtide path from clinical trials to the attempts to detail its
molecular-level mode of action. It is commonly accepted that this peptide would block the fusion between viral and cell
plasma membrane through binding to the N-terminal heptad repeat (NHR) region of the viral protein gp41. However,
there has been growing evidence that this model of action may be unrealistic, the action of enfuvirtide being more
complex and diverse than initially thought. Membrane-assisted local concentration increase and interference with
gp120/co-receptor docking may also contribute for the inhibitory action of the peptide. Selected HIV-entry inhibitors on
clinical trials are presented to characterize the future drugs in the market in this class.
Keywords: Entry, attachment, fusion, binding, entrance inhibitor, HIV, AIDS, virus, chemokine, peptide, receptor, co-receptor,
synergism, clinical trial, enfuvirtide.
1. INTRODUCTION
Combination therapy with reverse transcriptase and
protease inhibitors is the most common current treatment of
HIV-1 infection [1,2]. Despite the success of this therapy,
namely reducing morbidity and mortality of HIV-1 infected
patients [3-6], it has adverse effects and drug resistant HIV-1
strains emerged [7-11]. A new class of antiviral agents is in
development, the entry inhibitors. These molecules target the
first step in the HIV-1 replication cycle, the viral entry [12-
15]. Unlike reverse transcriptase and protease inhibitors,
which target post-entry steps, entry or fusion inhibitors act
extracellularly preventing viral entry into target cells. The
most advanced and already approved by the Food and Drug
Administration fusion inhibitor is enfuvirtide (T20; DP-178)
from Trimeris/Roche [16].
HIV-1 Entry
The HIV-1 envelope glycoproteins complex is expressed
on the surface of the viral membrane as an oligomeric
protein (trimer) and mediates the viral entry. The complex is
composed of two subunits noncovalently associated: gp120,
the surface glycoprotein, which interacts with cellular
receptors, and gp41, the transmembrane glycoprotein,
responsible for fusion of the viral and cellular membranes
[e.g. 12,17,18]. HIV-1 entry into target cells is a multi-step
process that is initiated by gp120 binding to the CD4
receptor, present in the target cells surface. This contact
*Address correspondence to this author at the Centro de Química e
Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo
Grande C8, 1749-016 Lisboa, Portugal; Tel: + 351 21 7500931; Fax: +351
21 7500088; E-mail: castanho@fc.ul.pt
induces a conformational change in gp120 enabling it to bind
to a cellular co-receptor, usually CCR5 or CXCR4. gp120
binding to CD4 and co-receptor induces conformational
changes in gp41 exposing the N-terminal fusion peptide and
allowing its insertion into target cell membrane, thereby
connecting both membranes. Subsequent changes within the
gp41 ectodomain involve the interaction of two heptad
repeat sequences (HR1, next the fusion peptide and HR2,
preceding the transmembrane domain) and a six-helix bundle
structure (also called hairpin structure) is formed. The
hairpin formation brings the viral and cell membrane into
closed proximity, allowing fusion of the membranes and then
entry of the virus [12,13,17-19].
Each of the main steps in the HIV-1 entry process can be
a target for entry inhibitors. The ones currently under
development fall into three categories: gp120-CD4 binding
inhibitors, gp120-co-receptors binding inhibitors, and
membrane fusion inhibitors, which interfere with gp41
conformational changes [2,14,16,20]. Fusion inhibitors are
the leading compounds, one of them, enfuvirtide, being
already approved for clinical applications.
2. ENFUVIRTIDE CLINICAL TRIALS
The publication in 1998 of the results of the TRI-001
clinical trial [21] is considered as the proof-of-concept that
the entrance of the virus in the cell of the host can be blocked
in vivo by enfuvirtide. This study evaluated the use of
enfuvirtide subcutaneous infusion, as monotherapy, during
14 days. The TRI-001 allowed concluding that the
administration, during a reduced period, is safe and induces a
significant (1.14 log10) viral charge decrease in the group
that received a 90 mg deliverable dose of enfuvirtide (100
mg nominal dose) twice daily.
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The TRI-003 phase II trial [22], conducted during 28
days with 78 patients, lead to the adoption of subcutaneous
injection as the preferential route of administration of
enfuvirtide, and evaluated the pharmacokinetics of this and
other forms of administration. This study results showed that
subcutaneous injection presents significant advantages when
compared with subcutaneous infusion, in terms of
administration simplicity, tolerability, plasma pharmaco-
kinetics and antiviral response predictability.
The phase II multicenter trial T20-205 [23] tested the
administration of 45 mg of enfuvirtide twice daily by
subcutaneous injection, in association with conventional
optimized therapy, to 71 patients, during 48 weeks, for tests
of genotype resistance. 56% of the patients who had kept the
treatment presented significant improvements, with a
decrease for less than 400 copies of HIV-1 RNA/mL.
The T20-206 assay had the purpose of comparing
different enfuvirtide therapeutic doses in addition to
conventional antiretroviral therapies [24]. The results of this
random study indicated the dose of 90 mg twice daily as the
one that, combined with other antiretrovirals, reduces the
viral load more efficiently.
The T20-208 phase II trial [25] had the purpose of
studying the pharmacokinetics and tolerability of the
administration of enfuvirtide in different doses and in
formulations of different strengths. This study enabled the
optimization of the formulation and dosage to be used in the
subsequent phase III trials: twice daily administration of 90
mg enfuvirtide in a single injection of a high-strength
formulation in carbonate (instead of the administration of the
same 90 mg in two 45 mg injections of a lower-strength
formulation, used in most of the previous clinical trials).
A study carried out with 12 HIV-infected patients
previously enrolled on the phase II T20-205, T20-206 or
T20-208 trials evaluated the pharmacokinetics and relative
bioavailability of enfuvirtide following subcutaneous
injection at three separate anatomical sites: abdomen, thigh
and arm [26]. The relative bioavailabilities of enfuvirtide,
taking abdomen as a reference site, were 101% for thigh and
117% for arm. Independently of the slightly higher
bioavailability observed for the arm injection, and of some
differences on the injection site reactions, the authors
considered that the comparability among the three injection
sites allows to the infected patients the freedom to choose
(and to rotate, if necessary) among these three possible sites
of injection.
The publication in 2001 of a study involving the follow-
up of 39 patients during 3 years demonstrated that the
primary resistance to enfuvirtide treatment is a rare event
[27]. However, the authors warned that the emergence of
future variants of the virus resistant to this therapy cannot be
ruled out. More recently, another study [28] also indicated
that primary genotypic enfuvirtide resistance seems to be
rare, regardless of subtype or prior antiretroviral therapy.
The emergence of enfuvirtide resistant virus in patients
receiving enfuvirtide monotherapy was identified by the first
time by Wei et al . [29], in patients enrolled in the TRI-001
clinical trial [21], receiving an antiretroviral dosage
considerably lower than the later approved for clinical use,
during only 14 days.
The enfuvirtide absorption and disposition
pharmacokinetics after both intravenous and subcutaneous
administration were evaluated in the controlled clinical
pharmacokinetic study T20-501 [30]. The same work
evaluated the dose proportionality of enfuvirtide
pharmacokinetic parameters at higher subcutaneous doses.
The 12 patients received randomly four different single
doses of enfuvirtide (90 mg intravenous and 45, 90, and 180
mg subcutaneous) separated by a one week washout. Based
on the results, a structural pharmacokinetic model was
developed, allowing the description of the absorption and
disposition kinetics of enfuvirtide plasma concentration after
subcutaneous administration. The study also indicated that
enfuvirtide is almost completely absorbed from
subcutaneous depot, and that the pharmacokinetic parameters
were linear up to a dose of 180 mg.
Based on the findings of the previous phases I and II
clinical trials, it were the two TORO (T-20 vs. Optimized
Regimen Only) phase III clinical trials that set the conditions
for the approval of enfuvirtide for clinical use. The TORO 1
trial [31] was conducted with patients from North-America
and Brazil, while TORO 2 [32] enrolled patients from
Europe and Australia. Both TORO studies compared the
efficacy and safety of 24 weeks of combined treatment with
enfuvirtide (90 mg twice daily) and an optimized
background antiretroviral regimen with the efficacy and
safety of the optimized background regimen alone. The
patients (491 in TORO 1 and 504 in TORO 2) had at least
six months of previous treatment with agents in three classes
of antiretroviral drugs, resistance to drugs in these classes, or
both, and at least 5000 viral copies/mL. At the end of the 24
weeks, the groups taking enfuvirtide had a least-squares
mean decrease from baseline in the viral load of 1.696 and
1.429 log10 copies/mL in TORO 1 and TORO 2,
respectively, compared with a decrease of 0.764 and 0.648
log10 copies/mL in the TORO 1 and TORO 2 control groups
(P < 0.001 for both pairs). The mean increases in CD4+ cell
counts were 76 and 65.5 mm-3 (TORO 1 and TORO 2
enfuvirtide groups, respectively), compared with 32 and 38.0
mm-3 for their control groups (P < 0.001 for both pairs).
These studies demonstrated the significance of the
antiretroviral and immunologic benefits of the addition of
enfuvirtide to optimized antiretroviral regimens in patients
with HIV-1 infections resistant to previously established
therapies, and in patients who had previously received
multiple antiretroviral drugs.
The most common adverse events associated with
enfuvirtide administration are injection-site reactions. The
TORO studies reported injection-site reactions in 98% of the
patients, including pain, discomfort, erythema, induration,
nodules, cysts, pruritus and ecchymosis associated with the
injection-site [31,32]. Despite this extremely high incidence,
only 4.4% of the patients abandoned the treatment due to
injection-site reactions [e.g. 33]. The biopsies carried out in a
study of injection-site reactions in 7 patients receiving
enfuvirtide revealed inflammatory responses consistent with
a localized hypersensitivity reaction, regardless of the type of
clinical lesion and even in its absence [34].
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The incidences of most of the other adverse events
reported in the TORO study for the group of patients treated
with enfuvirtide combined with background antiviral therapy
were not significantly different from those observed for the
control group, treated with the background antiretroviral
therapy only [31,32]. However, the incidences of pneumonia
(mainly bacterial) and lymphadenopathy were significantly
higher in the group using enfuvirtide, as indicated by the
combined analysis of the TORO studies after 48 weeks of
treatment [e.g. 33]. The statically significant increase on
pneumonia incidence in the group of patients taking
enfuvirtide combined with optimized background therapy
may be related with enfuvirtide administration, or it can also
result of an unexplained abnormally low incidence of
pneumonia in the control group. Studies carried out with
HIV-infected patients on highly active antiretroviral therapy
(HAART) indicate pneumonia incidences considerably
higher than those reported for the control groups of the
TORO studies, and comparable with the observed for the
groups taking enfuvirtide combined with optimized
background therapy [e.g., 35,36]. The results of the TORO
studies, at the 24th week of the treatment, also indicated a
higher incidence of some laboratory parameters outside the
upper limit of normal in the group taking enfuvirtide;
namely, eosinophilia, increased triglycerides, creatine
phosphokinase, amylase, lipase, alanine aminotransferase,
aspartate aminotransferase and g-glutamyl transferase levels,
and decreased hemoglobin concentration. However, at the
48th week of treatment the incidences of these laboratory
abnormalities were similar in the enfuvirtide and control
groups, or even lower in the enfuvirtide group.
The safety, tolerability, antiretroviral activity, dosage and
pharmacokinetics of the pediatric use of enfuvirtide were
evaluated in some phase I/II clinical trials [37-40], which
will not be described here.
3. RECENT HIGHLIGHTS IN THE MOLECULAR-
LEVEL ACTION OF THE FUSION INHIBITORS
ENFUVIRTIDE AND T-1249: A PLETHORA OF SITES
OF ACTION
Enfuvirtide is a synthetic 36 amino-acids peptide derived
from a C-terminal sequence of HIV-1 gp41 [41,42]. There
are several proposals for the enfuvirtide inhibitory action
mechanism involving target sites in gp41 and gp120. In the
most accepted mechanism of action model, enfuvirtide binds
to the HR1 region of gp41 preventing the formation of the
six-helix bundle structure and thereby fusion is blocked
[16,41,43-45]. Viral resistance to enfuvirtide is associated
with mutations in the GIV sequence of the HR1 region [45].
However, enfuvirtide lacks some amino-terminal residues
present in other gp41 HR2 sequence based peptides (C-
peptides) thought as essential for the binding to the HR1
region and HIV-1 entry inhibition [41,46]. Also it was
suggested that enfuvirtide binding affinity to the HR1 region
cannot justify its strong inhibitory activity [47], and most
recently Liu et al. showed that enfuvirtide cannot interact
with HR1 region derived peptides to form a stable six-helix
bundle [48]. The existence of a second binding site for
enfuvirtide on gp41 was proposed by Muñoz-Barroso et al.
[49], involving the contact site of gp41 oligomers cluster to
form a fusion pore, which is required for the occurrence of
the complete fusion process [18,50]. Kliger et al. showed
that enfuvirtide can bind membranes and oligomerize, but
unlike in aqueous solution, it cannot interact with the HR1
region in the membrane environment [51]. Thus, in
agreement with these ideas, there are two enfuvirtide binding
sites in gp41, contributing to fusion inhibition. By interacting
with the HR1 region in aqueous solution enfuvirtide inhibits
the formation of the six-helix bundle structure and by
interacting with the gp41 C-terminal region in the membrane
environment fusion pore formation is prevented [47,49,51].
Other studies suggest that membranes play a role in
enfuvirtide action, namely in increasing concentration in its
site of action [52,53]. A theoretical analysis of the
hydrophobicity and interface affinity of enfuvirtide amino
acids sequence clearly suggests that it may interact with
biological membranes, which is confirmed experimentally.
Enfuvirtide interaction with membranes has peculiar features
[53]: i) incorporation into neutral liquid-crystal lipid
membranes is extensive (Kp = (1.6–0.1)· 10
3; DG = -6.6 kcal
mol-1); ii) cholesterol and/or physiological concentrations of
negatively charged lipids modulate the incorporation in lipid
membranes; iii) a shallow position in the lipid membrane
makes it readily available for interaction with gp41; and iv)
it has similar secondary structure (random coil) whether in
aqueous or lipid environment, therefore no conformational
energetic barrier can prevent enfuvirtide from being active
both in aqueous solution and lipid membranes. An
alternative or additional model for the enfuvirtide action at
the molecular level was proposed (Fig. 1). It was also
proposed that enfuvirtide may bind to the gp41 fusion
peptide in aqueous medium preventing its insertion into the
target cell membrane. Thus, concomitant to the HR1 binding,
association with the fusion peptide may contribute to block
viral entry [54,55]. It appears that sensitivity to enfuvirtide
can be also modulated by co-receptor specificity, determined
by the V3 loop region of gp120. X4 viruses, that utilize
CXCR4 co-receptor for entry, are much more sensitive to
enfuvirtide than R5 viruses, which utilize CCR5 [56].
Reeves et al. showed that co-receptor binding affinity and
co-receptor expression levels are related with enfuvirtide
sensitivity [57]. More recently, it was proposed that
enfuvirtide can interact with the gp120 co-receptor binding
site, blocking gp120 binding to the co-receptor and thus
inhibiting viral infection [48,58,59]. This interaction occurs
in a CD4-induced manner [58,59] with the gp120 of X4
viruses, which could explain the increased sensitivity of
these viruses to enfuvirtide [58]. In this way gp120 can be
another target site contributing to enfuvirtide inhibitory
activity. However, different studies carried out with isolates
from different clinical trials have not identified significant
differences in enfuvirtide susceptibility for patients
harbouring CCR5, CXCR4 or dual tropic viruses, indicating
that viral tropism has no clinically relevant effect on the
enfuvirtide therapy efficiency [e.g. 60,61]. New studies are
needed to further clarify this matter of debate.
T-1249, a second generation fusion inhibitor that follows
enfuvirtide, is a 39 amino-acids peptide composed of
sequences derived from HIV-1, HIV-2 and simian
immunodeficiency virus (SIV) [62]. More potent than
enfuvirtide, this fusion inhibitor also retains activity against
most enfuvirtide-resistant HIV-1 strains [2,19,63,64].
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Although its mechanism of action is not well known, it is
believed that T-1249 acts like most C-peptides, interacting
with HR1 region preventing hairpin structure formation
[16,60]. It was suggested that T-1249 ability to bind both the
target cell and virus membranes may play an important role
in T-1249 mode of action and provide a peptide reservoir at
the action site [65]. At variance with enfuvirtide, T-1249
adsorbs to rafts and gel-like platforms in lipid membranes,
this difference being one possible explanation for its
improved activity.
In spite of the optimistic results in vitro, T-1249 clinical
trials were put on hold (Table 1).
4. TOWARDS THE FIRST GENERATION OF A NEW
CLASS OF DRUGS
While gp41/gp120-related inhibitors, mainly enfuvirtide,
are undoubtly in the front line of clinical applications of
HIV-entry inhibitors, an overview of the recent patents in
this field reveals an additional trend for the future.
Chemokine receptors are clearly the focus of attention [66-
80]. Table 1 lists some of the CCR5 and CXCR4 antagonists
currently under clinical trials. Altogether with CD4-targeted
strategies and enfuvirtide related peptides, these molecules
form a promising pool of candidate drugs to keep the pace in
the fight against HIV. A detailed analysis of their action can
be found in references 81-83. AMD3100 is a very specific
antagonist for CXCR4 and is a potent inhibitor of X4 HIV-1
replication. AMD070 is an orally bioavailable derivative of
AMD3100 as potent as its parent molecule. SCH-C can also
be administered orally and preliminary clinical data proved
its ability to significantly reduce R5 HIV-1 viral load.
Several related molecules allowed equal or better affinity for
the CCR5 receptor.
An obvious approach to HIV entry inhibition would be to
prevent gp120 to dock CD4 receptors. Soluble CD4 for
competitive inhibition of attachment would be the simplest
strategy. However, soluble CD4 performs poorly in AIDS
patients. CD4-immunoglobulins fusion proteins have better
pharmacokinetics, affinity for gp120 and minimal
immunogenic effects. PRO542 is CD4-IgG2, a tetrameric
CD4-based fusion protein comprising human IgG2 in which
the HIV-binding region of CD4 has replaced the Fv portions
of both heavy and light chains. In phase I clinical trials,
PRO542 showed antiviral activity as well as a favourable
safety and pharmacological profile. Enfuvirtide acts
synergistically with PRO542 [84].
A more indirect approach is to down-modulate the CD4
receptor. CADA (Table 1) inhibits HIV infection by the
specific down-modulation of CD4, probably by means of
down-regulation of CD4 expression at the (post)translational
level [81]. CADA also exhibits a synergistic action with
enfuvirtide, as well as AMD3100.
Fig. (1). A model for the enfuvirtide action at the molecular level. Enfuvirtide (T20) attaches to membranes in an interfacial position,
reaching high local concentrations. Translocation is prevented by phospholipid charge effects (among others). When the virus approaches the
cell surface, its outer membrane will not compete for enfuvirtide uptake due to its higher cholesterol content. Upon binding, gp41 is exposed
near the membrane interface, where enfuvirtide is present in high local concentrations (adapted from [53]).
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Table 1. Short Survey of Some Molecules for their Action Preventing the Entry of HIV into Target Cells. Most Information
Regarding Clinical Trials Status can be Found at www.clinicaltrials.gov and http://hiv.net (Accessed June 2005)
Name Molecule Site of action Company Clinical trials
T20 = Enfuvirtide 36 amino-acids peptide [53] gp41, gp120 Roche / Trimeris As Fuzeon on the market
T-1249 39 amino-acids peptide [65] gp41 (only?) Roche / Trimeris Stopped; Clinical
development on hold 1
CADA CD4 (down-
modulator)
--------- -----------
PRO542 CD4-IgG2 CD4/gp120 binding Progenics Phase II
SCH-C CCR5 antagonist Schering-Plough Stopped 2
SCH-D SCH-C derivative CCR5 antagonist Schering-Plough Phase II 3
UK427,857 ------------------ CCR5 antagonist Pfizer Phase II 4
AMD3100 CXCR4 antagonist AnorMED Stopped 5
AMD070 = AMD
11070
AMD3100 derivative CXCR4 antagonist AnorMED Phase I/II
1- http://trimeris.com/pipeline/t-1249.html (accessed June 2005): «In January 2004, the clinical development of T-1249 was put on hold due to challenges in achieving the desired
technical profile of the current formulation. The compound’s safety, efficacy and tolerability were no way related to the decision».
2- Heart rhythm disturbance was reported.
3- No serious side effects yet known.
4- No side effects occurred during Phase I.
5- Cardiotoxic.
5. CURRENT & FUTURE DEVELOPMENTS
The synergism among efficient HIV-entry inhibitors is
probably the main reason to be optimistic in having powerful
tools to interrupt the HIV life cycle in the first step.
Interruption of the entry step in the HIV life cycle may be of
comparable importance in the future to reverse transcriptase
or protease inhibition. This new front against HIV will
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further help controlling AIDS for the sake of the comfort and
longevity of the patients.
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SUMMARY. We have analysed and identified different mem-
brane-active regions of the Hepatitis C virus (HCV) core
protein by observing the effect of 18-mer core-derived
peptide libraries from two HCV strains on the integrity of
different membrane model systems. In addition, we have
studied the secondary structure of specific membrane-inter-
acting peptides from the HCV core protein, both in aqueous
solution and in the presence of model membrane systems.
Our results show that the HCV core protein region com-
prising the C-terminus of domain 1 and the N-terminus of
domain 2 seems to be the most active in membrane inter-
action, although a role in protein–protein interaction cannot
be excluded. Significantly, the secondary structure of nearly
all the assayed peptides changes in the presence of model
membranes. These sequences most probably play a relevant
part in the biological action of HCV in lipid interaction.
Furthermore, these membranotropic regions could be
envisaged as new possible targets, as inhibition of its
interaction with the membrane could potentially lead to
new vaccine strategies.
Keywords: assembly, capside, core protein, HCV, hepatitis,
lipid.
INTRODUCTION
Hepatitis C virus (HCV) is an enveloped positive single-
stranded RNA virus that belongs to the genus Hepacivirus in
the family Flaviviridae, and is the leading cause of acute and
chronic liver disease in humans, including chronic hepatitis,
cirrhosis, and hepatocellular carcinoma [1–3]. There exists
no vaccine to prevent HCV infection and current therapeutic
agents have limited success against HCV [4]. The HCV
genome consists of one translational open reading frame
encoding a polyprotein precursor, including structural and
non-structural proteins, that is cleaved by host and viral
proteases (Fig. 1a). The structural proteins consist of the
core protein, which forms the viral nucleocapsid, and the
envelope glycoproteins E1 and E2, both of them transmem-
brane proteins1 . The HCV cell entry is achieved by the fusion
of viral and cellular membranes, and the morphogenesis and
virion budding has been suggested to take place in the
endoplasmic reticulum [5]. HCV proteins are very sensitive
to folding, assembly, mutations or deletions. Besides, the
HCV genome is widely heterogeneous; the errors during its
replication cause a high rate of mutations. Therefore, the
region implicated in fusion and⁄or budding must interact
with the membranes and should be a conservative sequence.
Finding protein-membrane and protein–protein interaction
inhibitors could be a good strategy against HCV infection as
they might prove to be potential therapeutic agents.
The HCV core protein is highly basic and shows homology
with the nucleocapsid protein of other flaviviruses. This
protein is well conserved among the different HCV strains [6]
and is important for HCV infection diagnosis by the detection
of either specific anti-HCV core protein antibodies or circu-
latory viral antigens. The core protein has regulatory roles
on cell functions like immune presentation, apoptosis, lipid
metabolism and transcription [7–9]. Additionally, this pro-
tein has oncogenic potential playing an important role in the
regulation of HCV-infected cell growth, transformation to a
tumorigenic phenotype and development of hepatocellular
carcinoma [10]. Recombinant cDNA expression studies of
this protein have identified two major protein core species,
p23 and p21 [8]. The later is the predominant species and is
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egg l-phosphatidylcholine; HCV, hepatitis C virus; LUV, large
unilamellar vesicles; MLV, multilamellar vesicles; NBD-PE,
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-
3-phosphoethanolamine; N-RhB-PE, lissamineTM rhodamine B
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine; SM, egg
sphingomyelin; Tm, temperature of the gel–liquid crystalline phase
transition.
Correspondence: Dr. Jose´ Villalaı´n, Instituto de Biologı´a Molecular y
Celular, Campus de Elche, Universidad ‘‘Miguel Herna´ndez’’,
E-03202 Elche-Alicante (Espan˜a-Spain). E-mail: jvillalain@umh.es.
Journal of Viral Hepatitis, 2007 doi:10.1111/j.1365-2893.2007.00948.x
 2007 The Authors
Journal compilation  2007 Blackwell Publishing Ltd
149
found in viral particles from infected sera, probably being the
mature form of the protein. Although the three dimensional
structure of this protein is unknown three distinct domains
can be considered in the full-length immature protein
[11,12], i.e. domain 1, comprising amino acids 1–117 and
having several positive charges involved in RNA binding and
including the immunodominant antigenic site, domain 2,
comprising amino acids 117–171 and putatively responsible
of its association with lipid droplets, and domain 3, com-
prising amino acids 171–191, a signal peptide upstream of
the E1 glycoprotein. Significantly, the mature core protein is
a dimeric helical protein exhibiting membrane protein fea-
tures [11].
Recently, we have identified the membrane-active regions
of the HIV2,3 gp41, SARS-CoV spike and HCV E1 and E2 gly-
coproteins by observing the effect of glycoprotein-derived
peptide libraries on model membrane integrity [13–15].
These results have permitted us to suggest the possible
location of different segments in these proteins which might
be implicated in protein–lipid and protein–protein interac-
tions, helping us to understand the processes which give rise
to the interaction between the protein and the membrane.
Additionally, HCV membrane assembly and budding is
an attractive target for anti-HCV therapy, as it has been
proposed that the core protein has an important role in viral
assembly. To investigate the structural basis of the protein
core interaction with the membrane and identify new targets
for searching viral assembly inhibitors, we have analysed
and identified different membrane-active regions of the HCV
core protein by observing the effect of 18-mer core-derived
peptide libraries from two HCV strains, namely, HCV 1AH77
and HCV 1B4J, on the integrity of different membrane model
systems. Furthermore, we have studied the secondary
structure of specific membrane-interacting peptides, both in
aqueous solution and in the presence of model membrane
systems, to understand the molecular mechanism of viral
budding as well as making possible the future development
of HCV assembly inhibitors which may lead to new vaccine
strategies.
MATERIALS AND METHODS
Materials and reagents
Egg L-phosphatidylcholine (EPC), egg sphingomyelin (SM),
liver lipid extract (a 2:1 chloroform:methanol extract of liver
tissue) and cholesterol (Chol) were obtained from Avanti
Polar Lipids (Alabaster, AL, USA). 5-Carboxyfluorescein (CF)
(a)
(b)
Fig. 1 (a) Scheme of the hepatitis C virus (HCV) structural and non-structural proteins according to literature consensus. The
sequence and relative location of the twenty-seven 18-mer peptides derived from the HCV core protein are shown with respect
to the sequence of the protein. Maximum overlap between adjacent peptides is 11 amino acids. (b) Analysis of the hydro-
phobicity and interfaciality distribution according to the scales of Wimley and White [22,23] using a window of 11 amino
acids along the HCV core sequence without any assumption about secondary structure.
 2007 The Authors
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(>95% by high performance liquid chromatography), and
sodium dithionite were from Sigma-Aldrich (Madrid,4 , Spain).
Lissamine rhodamine B 1,2-dihexadecanoyl-snglycero-3-
phosphoethanolamine (N-RhB-PE) and N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phos-
phoethanolamine (NBD-PE) were obtained from Molecular
Probes Inc. (Eugene, OR, USA). Three sets of 18-mer peptides
derived from the core protein (Fig. 1a) of hepatitis C virus
strains 1B4J and 1AH77 having 11-amino acid overlap
between sequential peptides were obtained through the NIH
AIDS Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH, Bethesda, MD, USA). All other reagents
used were of analytical grade from Sigma-Aldrich. Water
was deonized, twice-distilled and passed through a Milli-Q
equipment (Millipore Ibe´rica, Madrid,5 Spain) to a resistivity
better than 18 mW cm.
Sample preparation
For infrared spectroscopy, aliquots containing the appropri-
ate amount of lipid in chloroform⁄methanol (2:1, v⁄v) were
placed in a test tube containing 100 lg of dried lyophilized
peptide to obtain a final lipid⁄peptide mole ratio of 50:1. After
vortexing, the solvents were removed by evaporation under
a stream of O2-free nitrogen, and finally, traces of solvents
were eliminated under vacuum in the dark for more than
3 h. The samples were hydrated in 100 lL of D2O buffer
containing 20 HEPES, 50 NaCl, 0.1 mm EDTA, pH 7.4 and
incubated at 10 C above the phase transition temperature
(Tm)6 of the phospholipid mixture with intermittent vortexing
for 45 min to hydrate the samples and obtain multilamellar
vesicles (MLV). The samples were frozen and thawed five
times to ensure complete homogenization and maximization
of peptide⁄lipid contacts with occasional vortexing. Finally
the suspensions were centrifuged at 15 000 rpm at 25 C
for 15 min to remove the peptide possibly unbound to the
membranes. The pellet was resuspended in 30 lL of D2O
buffer. The phospholipid and peptide concentrations were
measured by methods described previously [16,17].
Membrane-leakage measurement
Aliquots containing the appropriate amount of lipid in
chloroform⁄methanol (2:1 v⁄v) were placed in a test tube, the
solvents were removed by evaporation under a stream of O2-
free nitrogen, and finally traces of solvents were eliminated
under vacuum in the dark for more than 3 h. For assays of
vesicle leakage at pH 7.4, buffer containing 10 Tris–HCl, 20
NaCl, 40 CF, and 0.1 mm EDTA, pH 7.4, was used [13].
To obtain MLV, 1 mL of buffer was added to the dry phos-
pholipid mixture and vortexed at room temperature until a
clear suspension was obtained. Large unilamellar vesicles
(LUV) with a mean diameter of 90 nm were prepared from
MLV by the extrusion method [14] using polycarbonate fil-
ters with a pore size of 0.1 lm (Nuclepore Corp., Cambridge,
CA, USA). Breakdown of the vesicle membrane leads to
content leakage. Non-encapsulated CF was separated from
the vesicle suspension through a Sephadex G-75 filtration
column (Pharmacia, Uppsala, Sweden) eluted with buffer
containing either 10 Tris–HCl, 100 NaCl and 0.1 mm EDTA,
pH 7.4. Membrane rupture (leakage) of intraliposomal CF
was assayed by treating the probe-loaded liposomes (final
lipid concentration, 0.125 mm) with the appropriate
amounts of peptide on microtitre plates using a microplate
reader (FLUOstar; BMG Labtech, Offenburg, Germany), sta-
bilized at 25 C with the appropriate amounts of peptide,
each well containing a final volume of 170 lL. The medium
in the microtitre plates was continuously stirred to allow the
rapid mixing of peptide and vesicles. Leakage was assayed
until no more change in fluorescence was obtained. Changes
in fluorescence intensity were recorded with excitation and
emission wavelengths set at 492 and 517 nm, respectively.
Excitation and emission slits were set at 5 nm. One hundred
per cent release was achieved by adding Triton X-100 to the
microtiter plate to a final concentration of 0.5% (wt ⁄wt).
Fluorescence measurements were made initially with probe-
loaded liposomes, afterwards by adding peptide solution and
finally by adding Triton X-100 to obtain 100% leakage.
Leakage was quantified on a percentage basis according to
the equation,
%L ¼ ðFf  F0Þ  100
F100  F0
where Ff is the equilibrium value of fluorescence after pep-
tide addition, F0 is the initial fluorescence of the vesicle
suspension, and F100 is the fluorescence value after the
addition of Triton X-100.
Phospholipid-mixing measurement
Peptide-induced vesicle lipid mixing (hemifusion) was mea-
sured by resonance energy transfer [18]. This assay is based
on the decrease in resonance energy transfer between two
probes (NBD-PE and RhB-PE) when the lipids of the probe-
containing vesicles are allowed to mix with lipids from ves-
icles lacking the probes. The concentration of each of the
fluorescent probes within the liposome membrane was
0.6 mol%. For assays of lipid mixing, 1 mL of buffer (10
HEPES, 100 mm NaCl, pH 7.4) was added to the dry phos-
pholipid mixture (containing either 0.6 mol % NBD-PE and
N-RhBPE or 0.12 mol% NBD-PE and N-RhB-PE, or no
probes), and MLV were obtained by vortexing at room
temperature. LUV were prepared from MLV by the extrusion
method as above, using polycarbonate filters with a pore size
of 0.2 lm (Nuclepore Corp). The use of 0.2 lm pore-size
filters gives place to larger liposomes and henceforth greater
fluorescence intensity per surface unit. Labelled and unla-
belled vesicles in a proportion 1:4 were placed in a
5 mm · 5mm fluorescence cuvette at a final lipid
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concentration of 100 lm in a final volume of 400 lL, sta-
bilized at 25 C under constant stirring. The fluorescence
was measured using a Varian Cary Eclipse fluorescence
spectrometer using 467 nm and 530 nm for excitation and
emission, respectively. Excitation and emission slits were set
at 10 nm. As labelled and unlabelled vesicles were mixed in
a proportion of 1 to 4 respectively, 100% phospholipid
mixing was estimated with a liposome preparation in which
the membrane concentration of each probe was 0.12%.
Phospholipid mixing was quantified on a percentage basis
according to the equation,
% PM ¼ ðFf  F0Þ  100
F100  F0 ;
Ff being the equilibrium value of fluorescence after peptide
addition to a liposome mixture containing liposomes having
0.6% of each probe plus liposomes without any fluorescent
probe, F0 the initial fluorescence of the vesicles and F100 is
the fluorescence value of the liposomes containing 0.12% of
each probe.
Inner-monolayer phospholipid-mixing measurement
Peptide-induced phospholipid-mixing (fusion) of the inner
monolayer was measured by a modification of the phos-
pholipid-mixing measurement stated above [19]. LUVs were
treated with sodium dithionite to completely reduce the
NBD-labelled phospholipid located at the outer monolayer of
the membrane. Final concentration of sodium dithionite was
100 mm (from a stock solution of 1 m dithionite in 1 m TRIS,
pH 10.0) and incubated for approximately 1 h on ice in the
dark. Sodium dithionite was then removed by size exclusion
chromatography through a Sephadex G-75 filtration column
(Pharmacia, Uppsala, Sweden) eluted with buffer containing
10 TRIS, 100 NaCl, 1 mm EDTA, pH 7.4. The proportion of
labelled and unlabelled vesicles, lipid concentration and
other experimental and measurement conditions were the
same as indicated above for the phospholipid mixing assay.
Infrared spectroscopy
Approximately 30 lL of a pelleted sample in D2O were
placed between two CaF2 windows separated by 56-lm thick
Teflon spacers in a liquid demountable cell (Harrick, Ossin-
ing, NY, USA). The spectra were obtained in a Bruker IFS55
spectrometer7 using a deuterated triglycine sulphate detector.
Each spectrum was obtained by collecting 200 interfero-
grams with a nominal resolution of 2 ⁄ cm, transformed using
triangular apodization and, to average background spectra
between sample spectra over the same time, a sample shuttle
accessory was used to obtain sample and background spec-
tra. The spectrometer was continuously purged with dry
air at a dew point of )40 C to remove atmospheric
water vapour from the bands of interest. All samples were
equilibrated at the lowest temperature for 20 min before
acquisition. An external bath circulator connected to the
infrared spectrometer controlled the sample temperature. For
temperature studies, samples were scanned using 20 C
intervals and a 15-min delay between each consecutive
scan. Subtraction of buffer spectra taken at the same tem-
perature as the samples was performed interactively using
either GRAMS⁄32 or Spectra-Calc (Galactic Industries,
Salem, MA, USA) as described previously [20,21]. Frequen-
cies at the centre of gravity, when necessary were measured
by taking the top 10 points of each specific band and fitted to
a Gaussian band. The criterion used for buffer subtraction in
the C=O and amide regions was the removal of the band
near 1210 ⁄ cm, and a flat baseline between 1800 and
2100 ⁄ cm.
RESULTS
The peptide libraries used in this study and their correlation
with the HCV core protein sequence are depicted in Fig. 1a,
where it can be observed that the 18-mer peptide libraries
include the whole HCV core protein sequence. Second and
third consecutive peptides in the library have an overlap of
11 and 4 amino acids, respectively8 . The analysis of the
hydrophobicity and interfaciality distribution along the core
sequence of HCV 1B4J strain (the data obtained for the
HCV 1AH77 strain is nearly identical) without any
assumption about secondary structure is shown in Fig. 1b
[13,22,23]. Although the three dimensional structure of
the core protein is not known, these data give us a depic-
tion of the potential surface zones that could be possibly
implicated in either the modulation of membrane binding
or protein–protein interaction or both. As it is observed in
Fig. 1b, it is evident about the existence of different regions
with large hydrophobic and interfacial values along the
core sequence; these surfaces should be biologically func-
tional in their roles as these patches of positive hydro-
phobicity and interfaciality along the surface of the core
protein could favour the interaction with other similar
patches along other core proteins, different proteins or with
the surface of the membrane.
Membrane rupture, hemifusion and fusion
We have studied the effect of the 18-mer peptide libraries
derived from the HCV core protein 1AH77 and 1B4J strains
on membrane rupture, i.e. leakage, for different liposome
compositions (Fig. 2); the lipidic composition of the model
membranes have been EPC⁄Chol at a phospholipid molar
ratio of 5:1, EPC⁄SM at a phospholipid molar ratio of 5:1,
EPC⁄SM⁄Chol at a phospholipid molar ratio of 5:1:1, and a
lipid extract of liver membranes (containing 42% EPC, 22%
PE, 7% Chol, 8% PI9,10 , 1% LPC, and 21% neutral lipids). The
presence of both SM and Chol has been related to the
occurrence of laterally segregated membrane microdomains
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or lipid rafts, and it has been found that there is an
important relationship between membrane interaction and
Chol and SM membrane content for several viruses [24].
When the 18-mer peptides were assayed on EPC⁄Chol
liposomes, some peptides exerted a significant leakage ef-
fect (Figs 2a,f). The most remarkable effects were induced
(a)
(b)
(c)
(d) (h)
(g)
(f)
(e)
Fig. 2 Effect of the 18-mer peptides derived from the hepatitis C virus (HCV) core protein of HCV 1AH77 (a–d) and HCV 1B4J
(e–h) strains on the release (membrane rupture) of large unilamellar vesicles (LUV) contents for different lipid compositions.
Leakage data for LUVs composed of (a,e) egg l-phosphatidylcholine⁄cholesterol (EPC⁄Chol) at a phospholipid molar ratio of 5:1,
(b,f) EPC⁄egg sphingomyelin (SM) at a phospholipid molar ratio of 5:1, (c,g) EPC⁄SM⁄Chol at a phospholipid molar ratio of 5:1:1,
and (d,h) lipid extract of liver membranes. Vertical bars indicate SDs of the mean of triplicate samples. The dotted line divides
regions corresponding to core domains I and II.
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by peptide comprising residues 113–130. Other peptides
which elicited important leakage values were peptides
comprising residues 57–74, 85–102 and 92–109 for
strain 1AH77 and 29–46, 57–74, 64–81, 85–102 and
92–109 for strain 1B4J. The leakage pattern was slightly
different when liposomes composed of EPC⁄SM were tested
(Figs 2b,f), as the most significant effect appeared now for
peptides comprising residues 85–102 and 92–109. Peptide
113–130 also showed a significant leakage effect. Other
significant leakage values were found for peptides 22–39,
36–53, 57–74 and 64–81 for strain 1AH77 and 64–81
and 120–137 for strain 1B4J. When liposomes composed
of EPC ⁄ SM ⁄Chol at a molar ratio of 5:1:1 were assayed
(Figs 2c,g), a similar pattern to liposomes containing
EPC ⁄Chol was found. The most notable effect was induced
by peptide comprising residues 113–130, whereas peptides
57–74, 64–81, 85–102 and 92–109 for strain 1AH77
and peptides 57–74, 85–102, and 92–109 for strain 1B4J
elicited also significant leakage values. For liposomes
composed of a lipid extract of liver membranes, the same
peptide sequences displayed significant leakage values
(Figs 2d,h). As it was found above, the most significant
values were found for the peptide comprising residues
113–130, but peptides 85–102 and 92–109 showed
also significant leakage. Peptides 57–74 and 64–81 for
strain 1AH77 and peptide 57–74 for strain 1B4J displayed
significant leakage values.
When the 18-mer core derived peptides from strain
1AH77 were assayed for hemifusion on both EPC⁄SM⁄Chol
and liver extract liposomes, peptide comprising residues
29–46 displayed significant values (Figs 3a,b). Other
peptides which elicited important hemifusion values (10%)
defined a region comprising amino acids 85–130, with
hemifusion values ranging from 10 to 25%. Slightly lower
hemifusion values were found for core-derived peptides from
strain 1B4J than for strain 1AH77 using both types of
liposomes, EPC ⁄ SM ⁄Chol and liver extract (Figs 3e,f). When
the 18-mer core-derived peptides from strains 1AH77 and
1B4J were assayed for fusion on both EPC⁄SM⁄Chol and liver
extract liposomes, peptide comprising residues 29–46 was
the one which displayed significant fusion values
(Figs 3c,d,g,h). The region comprising amino acids 85–130
(five peptides in total) was also found to have relatively high
hemifusion and fusion values for both strains.
The summary of membrane leakage, membrane hemifu-
sion and membrane fusion results obtained for both 1AH77
and 1B4J strains is presented in Fig. 4a, whereas the global
average result is displayed in Fig. 4b. It is possible to detect
various segments with large leakage values, which coincide
with segments displaying significant hemifusion and fusion
values. However, it is also possible to detect segments dis-
playing high hemifusion and fusion values but low leakage
ones11 . These results have permitted us to study specific
peptides comprising different zones by infrared spectroscopy
as shown below.
Fourier-transformed infrared spectroscopy structural
assays
Peptides which displayed significant leakage, hemifusion and
fusion effects (Fig. 4b), i.e. peptides corresponding to se-
quences 29–46, 57–74, 85–102, 106–123, and 155–172
were chosen for structural infrared assays both in aqueous
solution (aqueous solutions of peptides 85–102 and 153–
172 additionally contained 10% TFE12 ) and in the presence of
membrane model systems composed of either EPC⁄SM⁄Chol at
a 5:1:1 molar ratio or a liver lipid extract (Fig. 5). Spectra
were obtained at five different temperatures (5, 25, 45, 65
and 85 C) and no any significant differences was found
between them, indicating a high degree of conformational
stability of the peptides. For simplicity, we will describe
spectra obtained at 25 C. The assignment of the Amide I¢
component bands to specific structural features has been
described previously [25]. As observed in Fig. 5, there were
significant changes in the Amide I¢ envelope band depending
on the peptide and the specific lipid composition used.
The Amide I¢ band of the peptide derived from the core
29–46 region in aqueous solution (Fig. 5a) displays a nar-
row band at 1672 ⁄ cm and a shoulder with at least two
broad bands at about 1645 and 1628 ⁄ cm. The band enve-
lope of the Amide I¢ band of the peptide bound to raft model
membranes was significantly different to that found for the
peptide in aqueous solution, as maximum of the band ap-
peared at about 1628 ⁄ cm with small bands at about 1672
and 1644 ⁄ cm (Fig. 5a). In the presence of liver lipid extract
membranes, the Amide I¢ band was similar to the one found
in the presence of raft-containing membranes, but a more
intense band at about 1671 ⁄ cm. These differences in band
intensities for the 29–46 peptide would imply that b-turn
should be the most significant secondary structure in
aqueous solution, whereas in the presence of both raft and
liver extract model membranes the most significant one
should be b-sheet.
The Amide I¢ band of the peptide derived from the core
57–74 sequence in aqueous solution displayed a broad band
with a maximum at about 1672 ⁄ cm and a shoulder at about
1648 ⁄ cm (Fig. 5b). The band envelope of the Amide I¢ band
of this peptide bound to raft model membranes was signifi-
cantly different to that found for the peptide in aqueous
solution, as the maximum of the band appeared at about
1637 ⁄ cm with a small shoulder at about 1648 ⁄ cm. In the
presence of model membranes composed of liver lipid extract,
the Amide I¢ band of the peptide displayed a maximum at
about 1648 ⁄ cm. The intensity maxima for the core 57–74
sequence would imply that the most significant structure in
aqueous solution and in the presence of liposomes composed
of a liver extract should be random, but b-sheet in the
presence of PC13 ⁄SM⁄Chol at a molar ratio of 2:1:1.
The peptides derived from the core 85–102 sequence of
strains 1AH77 and 1B4J have similar sequences: the cyste-
ine present in the 91 position of the strain 1AH77 is replaced
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(a)
(b)
(c)
(d) (h)
(g)
(f)
(e)
Fig. 3 Effect of the 18-mer peptides derived from the hepatitis C virus (HCV) core protein of HCV 1AH77 (a–d) and HCV 1B4J
(e–h) strains on hemifusion (a,b,e,f) and fusion (c,d,g,h) for large unilamellar vesicles composed of (a,c,e,g) egg l-phospha-
tidylcholine⁄egg sphingomyelin⁄cholesterol at a phospholipid molar ratio of 5:1:1, and (b,d,f,h) lipid extract of liver mem-
branes. Vertical bars indicate SDs of the mean of triplicate samples. The dotted line divides regions corresponding to core
domains I and II.
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by a leucine in the 1B4J strain. In aqueous solution, both
peptides show a relatively broad Amide I¢ band with a
maximum at approximately 1647 ⁄ cm and a shoulder at
about 1672 ⁄ cm, much more intense for the peptide derived
from the 1B4J strain than for the 1AH77 one (Figs 5c,d).
In the presence of raft model membranes, the maximum of
the Amide I¢ band in both cases is shifted to lower wave-
numbers, displaying an Amide I¢ maxima at about 1638 ⁄ cm
with a shoulder at about 1671 ⁄ cm. In the presence of liver
lipid extract membranes, the Amide I¢ band of both peptides
display a broad band with a maximum at about 1650 ⁄ cm.
These differences in band intensities would imply that dis-
ordered structure should be the most significant secondary
structure in aqueous solution for the 1AH77 derived peptide,
but random and b-turn for the 1B4J peptide; however, in the
presence of both raft and liver extract model membranes, the
most significant one should be either disordered structure
and⁄or b-sheet.
The Amide I¢ band of the peptide derived from the core
106–123 and 155–172 sequences in aqueous solution dis-
play a narrow band at about 1672 ⁄ cm and a shoulder at
about 1647 ⁄ cm (Figs 5e,f). The band envelope of the Amide
I¢ band of both peptides bound to raft model membranes was
significantly different to that found for the peptides in
aqueous solution, as the maximum of the band appeared at
about 1638 ⁄ cm with shoulders at about 1667 ⁄ cm. In the
presence of model membranes composed of liver lipid extract,
the Amide I¢ band of both peptides were rather similar to the
ones found in the presence of raft membranes, but the band
at 1665 ⁄ cm presented a higher intensity. These differences
in band intensities for the core 106–123 and 155–172 se-
quences would imply that b-turn should be the most sig-
nificant secondary structure in aqueous solution, together
with random structure, whereas in the presence of both raft
and liver extract model membranes, the most predominant
secondary structure should be b-helix followed by b-turn.
DISCUSSION
Viral morphogenesis is one of the most important steps in the
viral cycle involving lipid membranes and is not as well
characterized as the fusion event. For enveloped viruses, the
(a) (b)
(c)
Fig. 4 (a) Summary of all experimental membrane leakage, hemifusion and fusion data presented in this work corresponding
to the core-derived 18-mer peptides for both 1AH77 and 1B4J strains representing the full core sequence and for all liposome
compositions studied (the darker, the greater membrane-active effect). (b) Summary of all the experimental data along the
consensus scheme of the core protein highlighting the experimentally determined membrane-active regions. The dotted line
divides regions corresponding to core domains I and II. (c) Pictorial survey of the most important membrane-active regions of
hepatitis C virus (HCV) core protein. Membrane-active sequences found in this study (d,e,g,h) are depicted along sequences
reported in the literature (a,b,c,f). (a) Domain 1: this sequence is regarded as the RNA-binding region with immunodominant
antigenic properties [11,36]. (b) Domain 2: putatively responsible for the association with lipids [11,36]. (c) Domain 3: signal
peptide [11,36]. (d) Membrane-leakage, hemifusion, and fusion activities with high interfacial values (see text15 ). (e) Membrane-
leakage activity (see text). (f) Homotypic interactions [27] and association to ER16 and mithocondrial membranes [35].
(g) Maximal hemifusion and fusion activities (see text); part of the HCV major antigenic domain sequence; exposed region for
protein-membrane interaction. (h) Both sequences have low but constant rupture, hemifusion and fusion properties (see text).
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assembly of the virions takes place in the host cell membrane
and in the case of HCV it has been suggested that the virus
particles assembly occurs in the endoplasmic reticulum
membranes [26] where the core protein might play a central
role in viral particle formation as well as it might drive the
budding process [27]. Significantly, the HCV core protein is
very well conserved among different HCV strains [6] and has
important regulatory roles on different cell functions. Inter-
estingly, the HCV core protein has been reported to be
associated with raft sub-domains in the absence of other
viral non-structural proteins [28]. Rafts, rigid membrane
sub-domains located predominantly in the plasma mem-
brane are described to be important in the HCV replication
cycle, assembly of virions and budding from the host cell. For
this reason, we have chosen membrane model systems
composed not only of a liver lipid extract but also of EPC, SM
and Chol [29,30], as mimetic of model membranes con-
taining raft domains. As the biological roles of the HCV core
protein can be modulated by membranes, we have identified
the membrane-active regions of the HCV core protein
by studying the effect of two core-derived peptide libraries
from HCV on the integrity of membrane model systems.
Furthermore, to obtain information on the structural basis
of the interaction of the protein with model membranes,
we have studied the secondary structure of specific
membrane-interacting peptides both in aqueous solution
and in the presence of model membrane systems. In this
way, it would be possible to identify important regions which
might be implicated in the budding molecular mechanism,
and therefore could be used as new targets for searching
viral assembly inhibitors as well as making possible the
future development of HCV assembly inhibitors which may
lead to new vaccine strategies.
As it can be observed in Figs 4a,b, we have been able to
discern different zones along the core sequence displaying
different membranotropic properties. When leakage was
assayed, and all the values were taken into account for
all membrane compositions assayed, two zones displayed
significant membrane rupture activity, i.e. regions defined
by amino acids 85–102 and 106–123. The first region
displayed a high interfacial value along its sequence;
however, the second one did not show significant hydro-
phobic and interfacial values. In this context, it is inter-
esting to note that the region comprising residues 85–123
has been described to be important in homotypic interac-
tions which might be a prerequisite for assembly and
budding of HCV-like viral particles [27,31]. Significantly,
mutant core proteins without the 80–118 amino acid
residues reduced, but did not abolish the association with
lipid droplets [32,33]. Interestingly, the interaction of a
region composed of amino acids 72–91 with the E1 gly-
coprotein [34] has been described; this region might be also
important for association with the endoplasmic reticulum
and the mitochondrial outer membranes [35]. Notably,
region 85–102 coincides with a hydrophobic cluster
located in domain 1 of the core protein and region 106–
123 partially overlaps with another one located in domain
2 [36]. By infrared spectroscopy, it was possible to observe
that the 85–102 region displayed different types of sec-
ondary structure, as random structure was the major one
in aqueous solution but an increase in b-sheet in the
presence of model membranes was observed. Although
these regions present high levels of membrane rupture,
hemifusion and fusion in the whole protein context, this
region might be implicated in protein homodimerization
but not in protein-membrane interactions.
(a) (b) (c) (d) (e) (f)
Fig. 5 Amide I¢ band spectra of peptides at 25 C corresponding to core sequences (a) 29–46, (b) 57–74, (c) 85–102 (1AH77
strain), (d) 85–102 (1B4J strain), (e) 106–123 and (f) 155–172 in aqueous solution (lower spectra), in the presence of
liposomes composed of egg l-phosphatidylcholine⁄egg sphingomyelin⁄ cholesterol at a 5:1:1 molar ratio (middle spectra) and in
the presence of liposomes composed of a liver lipid extract (upper spectra).
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Sequences 85–102 and 106–123, apart from being the
ones which elicited the most leakage effect, displayed
also significant hemifusion and fusion activities but region
29–46 displayed the highest hemifusion and fusion values
together with low-leakage values (Fig. 4). As observed in
Fig. 1b, this region displays high hydrophobicity and
interfaciality values along its sequence. By infrared spec-
troscopy, it was determined that in aqueous solution, the
predominant secondary structure was b-turn but b-sheet in
the presence of model membranes composed of either raft
or liver extract lipids. This region has two sequential gly-
cines which might confer a high flexibility to the peptide
and might act as a hinge around which the conformation
could change. Moreover, this region is part of the HCV
major antigenic domain sequence [37], being probably
exposed and implicated in protein-membrane interactions.
On the other hand, it has been demonstrated that
uniformly packed virus particles are generated only by
segment composed by amino acid residues 1–82, whereas
region 29–46 is the only one in the N-terminal half of the
core protein found to interact with lipids [38]. For this
reason, this region might be an important one for the HCV
assembly. Another interesting core sequences pertain to the
57–74 and 155–172 regions, as they displayed low but
constant membrane rupture, hemifusion and fusion activ-
ities (Fig. 4a). It has been described that the ability of the
core protein to associate with lipid droplets is lost when the
153–172 region containing the YATG motif is deleted [27].
These regions, having low but significant membrane-active
activities, might be implicated in the interaction with
membranes.
Additionally to its role in the viral morphogenesis and
budding, the core protein is also important in the disas-
sembly event during the viral uncoating that occurs at the
target cell in a post-fusion stage. For this reason, this protein
is very flexible [5]. The predicted structure of the whole
protein using CD14 indicated that the protein has 16% of
b-helix structure, 29% b-sheet structure and b-turns and
55% of random coil, whereas the C-terminal truncated
protein was largely unordered [9]. As shown in this work,
nearly all the peptides we have assayed display a major
random coil or turn structure in solution; however, their
structure changes in the presence of model membranes. This
information could suggest that the membranotropic regions
which we have detected along the core sequence might be
involved in the interaction, not only with membranes, but
also with proteins, even other core proteins and therefore
responsible of their oligomerization.
Altogether, our results show that most of the HCV core
protein membrane-active regions we have presented in this
work are located in domain 1 (Fig. 4c), whatever interaction
parameter is considered. However, the prevalent idea is that
domain 1 might be the RNA-binding region whereas domain
2 of the HCV core protein would be responsible for mem-
brane-binding (domain 3 is a signal peptide) [11,12].
Gathering related results in the literature, it is clear that a
domain 1 vs domain 2 reasoning is not appropriate to un-
ravel the foundations of HCV core-protein interaction with
lipids. The region comprising the C-terminus of domain 1
and N-terminus of domain 2 seems to be the most active in
membrane interaction, although a role in protein–protein
interaction cannot be excluded. There is a sequence in do-
main 1 of maximal fusion and hemifusion (sequence f in
Fig. 4c) that belongs to the major antigenic sequence of
HCV. This sequence most probably plays a part in the bio-
logical action of HCV in lipid interaction whether during
assembly, or fusion, or both. A more exhaustive study of
these lipid–peptide interactions might help in the under-
standing of the HCV budding molecular mechanism as well
as making possible the future development of anti-HCV
drugs targeted to budding. These membranotropic regions
could be envisaged as new possible targets, as inhibition of
its interaction with the membrane could potentially lead to
new vaccine strategies.
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